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Abbreviations	(in	alphabetical	order)	
	
ADAM17	 A	disintegrin	and	metalloprotease	17;	f.k.a	TACE	
ALI-CFBE41o-		 CFBE41o-	a	CF	Bronchial	Epithelial	Cell	Line	cultured	at	Air-Liquid	Interface	
ALI-HBEC	 Primary	Human	Bronchial	Epithelial	Cells	cultured	at	Air-Liquid	Interface	
AREG	 Amphiregulin	
ASL	 Air	Surface	Liquid	
ASM	 Airway	Smooth	Muscle	cells	
ATP	 Adenosine	Triphosphate 	
BALF	 Bronchoalveolar	Lavage	Fluid	
cAMP	 Cyclic	Adenosine	Monophosphate	
CF	 Cystic	Fibrosis	
CFTR	 Cystic	Fibrosis	Transmembrane	Conductance	Regulator	
COPD	 Chronic	Obstructive	Pulmonary	Disease	
CS	 Cigarette	Smoke	
Duox1	 Dual	 oxidase	 1,	 NADPH	 oxidase	 (NOX)	 family;	 transmembrane,	 produces	
extracellular	peroxide	(ROS)	
Duox2	 Dual	 oxidase	 2,	 NADPH	 oxidase	 (NOX)	 family;	 transmembrane,	 produces	
extracellular	peroxide	(ROS)	
ECM	 Extracellular	Matrix	
EGFR	 Epidermal	Growth	Factor	Receptor	
ERK1/2	 Extracellular	Signal-Regulated	Kinase	1/2	
F508del	CFTR	 Most	prevalent	pathogenic	mutation	in	CF	patients,	deletion	of	a	phenylalanine	in	
the	 NBD1	 domain	 of	 the	 CFTR	 gene	 causes	 abnormal	 folding	 and	 trafficking	 of	
CFTR	protein	
G551D	CFTR	 A	missense	mutation	in	an	ATP	binding	pocket		of	CFTR,	causing	a	channel	gating	
defect	
Gp130	 Signal	Transducing	Glycoprotein	130,	IL-6ST,	CD130,	cytokine	receptor.	
Grx-1-roGFP	 Glutaredoxin-1	The	reduction-oxidation	sensitive	Green	Fluorescent	Protein	
Grx-1-roGFP-GPI	 Glutaredoxin-1-The	reduction-oxidation	sensitive	Green	Fluorescent	Protein	fused	
to	a	Glycosylphosphatidylinositol	anchor	
GSH	 Glutathione;	reduced	form	
GSSG	 Glutathione	dimer;	oxidized	form	of	glutathione	
IL1R	 Interleukin-1	Receptor	
IL-1β 	 Interleukin-1	beta	
IL-6	 Interleukin-6	
IL-6R	 Interleukine-6	Receptor		
IL-8	 Interleukin-8	
MAPK	 Mitogen-activated	protein	kinases		
MPD	 Membrane	proximal	domain	(of	ADAM17)	
MUC5AC	 Mucin	5AC	
MUC5B	 Mucin	5B	
NADPH	 Nicotinamide	Adenine	Dinucleotide	Phosphate	(reduced)	
P38	MAPK	 p38	Mitogen-Activated	Protein	Kinases	
PDI	 Protein	Disulfide	Isomerase	
ROS	 Reactive	Oxygen	Species		
S1P	 Sphingosine-1-Phosphate		
STAT3	 Signal	Transducer	and	Activator	of	Transcription	3	
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TACE	 TNF-α-Converting	Enzyme;	former	name	of	ADAM17	
TGF-α 	 Transforming	Growth	Factor	alpha	
TIMP-3	 Metalloproteinase	Inhibitor	3,	extracellular,	regulates	ADAM	activity	
TMI-1	 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-
(3S)thiomorpholinecarboxamide;	inhibitor	of	MMPs,	ADAM10	and	ADAM17		
TMI-2	 (2R,	 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide;	
selective	ADAM17	inhibitor		
TNF-α 	 Tumor	Necrosis	Factor	alpha	
VX-770	 Ivacaftor	(trade	name	KALYDECO®),	CFTR	potentiator		
VX-809	 Lumacaftor,	CFTR	corrector	
	
	 	
	 10	
SCOPE	OF	THE	THESIS	
Cystic	 fibrosis	 (CF)	and	Chronic	obstructive	pulmonary	disease	 (COPD)	are	progressive	and	
eventually	 fatal	 lung	 diseases	 characterized	 by	 airway	 inflammation,	 bacterial	 infection,	
viscous	mucus	 secretion	and	myofibroblast	hyperplasia.	An	effective	 cure	 is	not	available.	
Though	 the	etiology	of	 the	 two	diseases	 is	obviously	different,	 the	molecular	mechanisms	
involved	 are	 likely	 related,	 but	 not	 completely	 elucidated.	 By	 studying	 pathological	
processes	in	the	CF	and	COPD	airway	model	systems,	we	aim	to	establish	novel	therapeutic	
targets.	
	
In	this	thesis	we	focus	on	the	role	of	ADAM17	metalloprotease	activity,	which	sheds	a	range	
of	bioactive	protein	ligands,	including	most	epithelial	growth	factor	receptor	(EGFR)	ligands.	
We	 hypothesized	 that	 the	 ADAM17-EGFR	 axis	 is	 a	 link	 between	 CF	 and	 COPD	 lung	
pathology.	 When	 triggered	 by	 stress	 signals,	 ADAM17	 releases	 a	 number	 of	 protein	
substrates	 from	 airway	 epithelial	 cells,	 including	 IL-6	 receptor	 (IL-6R)	 and	 several	 growth	
factors	 such	 as	 amphiregulin	 (AREG)	 that	 activate	 gp130	 and	 EGFR	 respectively	 on	 the	
epithelial	cells	(autocrine)	and	the	underlying	tissues	(paracrine,	trans-activation).	Both	the	
IL-6/IL-6R/gp130	 and	 AREG/EGFR	 pathways	 converge	 in	 STAT3	 activation,	 a	 transcription	
factor	and	genetic	modulator	of	CF	lung	disease,	and	are	involved	in	the	lung	tissue	repair,	
inflammation	 and	 fibrosis.	 Thus	 the	 focal	 point	 of	 this	 thesis	was	 to	 establish	 the	 role	 of	
ADAM17	and	EGFR	in	pathology	of	CFTR-related	lung	diseases:	CF	and	COPD.		
	
Chapter	 1	 provides	 a	 general	 introduction	 to	 CF	 and	 COPD	 pathology	 and	 describes	 the	
importance	of	anti-inflammatory	therapy	in	CF.	In	the	second	part,	ADAM17	and	EGFR	are	
introduced	and	their	role	in	lung	inflammation	and	remodeling	is	underlined.		
	
Chapter	 2	 shows	 the	 responses	 of	 ADAM17	 and	 EGFR	 to	 whole	 cigarette	 smoke	 (CS)	
exposure	 in	 differentiated	 COPD	 and	 non-COPD	 primary	 human	 bronchial	 epithelial	 cells	
cultured	 at	 the	 air-liquid	 interface	 (ALI-HBEC).	 Further,	 it	 investigates	 the	 effect	 of	 CS	
exposure	 on	 localization	 and	 quantity	 of	 phospho-ADAM17/substrate	 interactions,	 and	
shows	the	involvement	of	the	EGFR-ADAM17	axis	in	regulation	of	mRNA	and	protein	levels	
of	 ADAM17	 substrates,	 providing	 new	 insight	 into	 the	 spatiotemporal	 ADAM17-mediated	
cleavage.		
	
Chapter	 3	demonstrates	that	CFTR	deficiency	hyperactivates	epithelial	ADAM17	and	EGFR	
as	 a	 cell-autonomous	 defect	 in	 a	 unique	model	 of	 immortalized	 CFTR	 deficient	 CFBE41o-	
airway	 epithelial	 cells	 with	 inducible	 CFTR	 expression.	 Druggable	 targets	 upstream	 and	
downstream	of	these	regulators	were	defined	in	order	to	understand	the	cascade	of	events	
leading	to	CFTR-mediated	activation	of	ADAM17-EGFR	axis	and	potentially	apply	them	as	an	
early	intervention	in	CF	lung	therapy.		
	
Chapter	 4	provides	evidence	of	 chronic	 lung	 inflammation	 in	a	mouse	model	of	 the	most	
common	CF	mutation	(F508del	CFTR).	 In	unchallenged	mutant	mice	we	observe	enhanced	
infiltration	with	activated	granulocytes	 and	an	abnormal	dendritic	 cell	 balance,	 consistent	
with	 basal	 pro-inflammatory	 signalling	 due	 to	 CFTR	 deficiency.	 Upon	 challenge	 with	
bacterial	 toxins,	 resolution	 of	 induced	 inflammation	 is	 delayed	 in	 mutant	 mice.	 This	
correlates	with	abnormal	sphingosine	metabolism,	in	particular	reduced	S1P	in	lung	tissue,	
which	is	known	to	be	associated	with	 inflammatory	processes	through	S1P	recpetors,	Oral	
administration	of	an	S1P-lyase	inhibitor	(LX2931),	corrected	the	S1P	deficiency	and	reduced	
basal	and	induced	inflammation	in	mutant	mice.		
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Chapter	 5	 Summarizes	 and	 critically	 discusses	 the	 studies	 presented	 in	 this	 thesis	 and	
provides	possible	future	directions	 in	 investigation	of	EGFR-ADAM17	axis	 in	the	context	of	
CF	and	COPD	lung	disease.		
	
APPENDIX	
Appendix	 presents	 further	 evidence	 that	 F508del	 CFTR	 mutant	 mice	 show	 excessive	
inflammation,	 increased	 IL-1β	 production	 and	 reduced	 bacterial	 clearance.	 CFTR	 deficient	
mice	with	the	IL-1R1	knock-out	(double	mutant	dd	x	IL-1R1)	have	attenuated	inflammation,	
providing	 a	 rationale	 for	 targeting	 IL-1β/IL-1R1	 pathway	 in	 CF	 patients.	 Importantly,	 in	
airway	epithelial	cell	lines	activation	of	IL-1R	activates	the	ADAM17/EGFR/IL8	signaling	(Kim	
et	al,	2013),	thus	intervention	in	IL-1β/IL-R1β	pathway	may	be	also	beneficial	in	attenuation	
of	EGFR/ADAM17	signaling	in	the	CF	or	COPD	disease	state,	which	can	be	further	evaluated	
in	differentiated	human	airway	epithelial	cells.		
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CHAPTER	1	
General	introduc.on	
The	EGFR-ADAM17	axis	in	pro-inﬂammatory	airway	
responses	and	remodeling	in	CFTR	related	lung	diseases:		
CF	and	COPD.	
		
(to	be	submiHed)	
	
Stolarczyk	M	and	Scholte	BJ	
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INTRODUCTION	
1.1	CYSTIC	FIBROSIS,	A	CONGENITAL	LUNG	DISEASE	WITH	AN	EARLY	ONSET	
Cystic	 Fibrosis	 (CF)	 is	 an	 autosomal	 recessive	 lung	 disease	 caused	 by	 more	 than	 2000	
different	mutations	in	the	cystic	fibrosis	transmembrane	conductance	regulator	(CFTR)	gene	
[1]	with	70-80.000	patients	worldwide.	The	most	common	CF	mutation	is	the	deletion	of	a	
phenylalanine	at	amino	acid	position	508	in	the	NBD1	domain	of	CFTR	protein	(F508del)	[2].	
The	CFTR	gene	encodes	the	Cystic	Fibrosis	Transmembrane	conductance	Regulator	protein,	
a	chloride	channel	mainly	expressed	in	the	apical	membrane	of	secretory	epithelial	cells	[3].	
Later	studies	showed	that	CFTR	is	also	involved	in	transport	of	other	molecules,	for	instance	
bicarbonate	 [4]	 and	 glutathione	 [5]	 [6].	 Bicarbonate	 is	 crucial	 to	 normal	 expression	 of	
mucins	that	in	CF	remains	aggregated	and	poorly	solubilized	[7],	whereas	glutathione,	as	a	
natural	antioxidant,	reduces	oxidative	cellular	stress	[8].		
	
CFTR	has	a	key	role	in	maintaining	ion	and	water	homeostasis	in	secretory	epithelia	[3],	thus	
mutations	in	CFTR	cause	a	multi-organ	CF	disease	affecting	lungs,	intestine,	pancreas,	liver,	
sinuses,	 and	 reproductive	 organs	 [9].	 However,	 under	 present	 treatment	 the	 main	
morbidity	and	mortality	among	CF	patients	is	due	to	lung	malfunction,	thus	most	available	
and	experimental	treatments	aim	to	prevent	the	progression	of	CF	lung	disease	[10].	
	
CF	lung	disease,	an	early	disorder	of	distal	airways	
Advances	 in	 imaging	and	monitoring	of	 the	 respiratory	 system	 in	 infant	patients	 [11]	 [12]	
[13]	 have	 revealed	 that	 severe	 CF	 lung	 pathology	 starts	 early	 in	 childhood	 [14]	 [15]	 and	
progresses	 irreversibly	 over	 time	 [16]	 [17].	 Characteristic	 lung	 functional	 and	 structural	
changes	are	observed	already	in	pre-school	patients	[15]	[17]	[18]	[19].	This	early	onset	of	
lung	 abnormalities	 includes	 bronchiectasis,	 diagnosed	 thickening	 and	 dilation	 of	 the	
bronchial	walls	[14]	[20]	[21],	air	trapping	and	atelectasis	(partial	collapse	of	the	lung)	[14]	
[22].	These	symptoms	occur	simultaneously	with	reduced	mucociliary	clearance	and	mucus	
plugging	 [20].	Quantitative	 and	 standardized	 tracking	 of	 early	 lung	 disease	 progression	 in	
infants	 with	 CT	 scans	 is	 pursued	 to	 advance	 the	 comparative	 analysis	 and	 provide	 the	
evaluation	of	the	treatment	[18]	[23].		
	
In	 a	 recent	 micro	 CT	 and	 histological	 study	 of	 end-stage	 CF	 lungs	 the	 dilatation	 and	
obstruction	of	distal	 airways	and	a	 severe	 reduction	 in	 the	number	of	 functional	 terminal	
bronchioles	 was	 clearly	 documented	 for	 the	 first	 time,	 confirming	 that	 obstruction	 and	
remodeling	of	peripheral	airways	 is	a	prominent	 feature	 in	CF	 lung	disease,	and	therefore	
are	 prime	 targets	 of	 experimental	 therapy	 [24].	 CF	 mouse	 models	 [25]	 (Chapter	 4,	
Appendix)	and	 large	CF	animal	models,	 like	pig	 [26]	 [27]	and	 ferret	 [28]	are	helpful	 in	 the	
investigation	 of	 the	 mechanism	 involved	 in	 this	 early	 onset	 of	 CF	 lung	 disease	 and	
intervention	 therapy,	 but	 all	 have	 considerable	 limitations.	 In	 addition	 to	 state	 of	 the	 art	
clinical	and	biomarker	studies,	there	is	an	urgent	need	for	the	development	of	organotypic	
cell	culture	models	in	which	the	complex	molecular	and	cellular	interactions	involved	in	CF	
lung	pathology	can	be	studied	(Chapter	2	and	3).	
	
Mucus,	Mucociliary	transport	and	ciliary	beat	frequency	
Healthy	airways	are	protected	by	mucociliary	 transport	 that	 removes	pathogens	and	toxic	
particles	 captured	 in	 mucus	 by	 ciliary	 beating.	 In	 healthy	 subjects	 this	 requires	 CFTR	
dependent	balanced	fluid	and	proper	mucus	secretion	from	surface	cells	and	sub-epithelial	
glands.	 However,	 CF	 lung	 epithelial	 cells	 produce	mucus	 (MUC5AC,	MUC5B)	with	 altered	
properties,	 characterized	mainly	 by	 high	 viscosity	 [29]	 [30].	 High	mucus	 viscosity	 in	 CF	 is	
caused	by	 reduced	CFTR-dependent	bicarbonate	 secretion,	 required	 for	proper	expansion	
of	secreted	mucus	molecules	[30]	[31].	
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Furthermore,	 CF	 patients	 have	 intrinsically	 impaired	 ciliary	 beat	 frequency	 (CBF),	 which	
additionally	reduces	muco-ciliary	transport	of	inhaled	chemical	particles	and	pathogens.	CBF	
is	 not	 only	 dependent	 on	 CFTR-mediated	 bicarbonate	 transport,	 but	 also	 regulated	 by	
soluble	adenyl	cyclase	(sAC)	[32]	[33].		
	
Taken	 together,	high	mucus	viscosity	 [29]	and	 impaired	CBF	disable	effective	clearance	of	
bacteria	and	inhaled	particles	[26]	[34],	which	has	been	recently	confirmed	by	less	effective	
removal	of	bacteria	introduced	into	the	CF	pig	lung	in	comparison	to	healthy	animals	[35].		
	
Air	Surface	Liquid	
Airway	epithelium	 is	covered	with	a	 thin	 layer	of	air-surface	 liquid	 (ASL).	Airway	epithelial	
cell	cultures	from	CF	patients	have	reduced	ASL	height,	presumably	due	to	defective	CFTR	
dependent	 fluid	 secretion	 [36]	 [37]	 [38].	 Additionally,	 as	 a	 consequence	 of	 reduced	
bicarbonate	 secretion,	 CFTR	 deficiency	 abnormally	 acidifies	 ASL	 [32]	 [33].	 Reduced	 pH	 of	
ASL	 impairs	 bacterial	 killing	 [39]	 [40],	 inhibits	 the	 activity	 of	 ASL	 antimicrobials	 [41],	 and	
increases	 ASL	 viscosity	 of	 newborn	 CF	 piglets,	which	 can	 be	 improved	 after	 reducing	 ASL	
Ca2+	levels	[26].		
	
Taken	together,	 the	careful	 regulation	of	the	balance	between	fluid	and	 ion	secretion	and	
resorption	at	 the	airway	surface,	maintenance	of	 the	optimal	 liquid	 layer	 (ASL)	height,	pH	
and	mucus	viscosity,	is	the	primary	role	of	CFTR	in	the	lungs.	Impaired	CFTR	function	leads	
to	 dehydration	 and	 acidification	 of	 ASL,	 which	 interferes	 with	 pathogen	 and	 mucus	
clearance	[34]	[36]	[39]	[42].	
	
Bacterial	infection	and	inflammation	
Impaired	 bacterial	 killing	 and	 mucociliary	 clearance	 facilitate	 bacterial	 colonization	 in	 CF	
lungs.	 Pseudomonas	 aeruginosa,	 Haemophilus	 influenza,	 Staphylococus	 aureus,	 generally	
harmless	 in	 normal	 individuals,	 are	 pathogens	 frequently	 found	 in	 CF	 patient	 lungs	 [43].	
Microbes	 that	 colonize	 airways	 frequently	 form	 biofilms,	 stimulating	 persistent	
inflammatory	responses	[44].	Despite	activation	of	inflammatory	responses	mediated	by	the	
innate	and	cellular	immune	system,	eradication	of	bacterial	infection	is	impaired	in	CF	lungs.	
It	 is	plausible	that	persistent	 inflammation	 is	caused	by	bacteria	captured	 in	sticky	mucus,	
which	produce	a	mucoid	biofilm	during	adaptation	to	the	CF	lung	environment.		
	
Recurrent	 infections	 (mainly	 with	 P.	 aeruginosa)	 and	 concomitant	 chronic	 inflammation,	
recognized	 as	main	 hallmarks	 of	 CF	 lung	 disease,	 worsen	 the	 lung	 pathology.	 In	 airways,	
bacterial	 infections	 induce	 a	 massive	 recruitment	 of	 neutrophils	 [45].	 Both	 bacterial	
infections	and	neutrophil	infiltration	have	been	correlated	with	progression	of	lung	disease	
[14].	 This	 ultimately	 leads	 to	 irreversible	 airway	 remodeling,	 observed	 as	 air	 trapping,	
bronchiolar	obstruction	and	bronchiectasis	[24].	
	
However,	 it	 still	 remains	 unknown	 whether	 elevated	 levels	 of	 inflammatory	 cytokines,	
growth	 factors	 and	 mucins	 always	 result	 from	 bacterial	 infection,	 or	 are	 an	 intrinsic	
property	of	CFTR	deficient	mucosa	(Chapter	4,	Appendix).	Some	reports	argue	that	bacterial	
infections	are	indispensable	to	inflammatory	responses,	providing	evidence	that	CF	lungs	do	
not	have	inflammation	at	birth	in	humans	[46]	or	CF	pig	[35].	However,	others	report	that	
CFTR	malfunction	leads	to	overexpression	of	pro-inflammatory	molecules	(such	as	IL-6,	IL-8,	
IL-17,	 CXCL1,	 CXCL2)	 as	 a	 cell-autonomous	 defect	 occurring	 before	P.aeruginosa	 infection	
[47]	 [48]	 [49]	 [50]	 [51]	 [52].	Thus,	 it	 is	 likely	 that	mucosal	 inflammation	 is	an	autonomous	
defect	of	CF	epithelial	cells,	which	may	occur	before	bacterial	 infection.	Furthermore,	 it	 is	
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also	unclear	whether	the	elevated	levels	of	inflammatory	mediators	in	the	bronchioalveolar	
lavage	 fluid	 (BALF)	 of	 young	 and	 adult	 CF	 patients	 [53]	 are	 caused	 by	 functional	
abnormalities	in	CF	myeloid	cells,	in	particular	macrophages	[54],	dendritic	cells	(Appendix:	
CF	 mouse	 studies),	 and	 neutrophils	 [55]	 or	 are	 primarily	 related	 to	 abnormal	 cytokine	
signaling	by	CFTR	deficient	airway	epithelial	cells.	This	thesis	aims	to	address	the	question	
whether	inflammation	is	an	inherited	property	of	CF	airway	epithelial	cells,	which	is	covered	
by	Chapter	2.	
	
In	summary,	due	to	the	early	onset	of	the	lung	disease	and	its	irreversible	nature,	it	is	clear	
that	 CF	 patients	 require	 early	 intervention	 therapy	 [17].	 Excessive	 lung	 inflammation	 and	
tissue	 remodeling	 observed	 in	 CF	 may	 be	 an	 inherent	 property	 of	 CFTR	 deficient	 lung	
mucosa.	 Therefore,	 it	 is	 important	 to	 establish	 whether	 alleviation	 of	 inflammatory	
responses	is	beneficial	in	management	of	CF	lung	disease	[56].	
	
1.2	STRATEGIES	OF	CF	THERAPY	
The	most	prominent	cause	of	death	of	CF	patients	 is	 lung	malfunction	caused	by	frequent	
airway	 infections,	 persistent	 inflammatory	 responses,	 mucus	 plugging	 and	 airway	
remodeling	 (bronchiectasis,	 scarring)	 [24].	 Indirect	 pharmacological	 management	 targets	
these	 different	 pathophysiological	 aspects	 of	 the	 disease	 and	 mainly	 focuses	 on	 anti-
inflammatory	agents	 [57]	 [58],	antibiotics	 [59],	and	mucolytic	agents	 [60]	 [61]	 [62].	Direct	
pharmacological	management	of	CF	disease,	which	is	being	developed	at	this	time,	intends	
to	 restore	 the	 functional	 expression	 of	 mutated	 CFTR	 at	 the	 plasma	 membrane	 by	
correcting	 its	 folding	and	gating	defect	[63]	and	thus	reverse	the	abnormalities	 in	chloride	
transport.	 Many	 attempts	 have	 been	 made	 to	 define	 correctors	 that	 aim	 to	 correct	 the	
folding	defect	and	enable	mutant	CFTR	to	reach	the	apical	membrane,	and	potentiators	that	
increase	 the	 open-probability	 of	 the	 mutant	 CFTR	 channel	 at	 the	 plasma	 membrane,	
thereby	increasing	CFTR	conductance	[64]	[65]	[66]	[67]	[68].	On	the	basis	that	patients	with	
residual	CFTR	activity	have	 less	 severe	disease	 [69]	 [70],	 it	 is	 claimed	 that	 for	 therapeutic	
strategies	aimed	at	correcting	mutant	CFTR	function	or	gene	therapy	around	10	%	of	normal	
CFTR	activity	is	required	to	restore	chloride	transport	[71].	
	
So	far,	a	potentiator	 Ivacaftor	(VX-770,	trade	name	KALYDECO®)	was	tested	with	excellent	
results	in	G551D	CFTR	patients	[72]	[73]	and	has	been	approved	by	the	U.S	Food	and	Drug	
Administration	(FDA)	for	patients	with	gating	mutations	(G551D,	G1244E,	G1349D,	G178R,	
G551S,	S1251N,	S1255P,	S549N,	or	S549R),	which	together	account	for	4-5%	of	all	CF	alleles	
[3].	In	clinical	trial,	the	corrector	VX-809	(lumacaftor)	resulted	in	significant	improvement	of	
lung	disease,	albeit	only	 in	a	subpopulation	of	homozygous	F508del	CFTR	mutants	 [68].	 In	
2015	the	FDA	approved	ORKAMBI®	for	homozygous	F508del	CFTR	patients,	the	combination	
of	CFTR	corrector	 Lumacaftor	 (VX-809)	and	potentiator	 Ivacaftor	 (VX-770)	 in	one	pill.	 This	
therapy	improves	lung	function	in	patients	homozygous	for	the	F508del	mutation,	although	
modestly	 and	 not	 in	 all	 patients	 [10]	 [74],	 so	 further	 investigations	 with	 different	
combinations	 of	 new	 correctors	 and	 potentiators	 are	 in	 progress	 to	 find	 more	 effective	
therapy	 [75]	 [76].	 Long-term	effects	on	 lung	 function	after	 treatment	with	 correctors	and	
potentiators	 are	 still	 not	 well	 investigated.	 Current	 developments	 use	 stem	 cell	 based	
intestinal	organoids	as	a	new	test	platform	for	high	throughput	screening	and	personalized	
evaluation	 of	 available	 compounds	 and	 combination	 therapies	 [77]	 [78]	 [79].	 Gene	
therapies	(viral	and	non-viral	gene	transfer,	gene	editing,	mRNA	repair)	as	well	as	strategies	
targeting	protein	repair	other	than	potentiators	and	correctors	(like	premature	termination	
codon	(PTC)	read-through	drugs	or	proteostasis	regulators)	are	also	under	investigation,	but	
so	 far	with	 limited	 success	 in	 clinical	 trials	 [65]	 [66]	 [67]	 [80]	 [81].	 Editing	 the	 CFTR	 gene	
using	 the	CRISPR-Cas9	system	 in	stem	cells	 is	a	potential	next	step	to	 improve	CF	 therapy	
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[82].	 However,	 this	 approach	 has	 to	 overcome	 similar	 issues	 of	 efficiency,	 delivery	 and	
safety	as	conventional	gene	therapy.	
	
Since	 the	 1990s	 excessive	 airway	 inflammation,	 which	 positively	 correlates	 with	 the	
progression	of	CF	lung	malfunction,	is	recognized	as	the	major	factor	in	the	pathogenesis	of	
CF	lung	disease	[83].	However,	so	far	the	effects	of	correctors	and	potentiators	on	infections	
and	 the	 release	 of	 inflammatory	mediators	 have	 not	 been	 broadly	 investigated	 in	 clinical	
studies.	In	vitro	studies	by	Pohl	et	al.	show	that	Ivacaftor	improves	extracellular	P.aerugnosa	
killing	 by	 neutrophils	 isolated	 from	 F508/G551D	 or	 F508del	 homozygous	 patients	 and	
corrects	 neutrophilic	 degranulation	 and	 Rab27a	 activation	 [84].	 Rowe	 et	 al.	 showed	 that	
Ivacaftor	 also	 reduces	P.	 aeruginosa	 isolated	 from	CF	 patients	 after	 6	months	 treatment.	
However,	 the	 free	neutrophil	elastase	and	other	 inflammation	markers	 like	 IL-1β,	 IL-6	and	
IL-8	 in	 sputum	 samples	 remained	 unchanged	 [73].	 Therefore	 anti-inflammatory,	 anti-
bacterial	and	other	additional	therapies	are	still	important	targets	of	investigation	[85].		
	
In	 summary,	 recent	 breakthroughs	 in	 the	 development	 of	 small-molecule	 compounds	
targeting	 the	mutant	 CFTR	 protein	 have	 raised	 hope	 to	 find	 a	 cure	 for	 CF.	 However,	 the	
presently	 available	 CFTR	 correctors	 and	 potentiators	 are	 not	 sufficiently	 effective	 in	 a	
majority	of	CF	patients,	and	the	search	for	new	compounds	and	additional	therapies	is	still	
highly	 relevant.	 Targeting	 the	 CFTR	 gene	 by	 gene	 editing	 in	 stem	 cells	 is	 a	 next	
development.	 At	 this	 point,	 anti-inflammatory	 and	 anti-bacterial	 therapies	 remain	
important	targets	of	investigation.	
	
1.3	COPD,	ACQUIRED	CF?	
Chronic	obstructive	pulmonary	disease	(COPD),	the	5th	ranking	cause	of	death	worldwide,	is	
a	 complex	 inflammatory	 lung	 condition	 that	 interferes	 with	 normal	 breathing	 due	 to	
obstruction	of	the	 lung	airflow,	excessive	sputum	production	and	a	chronic	cough.	Usually	
COPD	is	characterized	by	chronic	bronchitis	 (inflammation	of	the	bronchi	and	bronchioles)	
and	emphysema	[86].	Similar	to	CF,	bronchiectasis	and	peripheral	airway	thickening	are	also	
observed	 in	 the	 lungs	 of	 COPD	 patient	 [87].	 Phenotypic	 expression	 of	 COPD	 is	 highly	
variable.	 Some	 individuals	 develop	 lung	 disease	 dominated	 by	 emphysema,	 while	 others	
exhibit	chronic	bronchitis.	This	heterogeneous	phenotype	likely	reflects	the	contribution	of	
multiple	 pathogenic	 mechanisms.	 Once	 COPD	 starts	 to	 develop,	 it	 tends	 to	 worsen	 over	
time,	and	so	far	its	progress	cannot	be	controlled	effectively	in	most	patients.		
	
The	most	prominent	etiological	factor	leading	to	COPD	is	cigarette	smoke,	but	also	exposure	
to	 fumes,	 chemicals	 and	 dust	 [88].	 Although	 COPD	 and	 CF	 differ	 in	 primary	 cause,	 the	
spectra	 of	 the	 pathological	 events	 overlap	 considerably	 (Figure	 1).	 Both	 diseases	 are	
characterized	 by	 excessive	mucus	 production	 and	 insufficient	 clearance,	 leading	 to	 lower	
airways	 obstruction	 with	 chronic	 neutrophilic	 infiltration.	 In	 CF	 and	 COPD	 airway	 surface	
liquid	 (ASL)	 dehydratation	 and	 viscous	 mucus	 secretion	 impair	 mucociliary	 and	 bacterial	
clearance,	 causing	 chronic	 inflammation	 and	 facilitating	 recurrent	 infections	 [89].	
Furthermore,	during	chronic	CF	lung	disease,	P.aeruginosa	clones	adapt,	resulting	in	a	highly	
diverse	bacterial	 community	 that	 is	extremely	difficult	 to	eradicate	 therapeutically.	This	 is	
also	observed	 in	severe	COPD,	but	not	 in	mild	disease	[90]	 [91].	Recent	publications	show	
the	involvement	of	a	wide	variety	of	inflammatory	mediators	in	COPD	(like	IL8,	IL-6,	CCL18),	
that	overlap	with	CF	related	mediators	[85]	[92].	There	are	also	parallels	on	the	cellular	level	
that	include	goblet	cell	metaplasia,	hyperplasia	of	myoblasts,	extensive	extracellular	matrix	
production	[93].		
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Figure	1.	Common	features	of	CF	and	COPD.	CF	and	COPD	despite	the	distinct	nature	of	the	disease	
development	share	many	common	clinical	manifestations.	Mutations	in	CFTR	gene	contribute	to	the	
CF	outcome.	Recently	CS	has	been	shown	to	affect	CFTR	channel	activity	and	since	is	recognized	as	a	
factor	that	may	contribute	to	a	CF-like	phenotype	in	COPD.	Thus	COPD	has	been	recently	described	
as	acquired	CF.		
	
The	broad	spectrum	of	common	features	and	events	observed	in	CF	and	COPD	encouraged	
researchers	to	seek	for	the	common	factors	for	both	diseases.	Studies	showed	that	cigarette	
smoke	 decreases	 CFTR	 mRNA	 expression,	 and	 reduced	 CFTR	 protein	 level	 through	
accelerated	degradation	and	altered	 channel	 activity	 [94]	 [95]	 [96]	 [97].	CFTR	dysfunction	
and	 a	 clinical	 phenotype	 similar	 to	 mild	 CF	 developed	 by	 COPD	 patients	 has	 made	
researchers	 to	 describe	 COPD	 as	 an	 “acquired	 CF”	 [89]	 [93]	 [98]	 [99].	 Nasal	 potential	
differences	 (NPD)	 in	 patients	with	 no	 detectable	 CFTR	 gene	mutation	 reflected	 a	 pattern	
typical	of	CFTR	deficiency	[100].	As	a	result	of	CS	exposure,	CFTR	rapidly	internalizes	leading	
to	 its	decreased	activity,	diminished	CFTR-mediated	anion	 transport,	 impaired	mucociliary	
clearance	and	depleted	ASL	 in	vitro	and	 in	vivo	[94]	[95].	However,	the	effect	presented	in	
these	 papers	 is	 transient,	 so	 whether	 CS-induced	 inhibition	 of	 CFTR	 contributes	 to	 the	
chronic	COPD	in	ex-smokers	remains	to	be	investigated.		
	
1.4	STRATEGIES	OF	THERAPIES	IN	COPD		
The	CF-like	symptoms	of	COPD,	impaired	CFTR	function	observed	in	COPD	patients,	and	the	
direct	evidence	that	CS	exposure	inhibits	CFTR	activity	have	led	to	a	trial	in	which	smokers	
were	treated	with	a	CFTR	potentiator.	Sloane	et	al.	showed	that	Ivacaftor	(VX-770)	activated	
CFTR-dependent	chloride	transport	in	non-CF	patients,	increased	ASL	height	and	mucociliary	
transport	 [95].	 These	 findings	 contrasted	 with	 the	 results	 of	 Cholon	 et	 al	 showing	 that	
chronic	 treatment	with	VX-770	 reduced	non-CF	CFTR	 function	and	 the	 amount	of	mature	
CFTR	 [101].	 These	 results	 thus	 discredit	 the	 possibility	 to	 use	 VX-770	 as	 an	 additional	
therapy	to	enhance	CFTR	function	in	COPD.	
							COMMON	FEATURES	
• progress	over	time,	irreversible		
• chronic	bronchitis		
• bronchiectasis	
• reduced	mucociliary	clearance	
• mucus	plugging	
• depletion	of	the	ASL	
• bacterial	colonization	
• recurrent	infections	
• chronic	inflammation	
• tissue	remodeling		
(scars,	fibrosis,	emphysema)	
CF	
-	genetic	disease	
-	starts	early	in	childhood	
-	presently	described	as						
		progressive	lung	disease	
	COPD	
-	smoke	induced	
-	diagnosed	at	>		40	yr	
-	develops	slowly	
-	recently	described	as		
		“acquired	CF”		
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Inflammation	 is	 recognized	 as	 the	 major	 pathophysiological	 mechanism	 of	 COPD	
progression,	with	molecular	targets	overlapping	those	of	CF	(IL-6,	IL8,	CCL18)	[85].	It	is	also	
chronic	and	persists	even	after	cessation	of	smoking,	suggesting	that	apart	from	the	role	of	
CFTR	also	epigenetic	changes	may	play	a	role	[102]	[103].	Thus	airway	inflammation	remains	
an	 important	 therapeutic	 target	 in	 COPD	 management.	 	 Presently,	 several	 compounds	
targeting	 inflammatory	responses	 in	COPD	are	under	 investigation	[104]	[105]	[106]	[107],	
though	none	of	these	have	been	shown	to	be	beneficial	in	COPD	patients	as	yet.		
	
COPD	is	a	complex	multifactorial	disease,	with	large	variation	in	the	patient	population	due	
to	undefined	genetic	and	environmental	factors.	Therefore,	a	personalised	approach	using	
multiple	 treatments	will	 likely	 be	 required,	 but	 a	 robust	 trial	 strategy	 is	 elusive.	 This	 also	
applies	to	CF	anti-inflammatory	treatment,	though	this	disease	is	considered	monogenetic,	
the	downstream	 responses	 to	CFTR	deficiency,	 and	 responses	 to	 therapeutic	 intervention	
are	 highly	 variable	 in	 the	 population.	 The	 perfect	 corrector	 and	 potentiator	 combination	
tailored	 to	 the	 individual	 patient,	 supported	 by	 additional	 anti-inflammatory	 medication,	
would	likely	be	the	best	solution.	
	
1.5	EPITHELIAL	EGFR/ADAM17	AXIS,	A	POTENTIAL	THERAPEUTIC	TARGET	IN	CF	AND	COPD	
LUNG	DISEASE		
For	 decades	 the	 design	 of	 anti-inflammatory	 agents	 aimed	 mainly	 to	 decrease	 the	
neutrophil	 influx	 into	 the	 lung	 and	 concomitant	 inflammatory	 responses	 mediated	 by	
eosinophils,	macrophages,	basophils,	mast	cells,	NK,	dendritic	cells,	B	cells	and	T	cells	[108].	
Recently	the	importance	of	airway	epithelial	cells	in	inflammatory	responses	has	been	also	
recognised	 [109].	 Airway	 epithelium	 serves	 as	 a	 first	 barrier	 and	 acts	 as	 defence	 against	
daily	inhaled	air	pollutants	and	microbes	by	mucociliary	clearance	and	secretion	of	a	range	
of	cytokines,	cytokines	receptors,	growth	factors,	growth	factor	receptors	and	antimicrobial	
peptides	[110]	[109].	Airway	epithelial	cells	not	only	release	inflammatory	mediators	to	ASL,	
but	they	also	signal	to	the	underlying	tissues	(myocytes	or	fibroblasts).	
	
A	 disintegrin	 and	 metalloproteinase	 17	 (ADAM17)	 is	 involved	 in	 the	 immune	 defence	
mechanisms	mediated	by	epithelial	cells.	ADAM17,	also	known	as	a	Tumor	Necrosis	Factor-
α	 Converting	 Enzyme	 (TACE),	 is	 an	 enzyme	 with	 proteolytic	 activity	 that	 releases	
extracellular	 domains	 of	 transmembrane	 proteins	 to	 produce	 soluble	 bioactive	 signaling	
proteins.		
Mature	 ADAM17	 consists	 of	 metalloprotease	 domain	 (catalytic),	 a	 disintegrin	 domain,	
membrane	proximal	 domain	 (MPD)	 rich	 in	 cysteine	 residues	 comprising	 5	 disulfide	 bonds	
(this	 cysteine-rich	segment	 is	 shorter	 in	comparison	 to	other	ADAMs),	 “Conserved	ADAM-
seventeeN	Dynamic	Interaction	Sequence”	(CANDIS),	unlike	other	ADAM	family	members	it	
lacks	 EGF-like	 domain	 [111]	 [112]	 [113]	 [114]	 [115].	 These	 extracellular	 domains	 are	
followed	 by	 transmembrane	 region	 and	 cytoplasmic	 tail	 with	 phosphorylation	 sites	 that	
potentially	are	involved	in	ADAM17	activation	(Figure	2).		
Ectodomain	 shedding	 mediated	 by	 the	 metalloprotease	 domain	 of	 ADAM17	 provides	 a	
mechanism	 for	 both	 membrane	 protein	 downregulation	 and	 subsequent	 initiation	 or	
inhibition	 of	 autocrine/paracrine	 signaling.	 So	 far	 76	 proteins	 have	 been	 identified	 as	
substrates	 of	 ADAM17	 [116].	 They	 encompass	 membrane	 bound	 cytokines	 (TNF-α),	
cytokine	 receptors	 (IL-6R,	 TNF-R),	 growth	 factors	 (AREG),	 ligands	 of	 EGFR	 (TGF-α,	 AREG,	
EREG,	HB-EGF,	Epigen),	adhesion	proteins	(L-selectin,	 ICAM-1)	and	transmembrane	mucins	
(MUC-1).	The	shed	soluble	forms	of	these	proteins	are	bioactive	transducers	of	cell	signaling	
via	activation	of	cellular	receptors	on	underlying	cells	(transactivation/paracrine	activation),	
but	 they	 also	 are	 involved	 in	 activation	 of	 the	 shedding	 cells	 and	 neighbouring	 cells	
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(autocrine	activation)	(Figure	3).	
Figure	2.	ADAM17	domain	structure.	
ADAM17	(and	its	close	relative	ADAM10)	is	an	atypical	member	of	the	ADAM	family.	It	has	additional	
disulfide	 bonds	 in	 the	 metalloprotease	 domain,	 it	 lacks	 two	 calcium	 binding	 sites	 in	 disintegrin	
domain.	The	Membrane	Proximal	Domain	 (MPD),	 replacing	the	cysteine-rich	and	EGF-like	domains,	
with	 a	 novel	 alpha/beta	 fold	 has	 a	 shorter	 cysteine-rich	 segment	 [111]	 [113]	 [114].	 The	MPD	 has	
cysteine	 residues	 determining	 the	 ADAM17	 conformation	 (open/closed)	 and	 ADAM17	 protease	
activity	 (active/inactive	 switch).	 The	MPD	 is	 in	 close	 proximity	 to	 the	 active	 site	 likely	 due	 to	 a	 C-
shaped	conformation	of	the	extracellular	part	of	mature	ADAM17	[111]	[112].	ADAM17	lacks	an	EGF-
like	 domain,	 so	 the	MPD	 is	 followed	 by	 the	 juxtamembrane	 region	 “Conserved	 ADAM17	Dynamic	
Interaction	Sequence”	(CANDIS)	 involved	in	some	substrate	recognition	(IL-6R,	but	not	TNFα)	[117],	
transmembrane	 region	 and	 a	 cytoplasmic	 tail	 [111]	 [112]	 [113]	 [114]	 [115]	 with	 phosphorylation	
sites,	which	are	likely	important	for	ADAM17	activity.		
	
	
Because	 most	 of	 the	 epidermal	 growth	 factor	 receptor	 (EGFR)	 ligands	 are	 cleaved	 by	
ADAM17,	 this	 sheddase	 has	 emerged	 as	 an	 important	 transducer	 of	 the	 airway	 epithelial	
autocrine	 and	 paracrine	 signaling	 (Figure	 3).	 EGFR	 and	 ADAM17	 are	 both	 involved	 in	 the	
broad	 spectrum	 of	 events	 that	 is	 characteristic	 of	 both	 CF	 and	 COPD	 lung	 disease,	 like	
excessive	mucus	expression	[118]	[119]	[120],	cytokine	secretion	[121],	airway	epithelial	cell	
wound	 healing	 [122]	 [123],	 abnormal	 airway	 proliferation	 [124],	 maintenance	 of	 barrier	
integrity	and	progressive	lung	tissue	scarring	[125].	They	both	are	activated	upon	bacterial	
or	viral	 infection	and	during	 inflammation	[126]	 [127]	 [128].	While	 this	 is	an	effective	and	
necessary	 response,	 it	 is	 suggested	 that	 exaggerated	 airway	 epithelial	 signaling	 in	 the	
chronic	state	may	enhance	inflammation	and	may	lead	to	damage	of	the	lung	structure.		
EGFR	functions	as	a	sensor	of	airway	epithelial	integrity	[129].	When	cells	have	intact	tight	
junctions	 EGFR	 is	 not	 activated.	 But	 disruption	 of	 the	 epithelial	 cell	 integrity,	 either	 by	
mechanical	 injury	or	cytokine	treatment	(TNF-α/IFN-γ),	 leads	to	EGFR	phosphorylation	and	
concomitant	inhibition	of	protein	phosphatase	2A	activity	[130].	Cigarette	smoke	exposure	
of	differentiated	HBEC	also	 leads	 to	damage	of	 the	 lung	 tissue	observed	as	destruction	of	
epithelial	cell	integrity,	loss	of	E-cadherin/β-catenin	complex	and	disappearance	of	cilia	[42].	
This	coincides	with	phosphorylation	and	peri-nuclear	trafficking	of	EGFR	[42]	suggesting	the	
importance	 of	 EGFR	 in	 maintenance	 of	 epithelial	 cell	 barrier	 integrity.	 The	 response	 of	
ADAM17	to	loss	of	pulmonary	epithelial	cell	integrity	has	been	also	shown	by	neuregulin-1	
(NRG-1)	shedding	and	concomitant	activation	of	human	epidermal	growth	factor	receptor-2	
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(HER2)	 [131].	This	 raises	 the	question	whether	and	how	EGFR	and	ADAM17	co-operate	 in	
sensing	responses	to	airway	injury.	
	
Taken	together,	EGFR	and	ADAM17,	expressed	by	airway	epithelial	cells,	have	emerged	as	
potential	therapeutic	targets	in	COPD	and	CF	lung	disease	[125]	[132].	Therefore,	we	aimed	
to	 understand	 the	 mechanism	 that	 provides	 a	 link	 between	 the	 loss	 of	 functional	 CFTR	
expression	and	the	EGFR/ADAM17	axis.	In	order	to	do	this,	we	studied	the	involvement	of	
EGFR	and	ADAM17	 in	models	of	COPD	and	CF	disease	 together,	 since	 it	 seems	 likely	 that	
they	share	molecular	mechanisms	and	therapeutic	options.	
	
	
	
	
	
Figure	3.	ADAM17	dependent	paracrine	and	autocrine	signaling.		
A	 Disintegrin	 and	 Metalloproteinase	 17	 (ADAM17),	 also	 known	 as	 a	 Tumor	 Necrosis	 Factor-α	
converting	enzyme	(TACE),	is	involved	in	the	immune	defense	mechanisms	mediated	by	the	epithelial	
cells.	 ADAM17	 releases	 extracellular	 domains	 of	 transmembrane	 proteins	 to	 produce	 soluble	
bioactive	 signaling	 proteins	 taking	 part	 in	 autocrine	 (activation	 of	 receptors	 within	 the	 same	
epithelial	 cell	 layer)	 and	 paracrine	 signaling	 (activation	 of	 cellular	 receptors	 on	 underlying	
neighbouring	cells,	also	termed	trans-activation).	Among	ADAM17	substrates	there	are	(1)	adhesion	
proteins	 (L-selectin,	 ICAM)	 (2)	 transmembrane	 mucins	 (MUC-1),	 (3)	 membrane	 bound	 cytokines	
(TNF-α),	 (4)	 growth	 factors	 (AREG)	 and	 other	 ligands	 of	 EGFR	 (TGF-α,	 EREG,	 HB-EGF,	 Epigen),	 (5)	
cytokine	 receptors	 (IL-6R,	 TNF-R);	 in	 this	 picture	 the	 examples	 of	 these	 proteins	 are	 presented.	
Ectodomain	 shedding	 provides	 the	 mechanism	 for	 membrane	 protein	 downregulation	 and	
subsequent	 initiation	 or	 inhibition	 of	 autocrine/paracrine	 signaling.	 For	 instance,	 shed	 IL-6R	 from	
epithelial	 cells	 transactivate	 gp130	 on	 the	 underlying	 myofibroblasts,	 whereas	 shed	 AREG	 from	
epithelial	 cells	 autocrinally	 activate	 EGFR	 on	 the	 neighboring	 epithelial	 cells	 or	 paracrinally	 on	 the	
underlying	fibroblasts.	ADAM17	natural	inhibitor	TIMP-3	inhibits	ADAM17	proteolytic	activity.		
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EGFR	and	ADAM17	are	important	in	developmental	processes		
ADAM17	knockout	mice	survive	between	17.5	embryonic	days	up	to	a	few	days	after	birth,	
underlining	the	need	of	the	ectodomain	shedding	in	development.	The	few	survivors	have	
defects	in	epithelium	and	lung	and	also	in	vascular	system,	eye,	hair,	heart,	and	skin	[133].	
Tissue	specific	deletions	of	ADAM17	or	hypomorphic	ADAM17	knock-in	demonstrate	an	 in	
vivo	 role	 of	 ADAM17	 in	 controlling	 inflammation	 and	 regeneration	 [134]	 [135].	 Similar	 to	
ADAM17-KO	 mice,	 EGFR-KO	 mice	 survive	 for	 up	 to	 8	 days	 after	 birth	 and	 suffer	 from	
impaired	epithelial	development	 in	several	organs,	 including	 lung,	 indicating	the	need	of	a	
functional	ADAM17/EGFR	axis	 for	proper	 functioning	and	development	of	 lung	epithelium	
[136].	
	
ADAM17	and	EGFR	crosstalk	
ADAM17	works	in	association	with	a	tyrosine	kinase	receptor	EGFR	by	shedding	most	of	its	
ligands	(e.g.	AREG,	HB-EGF,	TNF-α,	EPGN	(Epigen),	Epiregulin)	[116].	Only	two	EGFR	ligands,	
EGF	and	betacellulin	 are	 shed	by	ADAM10	 [137]	 [138],	 a	 close	 relative	of	ADAM17	 [116].	
Crosstalk	of	ADAM17	and	EGFR	in	inflammatory	signaling	transduction	is	also	defined	by	the	
establishment	 of	 a	 positive	 ADAM17/EGFR	 feedback	 loop	 likely	 involving	 activation	 of	
ADAM17	 via	 the	 EGFR/MAPK	 pathway	 [126]	 [139]	 (Figure	 4).	 The	 exact	 molecular	
mechanism	of	this	feedback	signaling	has	not	been	firmly	established.	
	
																						
	
	
Figure	 4.	 A	 positive	 ADAM17/EGFR	 feedback	 loop.	 	ADAM17/EGFR	 positive	 feedback	 loop	 likely	
involves	 activation	of	ADAM17	 via	 the	 EGFR/MAPK	pathway	 and	direct	 interaction	of	 ERK1/2	with	
ADAM17.	 Additionally,	 by	 cleavage	 of	 Notch1	 from	 a	 non-small	 lung	 carcinoma	 cell	 line	 ADAM17	
regulates	transcription	of	EGFR	mRNA	and	 increases	EGFR	expression	on	the	cell	surface,	providing	
other	mechanism	contributing	to	positive	feedback	regulation	of	the	ADAM17/EGFR	axis.	
	
	
	
ADAM17	regulates	transcription	of	EGFR	mRNA	by	cleavage	of	Notch1	and	increases	EGFR	
expression	 on	 the	 cell	 surface,	 as	 shown	 in	 a	 non-small	 lung	 carcinoma	 cell	 line	 [140],	
providing	another	positive	 feedback	mechanism	of	 the	ADAM17/EGFR	axis.	 In	our	 studies	
we	 aimed	 to	 understand	 the	 mechanism	 of	 cigarette	 smoke	 induced	 activation	 of	 the	
EGFR/ADAM17	cascade	(Chapter	2),	and	the	role	of	CFTR	in	this	process	(Chapter	3).		
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The	 role	 of	 ADAM17	 and	 EGFR	 in	 balanced	 regulation	 of	 lung	 inflammation	 and	
regeneration	
ADAM17,	expressed	in	human	bronchial	epithelial	cells	from	the	large	and	small	bronchi,	in	
lung	 smooth	 muscle	 cells,	 lung	 muscular	 vessels,	 alveolar	 macrophages,	 perivascular	
leukocytes	and	 lung	endothelial	cells,	 is	an	 important	regulator	of	 lung	tissue	homeostasis	
[132]	[141]	[142]	and	development	[133],	pro-	and	anti-inflammatory	responses	[116]	and	is	
involved	in	tissue	regeneration	[139]	[143]	[144].	
	
The	anti-	and	pro-inflammatory	properties	of	the	EGFR/ADAM17	signaling	pathway	are	very	
much	 context	 dependent	 [116].	 For	 instance,	 in	 vitro	 in	 airway	 epithelial	 cells	 ADAM17	
together	 with	 EGFR	 induces	 mRNA	 expression	 and	 protein	 release	 of	 IL8,	 a	 neutrophil	
chemotactic	 factor	 that	 promotes	 inflammation	 [121]	 [145].	 Whereas,	 by	 shedding	 TNF	
receptor	 type	 2	 (TNFR2)	 [146],	 which	 antagonises	 TNF-α,	 ADAM17	 exhibits	 also	 anti-
inflammatory	 properties	 [147].	 Thus	 it	 is	 likely	 that	 the	 type	 of	 stimulus	 and	 substrate	
selection	determine	the	nature	of	the	EGFR	and	ADAM17	activity	[148]	[149]	[150].		
	
The	 involvement	 of	 EGFR/ADAM17	 signaling	 in	 tissue	 regeneration	 encompasses	 wound	
healing	[139],	proliferation	[143]	[144],	differentiation	[151]	[152]	and	cell	migration	[153].	
However,	when	 pathogenic	 stimuli	 or	 cell	 stress	 induces	 ADAM17	 and	 EGFR	 activity,	 this	
contributes	 to	 cancer	 development	 [116]	 [154]	 [155]	 [156]	 and	 cardiac	 tissue	 remodeling	
after	an	infarct	[157].		
	
Due	to	the	involvement	of	ADAM17/EGFR	paracrine	and	autocrine	signaling	in	several	lung	
disorders	 [125]	 [132],	 modulation	 of	 ADAM17	 and	 EGFR	 activation	 in	 COPD	 and	 CF	 is	
important,	 to	 keep	 the	 balance	 between	 anti-inflammatory	 processes	 and	 promotion	 of	
inflammation,	 and	 also	 between	 regeneration	 and	 excessive	 tissue	 remodeling.	 However,	
the	mechanism	of	this	modulation	is	still	not	fully	understood.		
	
Does	CFTR	deficiency	affect	the	ADAM17/EGFR	axis?		
EGFR	activation	has	been	observed	in	NCI-H292	cells	after	inhibition	of	CFTR	(inh-172)	[49].	
This	CFTR-dependent	induction	of	EGFR	activity	was	likely	ADAM17	dependent	[49].	In	CFTR	
deficient	IB3	cells	EGFR	phosphorylation	was	markedly	diminished	by	inhibition	of	ADAM17	
(siRNA	knockdown	and	broad	 spectrum	MMPs	 inhibitor	 TAPI-1),	 plausibly	due	 to	 reduced	
shedding	of	EGFR	substrates.	Interestingly,	the	inhibitory	effect	was	much	lower	in	C38	cells	
with	 corrected	 CFTR	 expression	 [49],	 suggesting	 that	 aberrant	 ADAM17	 activity	 may	
contribute	 to	 induced	 activation	 of	 EGFR	 in	 CFTR	 deficiency.	 However,	 the	 relationship	
between	ADAM17/EGFR	signaling	and	CFTR	deficiency	 is	 still	poorly	understood	 [158]	and	
may	 involve	a	variety	of	actions.	As	a	consequence	of	ADAM17-mediated	 release	of	EGFR	
ligands,	 the	 activation	 of	 downstream	 signaling	 occurs	 (i.e.	MEK/ERK,	 PI3K/AKT,	 STAT3	 or	
mTOR),	which	suggest	that	EGFR/ADAM17	pathway	may	be	also	abnormal	in	CF	and	COPD	
lung	diseases	[125]	[132].		
	
In	our	laboratory	it	was	observed	that	F508del	CFTR	mutant	mice	compared	to	normal	mice	
develop	spontaneous	and	progressive	chronic	lung	inflammation	[25]	(Chapter	4,	Appendix).	
Additionally,	 naphthalene	 provoked	 injury	 induced	 abnormal	 responses	 in	 mutant	 mice	
compared	 to	 normal	 [159]	 with	 stronger	 expression	 of	 AREG,	 IL-6,	 elastin	 and	 collagen	
mRNA	 levels	 seven	 days	 after	 injury.	 Exaggerated	 responses	 mediated	 by	 the	
EGFR/ADAM17/ERK1/2/MAPK	 pathway	 have	 also	 been	 reported	 in	 CFTR	 deficient	 cells.	
Martel	et	al.	showed	that	CFTR	deficient	cell	line	(CuFi-1)	in	response	to	heat-inactivated	P.	
aeruginosa	produce	more	 IL-8	 than	non-CFTR	deficient	 cell	 line	 (NuLi-1)	 and	 this	 involves	
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EGFR	 phosphorylation	 and	 ERK1/2	 activation	 [160].	 However,	 CuFi	 and	 NuLi	 are	
independent	 subclones	 and	 genetically	 different,	 and	 therefore	 not	 comparable	 models.	
Further	studies	by	Kim	et	al.	showed	that	inhibition	of	CFTR	with	CFTR-inh172	induces	IL-8	
production	in	ADAM17	and	EGFR	dependent	manner	and	involves	binding	of	IL-1α	to	IL-1R	
[49].	 These	 observations	 led	 to	 the	 hypothesis	 that	 ADAM17	 dependent	 IL-6/IL-6R/gp130	
and	AREG/EGFR	pathways	contribute	to	abnormal	resolution	of	injury	and	inflammation	in	
CF	lung	disease.		
	
These	data	 together	 suggest	altered	 responses	of	 the	ADAM17-EGFR	signaling	pathway	 in	
CFTR	deficiency.	However,	most	of	the	studies	cited	here	use	undifferentiated,	submerged	
immortalized	cell	lines	[161],	compare	different	cell	lines	(like	CuFi	and	NuLi	or	IB3	and	C38	
cells)	 [49]	 [160]	 [162]	 [163]	 or	 use	 a	 CFTR	 inhibitor	 [49]	 with	 reported	 off-target	 effects	
[164].	 Therefore,	 we	 addressed	 the	 mechanism	 by	 which	 CFTR	 deficiency	 activates	 the	
EGFR/ADAM17	axis	in	differentiated	CFBE	cells	with	inducible	CFTR	expression	(Chapter	3),	
thereby	overcoming	both	the	high	donor	variation	observed	in	primary	airway	cell	culture,	
and	the	genetic	and	epigenetic	variability	of	distinct	immortalized	cell	lines.	
	
Release	of	cytokines,	growth	factors	and	mucins	depends	on	ADAM17/EGFR	signaling	
External	 stress	 factors	 like	 oxidative	 stress,	 viral	 and	 bacterial	 toxins,	 and	 CS	 exposure	
activate	 the	 EGFR/ADAM17	 signaling	 pathway.	 Several	 studies	 showed	 that	 pathogens	
inhaled	 into	 the	 airways,	 or	 exposure	 of	 airway	 epithelial	 cells	 to	 other	 external	 stimuli	
activate	 toll-like	 receptors	 (TLR)	 [165]	 [166]	 [167]	 and	 G-coupled	 receptors	 (GPCR)	 [168]	
that	 cross	 talk	with	downstream	EGFR/ADAM17	 signaling.	 	 As	 a	 result	 of	 cigarette	 smoke	
extract	exposure,	secretion	of	downstream	proinflammatory	cytokines	(including	IL8)	[121]	
[169]	 [145],	 growth	 factors	 (TGFα,	 AREG,	 HB-EGF)	 [121],	 mucins	 (MUC5AC)	 and	
phosphorylated	MUC1	is	induced	in	an	ADAM17/EGFR	dependent	manner	[119]	[170]	[171]	
[42].	 Rhinovirus	 infection	 of	 airway	 epithelial	 cells	 showed	 that	 this	 cascade	 of	 events	
involves	 ERK1/2,	MAPK	 and	 p38	MAP	 kinase	 [127]	 [172].	 Particular	matter	 exposure	 also	
induces	 IL-8	secretion	 in	an	EGFR/ERK1/2/MAPK	dependent	manner,	but	does	not	 involve	
p38	 MAP	 kinase	 [173].	 Upon	 activation	 of	 the	 ERK	 or	 p38	 MAPK	 pathway,	 ADAM17	
dissociates	from	an	endogenous	extracellular	tissue	inhibitor	of	metalloproteinase-3	(TIMP-
3)	[174]	[175]	[176]	[177],	accumulates	on	the	cell	surface	[157]	[178]		and	induces	release	
of	 TGF-α	 [157]	 [178].	 Acrolein,	 an	 active	 component	 of	 cigarette	 smoke,	 which	 induces	
MUC5AC	 mRNA	 in	 an	 ADAM17	 and	 EGFR	 dependent	 manner,	 also	 decreases	 TIMP-3	
transcript	 levels,	suggesting	a	role	of	TIMP-3	 in	ADAM17	activation.	However	 in	TIMP3-KO	
cells	PMA-stimulated	shedding	of	ADAM17	is	not	affected,	which	contradicts	the	model	 in	
which	pre-bound	TIMP3	needs	to	be	removed	for	ADAM17	activation	[138]	and	supporting	
that	ADAM17	can	be	rapidly	activated	by	conformational	changes	 [138]	 [179]	 [180].	Thus,	
the	role	of	TIMP-3	in	HBEC	signaling	is	still	unclear.		
	
Is	Redox	potential	a	link	between	CFTR	deficiency	and	ADAM17/EGFR	signaling?	
The	 intra	and	extracellular	 redox	potential	 changes	 in	 response	 to	physiological	processes	
and	in	pathophysiological	conditions	[181].	Reactive	oxygen	species	(ROS),	produced	during	
cellular	stress	[85],	is	an	important	regulator	of	redox	state	and	is	also	involved	in	activation	
of	 the	 EGFR/ADAM17	 signaling	 pathway,	 affecting	 TGF-α	 and	 AREG	 release	 and	 mucin	
expression	[119]	[120]	[165]	[173].	Some	studies	point	towards	the	role	of	NADPH	oxidases	
(NOX),	 in	 particular	 dual	 oxidase	 1	 (DUOX1)	 [120]	 [165]	 [182]	 or	 dual	 oxidase	 2	 (DUOX2)	
[166],	 which	 produce	 ROS	 at	 an	 extracellular	 or	 possibly	 intra-vesicular	 domain.	 ATP-
mediated	 DUOX1	 activation	 has	 been	 shown	 to	 involve	 a	 TGF-α/ADAM17/ERK1/2/EGFR	
signaling	pathway	[182].	Other	studies	point	towards	intracellular	NOX/ROS	dependent	SRC	
activity	 in	 EGFR/ADAM17	 activation	 [139].	 Recent	 studies	 indicated	 the	 involvement	 of	
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DUOX1	 in	 allergen	 dependent	 SRC/EGFR	 activation	 in	 airway	 cells	 [183].	 However,	 the	
mechanism	by	which	ROS	affects	the	EGFR/ADAM17	signaling	pathway	in	intact	airway	cells	
is	likely	highly	complex	and	still	remains	not	well	understood.	
	
ROS	 not	 only	 affects	 signaling	molecules	 in	 the	 EGFR/ADAM17	 pathway,	 but	 it	 has	 been	
shown	 that	 ADAM17	 [180]	 and	 EGFR	 [184]	 are	 redox	 sensitive	 proteins.	 EGFR	 has	
intracellular	cysteine	residues	in	the	active	site	that	are	direct	targets	of	ROS	and	determine	
EGFR	kinase	activity,	 likely	 through	association	of	EGFR	with	NADPH	oxidase,	NOX2	 [184].	
ADAM17	activity,	however,	 is	regulated	by	thiol-disulfide	 isomerisation	 in	the	extracellular	
MPD	domain	mediated	by	protein	disulfide	isomerase	(PDI),	an	oxidoreductase	sensitive	to	
redox	changes	[179].	PDI,	by	direct	interaction	with	the	membrane	proximal	domain	(MPD)	
[180],	 changes	 the	disulfide	bridge	pattern	and	 thus	 the	conformation	of	 the	extracellular	
protease	 domain	 from	 open,	 active	 to	 closed,	 inactive	 state,	 leading	 to	 the	 inhibition	 of	
ADAM17	proteolytic	activity	(Figure	5)	[111]	[112]	[113]	[114]	[115]	[117]	[179]	[180].	Redox	
dependent	conformational	changes	likely	make	ADAM17	sensitive	to	the	extracellular	redox	
potential	[180].	These	findings	are	in	line	with	previous	observations	showing	that	ADAM17	
activity	 is	 redox	 sensitive	 [185]	 and	 blocking	 PDI	 induces	 ADAM17-mediated	 L-	 selectin	
shedding	[186].	
	
	
Figure	5.	ADAM17	is	a	redox	sensitive	protein.		
The	 ADAM17	membrane	 proximal	 domain	 (MPD),	which	 is	 in	 close	 proximity	 to	 the	 active	 site,	 is	
sensitive	 to	extracellular	 redox	changes.	This	 redox-sensitive	ADAM17	activity	 is	 regulated	by	 thiol-
disulfide	isomerisation	mediated	by	protein	disulphide	isomerase	(PDI),	an	oxidoreductase	sensitive	
to	 redox	 changes.	 PDI	 by	 direct	 interaction	 with	 membrane	 proximal	 domain	 (MPD)	 changes	 the	
disulfide	bridge	pattern	and	thus	the	conformation	of	the	extracellular	protease	domain	from	open,	
active	 to	 closed,	 inactive	 state,	 leading	 to	 the	 inhibition	 of	 ADAM17	 proteolytic	 activity.	 Redox	
sensitive	conformational	changes	likely	make	ADAM17	sensitive	to	the	extracellular	redox	potential.		
	
Since	 CFTR	deficiency	 is	 thought	 to	 increase	ROS	 levels	 [187],	which	 in	 turn	may	 activate	
ADAM17	and	EGFR	[139]	and	inactivate	protein	phosphatases	[188],	we	propose	that	it	is	a	
link	between	EGFR/ADAM17	signaling	and	CFTR	deficiency.	CFTR	deficiency	may	also	affect	
the	redox	potential	of	ASL,	due	to	CFTR	mediated	trans-epithelial	glutathione	transport	at	
the	 apical	 membrane,	 which	 serves	 as	 a	 natural	 antioxidant	 [8].	 Thus,	 by	 using	 the	
ratiometric	 fluorescence	 measurements	 [181],	 we	 questioned	 whether	 extracellular	 or	
intracellular	redox	potential	is	affected	by	CFTR	and	takes	part	in	CFTR-mediated	activation	
of	EGFR/ADAM17	pathway	(Chapter	2).		
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All	 in	all,	 these	studies	 show	the	 involvement	of	different	 regulatory	molecules	 leading	 to	
activation	of	EGFR/ADAM17	signaling,	however,	the	exact	cascade	of	events	is	still	not	well	
defined.	 In	 order	 to	 understand	 the	 regulation	 of	 EGFR/ADAM17	 signaling,	 we	 aimed	 to	
define	the	molecules	regulating	ADAM17	shedding	activity	in	CF	and	COPD.	SRC	[139],	ROS	
[139],	P38MAP	[143]	and	ERK1/2	[189]	appear	to	be	the	most	important	modulators	of	the	
ADAM17/EGFR	 pathway.	 Therefore,	 this	 thesis	 focuses	 on	 the	 role	 of	 these	molecules	 in	
EGFR/ADAM17	signaling	cascade	in	advanced	COPD	and	CF	cellular	models	(Chapter	2	and	
Chapter	3).	
	
1.6	 ROLE	 OF	 AREG	 IN	 EGFR/ADAM17	 DEPENDENT	 MUCUS	 AND	 CYTOKINE	 SECRETION,	
AND	REMODELING	
Amphiregulin	(AREG)	 is	an	ADAM17	substrate	and	EGFR	agonist,	expressed	ubiquitously	 in	
the	human	lung	[190]	by	human	airway	epithelial	cells	[121],	smooth	muscle	cells	[191]	and	
fibroblasts	 [192].	 AREG	 is	 also	 expressed	 by	 infiltrating	 and	 resident	 lung	 myeloid	 cells,	
including	activated	macrophages	[193],	eosinophils	 [194],	dendritic	cells	 [195],	neutrophils	
[196]	 and	 mast	 cells	 [197].	 Human	 AREG	 is	 synthetized	 as	 an	 N-glycosylated	 trans-
membrane	precursor	(50	kDa)	[198]	with	a	basolateral	sorting	motif	[199]	and	shed	mainly	
by	ADAM17	 [126].	 Proteolytic	 cleavage	of	 the	AREG	extracellular	 domain	 releases	 several	
AREG	soluble	forms,	predominantly	an	α-N-glycosylated	43	kDa	form	[198],	which	is	one	of	
the	EGFR	ligands,	with	lower	affinity	to	EGFR	than	EGF	and	TGF-α	.	
	
AREG	is	induced	in	lung	disease	
AREG	 is	 involved	 in	 inflammation	 and	 repair	 responses	 through	 autocrine	 and	 paracrine	
activation	 of	 EGFR,	 and	 generally	 induced	 in	 lung	 disease	 [200].	 In	 CF	 sputum	 samples,	
elevated	levels	of	AREG	have	been	shown	in	airway	blood	neutrophils	[196].	Until	now,	the	
airway	epithelial	secretion	of	AREG	has	not	been	investigated	in	CF	and	COPD	condition	in	
comparison	to	controls	(Chapters	2	and	3).	However,	in	lung	biopsies	from	asthma	patients	
more	AREG	is	expressed	than	in	healthy	controls	[190],	suggesting	that	this	is	also	a	case	in	
CF	and	COPD	lung	disease.	Other	studies	showed	that	in	sputum	of	asthma	patients	AREG	is	
upregulated	only	during	an	acute	attack,	which	contrasts	with	the	presence	of	EGF	up	to	7	
days	after	an	acute	asthma	attack	[201],	suggesting	its	role	in	a	quick	cellular	responses	to	
the	 triggers.	 Increase	 of	 AREG	 in	 sputum	 samples	 from	 children	 with	 asthma	 negatively	
correlates	with	lung	function	[202]	and	positively	correlates	with	the	number	of	eosinophils	
[203].	
	
Regulation	of	AREG	transcription	and	shedding	
In	vitro	AREG	mRNA	expression	and	protein	release	are	induced	upon	exposure	to	different	
stress	 factors	 like	 histamine	 [190],	 diesel	 exhaust	 particles	 [204],	 cigarette	 smoke	 extract	
exposure	 [121]	 [124]	 [205]	 and	 rhinoviruses	 [206]	 [127].	 Human	 airway	 trypsin-like	
protease,	a	serine	protease	 found	 in	 the	sputum	of	patients	with	chronic	airway	diseases,	
induces	 AREG	 mRNA	 by	 the	 protease-activated	 receptor-2	 (PAR-2)/ERK	 pathway	 in	 the	
human	 airway	 cell	 line	 (NCI-H292)	 [207].	 Du	 et	 al	 showed	 that	 cigarette	 smoke	 extract	
triggered	transcription	of	AREG	is	cAMP	and	EGFR	dependent	in	the	epithelial	cell	line	MSK-
Leuk1,	and	 involves	binding	of	 the	cAMP-responsive	element	binding	protein	 to	 the	AREG	
gene	 promoter	 in	 an	 EGFR	 dependent	 manner	 [208].	 Also,	 AREG	 protein	 secretion	 is	
dependent	on	the	EGFR/ERK1/2/MAPK	pathway	in	an	airway	epithelial	cell	line	treated	with	
particulate	matter	[173].	
	
These	data	together	suggest	the	role	of	EGFR/ADAM17	signaling	in	regulation	of	AREG	and	
IL-6R	 mRNA	 production	 and	 shedding	 in	 COPD	 human	 airway	 epithelial	 cells	 and	 in	
CFBE41o-	 cells	 with	 inducible	 CFTR	 expression,	 which	 is	 covered	 by	 Chapter	 2	 and	 3,	
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respectively.	
AREG	affects	mucus	and	cytokine	secretion	
In	 asthmatic	 patients	 AREG	 produced	 by	mast	 cells	 enhances	mucus	 production	 [209].	 In	
vitro	 the	AREG-dependent	MUC5AC	mRNA	level	 induction	has	been	shown	upon	exposure	
to	 particulate	 matter	 in	 NCI-H292	 cells	 [210].	 Importantly,	 prolonged	 exposure	 to	 AREG	
induces	 MUC5AC	 expression	 in	 NHBE-ALI	 [201]	 and	 promotes	 also	 TNF-α-induced	 IL-8	
secretion	 from	NCI-H292	 cells	 [211].	 Interestingly,	 in	 vitro	 eosinophil-airway	epithelial	 cell	
line	interaction	induces	AREG	dependent	secretion	of	MUC5AC,	TGF-β1,	and	IL-8	in	culture	
supernatants	 [203].	All	 these	 findings	show	an	 important	 role	of	AREG	 in	mucus	secretion	
and	cytokine	release	in	airway	epithelial	cells.	
	
AREG	in	paracrine	signaling	and	tissue	remodeling	
The	role	of	airway	epithelial	AREG	in	activation	of	underlying	tissues	has	also	been	studied.	
Conditioned	media	from	AREG-stimulated	airway	epithelial	cells	 induced	expression	of	IL8,	
VEGF,	COX-2	and	AREG	in	human	airway	smooth	muscle	cells	(HASMC),	providing	proof	for	
crosstalk	 between	 epithelial	 cells	 and	HASMC	 in	 an	 AREG-dependent	manner	 [191],	 	 and	
underlined	the	important	role	of	AREG	in	paracrine	signaling.	Inhibition	of	AREG	or	EGFR	in	
TGF-β1-stimulated	 lung	 fibroblasts	 diminished	 AREG-dependent	 fibroblast	 proliferation,	
expression	 of	 α-smooth	 muscle	 actin	 and	 collagen	 [212],	 strongly	 suggesting	 a	 role	 of	
AREG/ADAM17/EGFR	signaling	in	pulmonary	fibrosis	 in	vivo.	AREG	stimulation	also	induces	
airway	 smooth	muscle	 cell	 (ASM)	 proliferation,	 which	 leads	 to	 airway	 remodeling	 in	 vivo	
[213].	 The	 AREG/EGFR/ERK1/2/MAPK	 signaling	 pathway	 is	 also	 involved	 in	 cell	 migration	
through	 extracellular	 matrix	 (ECM),	 due	 to	 plasmin-dependent	 degradation	 of	 matrix	
proteins	in	MSK-Leuk1	cells	treated	with	a	saline	extract	of	cigarette	smoke	(CSE)	[214].	CSE	
and	 exogenous	 AREG	 treatment	 also	 lead	 to	 induction	 of	 DNA	 synthesis	 in	 an	 EGFR	
dependent	 manner,	 providing	 further	 proof	 of	 AREG	 and	 EGFR	 involvement	 in	 cell	
proliferation	[208].	
	
These	data	together	suggest	that	exaggerated	and	chronic	AREG	release	may	contribute	to	
mucus	 plugging	 and	 excessive	 inflammation	 and	 tissue	 remodeling	 in	 CF	 and	 COPD.	
Therefore,	 the	AREG/EGFR/ADAM17	signaling	pathway	 is	a	potential	 therapeutic	 target	 to	
regulate	 both	 inflammation	 and	 lung	 cell	 proliferation	 and	migration,	which	may	 prevent	
lung	 tissue	 inflammation,	 remodeling	and	 fibrosis	 in	COPD	and	CF.	However,	AREG	 is	only	
one	of	the	many	players	involved	in	lung	tissue	autocrine	and	paracrine	signaling	leading	to	
lung	pathology.	There	is	no	available	literature	presenting	intervention	in	AREG	function	in	
clinical	trials.	
	
The	role	of	AREG	and	EGFR	trafficking	in	cellular	signaling		
The	 majority	 of	 EGFR	 signaling	 is	 believed	 to	 occur	 at	 the	 plasma	 membrane.	 However,	
many	studies	show	that	upon	ligand-dependent	activation,	EGFR	is	rapidly	internalized	into	
endosomes,	where	hypothetically	it	may	continue	to	signal	[215]	[216]	[217]	[218]	[219].	Up	
till	now,	the	endocytic	transport	of	EGFR	has	been	interpreted	as	a	signal	attenuation,	due	
to	 lysosomal	 degradation	 [220].	 However,	 recent	 reviews	 elaborate	 on	 the	 role	 of	 EGFR	
endocytic	 trafficking	 and	 recycling	 in	 active	 signal	 transduction	 	 [220]	 [221]	 [222]	 [223]	
[224].		
	
The	 full-length	 forms	 of	 AREG	 and	 other	 EGFR	 substrates	 have	 also	 been	 observed	 in	
intracellular	 vesicular	 compartments,	 i.e.	 lysosomes	 [225]	 and	 endosomes	 [199].	 Mono-
ubiquitination	of	 pro-AREG	at	 Lys240	 (pro-AREGmUb)	 leads	 to	 quick	 endocytosis	 of	AREG	
from	 the	 cell	 surface	and	 its	 localization	 into	early	endosomes	 [226].	AREG	has	been	also	
observed	 in	 exosomes	 negative	 for	 the	 ER	marker	 calreticulin	 [224].	 Higginbotham	 et	 al.	
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showed	 the	 importance	 of	 paracrine	 exosomal	 AREG-mediated	 signaling	 in	 breast	 cancer	
cells	[224].	Recipient	LM2-4175	cells	rapidly	take	up	AREG	containing	exosomes	in	an	EGFR-
dependent	manner.	 In	 comparison	 to	 other	 EGFR	 substrates,	 namely	 TGF-α	 and	 HB-EGF,	
exosomal	 AREG	uptake	 enhanced	 invasion	 of	 LM2-4175	 cells	 through	 the	Matrigel	 to	 the	
recipient	 cells,	 which	 were	 placed	 under	 the	 Transwell	 filter	 [224].	 These	 exosomes	 also	
improve	wound	healing.		
	
Taken	 together,	 presented	 data	 indicate	 the	 existence	 of	 a	 non-canonical	 trafficking	
pathway	 of	 EGFR-mediated	 signaling	 after	 EGFR	 endocytosis.	 So	 far,	 these	 studies	 largely	
focus	on	deregulated	EGFR	trafficking	in	the	context	of	carcinogenesis.	However,	the	EGFR	
trafficking	 in	 CFTR	 deficiency	 and	 its	 effect	 on	 the	 signaling	 cascade	 has	 not	 been	
investigated	 yet.	 As	 a	 first	 step	 to	 study	 the	 role	 of	 ADAM17	 substrate	 and	 receptor	
trafficking,	we	investigated	the	intracellular	localization	of	EGFR,	ADAM17	and	its	substrates	
in	CS	treated	ALI-HBEC	and	in	CFBE41o-	cells	with	induced	CFTR	activity	(Chapter	2	and	3).	
	
1.7	ROLE	OF	IL-6-R	IN	HUMAN	LUNG	INFLAMMATION	AND	FIBROSIS	
Pro	and	anti-inflammatory	responses	of	IL-6R	
The	IL-6	co-receptor	(IL-6R)	is	a	transmembrane	receptor	type	I	that	in	classic	signaling	binds	
to	IL-6,	which	evokes	an	association	with	the	homodimer	of	signal	transducing	glycoprotein,	
gp130.	 This	 trimer	 dimerises	 to	 form	 a	 hexameric	 complex	 composed	 of	 IL-6,	 IL-6R	 and	
gp130	[227]	(Figure	6).	 IL-6R	can	also	evoke	a	trans-mediated	signaling	cascade,	when	it	 is	
shed	close	 to	 the	 transmembrane	region	by	ADAM17	 [228]	or	ADAM10	 [229]	 [228]	 [230].	
Subsequently,	γ-secretase	cleaves	the	IL-6R	C-terminal	fragment,	which	is	rapidly	degraded,	
so	 intracellular	 part	 does	 not	 take	 part	 in	 further	 signaling	 [231].	 sIL-6R	 can	 be	 also	
generated	 by	 alternative	 splicing	 [232]	 [233]	 [234],	 however	 it	 is	 thought	 that	 shedding	
rather	 than	 the	alternative	 splicing	 takes	part	 in	 regulated	generation	of	 the	 sIL6-R	 [146].	
Both	 the	 alternatively	 spliced	 form	 and	 the	 shed	 form	 of	 sIL-6R	 can	 create	 functional	
complexes	 with	 IL-6	 (IL-6/sIL-6R)	 to	 dimerize	 and	 trans-activate	 gp130	 finally	 creating	 a	
hexameric	complex	on	the	underlying	myofibroblasts	[227]	[232]	[235]	[236]	(Figure	6).	The	
soluble	 form	 of	 gp130	 (sgp130)	 selectively	 blocks	 trans-signaling	 and	 is	 described	 as	 a	
natural	inhibitor	of	IL-6R	trans-signaling	in	vivo	[237]	[238]	[239].		
It	 is	 thought	 that	 IL-6	 activated	 membrane	 bound	 IL-6R	 has	 anti-inflammatory,	 anti-
apoptotic	 and	 regenerative	 properties	 [146]	 [235]	 [240]	 [241].	 In	 contrast	 to	 classic	 IL-6R	
signaling	 in	 which	 IL-6	 binds	 to	 membrane	 bound	 IL-6R	 associating	 with	 gp130,	 trans-
signaling	 responses	 mediated	 by	 IL-6/sIL-6R	 complexes	 binding	 to	 gp130	 are	 thought	 to	
maintain	inflammation	and	promote	inflammation-associated	cancer	[146]	[235]	[242]	[243]	
(Figure	6).	IL-6R-mediated	signaling	leads	to	activation	of	STAT3	[239]	[244],	ERK	[245]	and	
PI3K	[246],	linking	this	signaling	pathway	with	the	EGFR/ADAM17	axis,	which	also	activates	
STAT3	through	a	different	pathway.	
	
IL-6R	expression	is	restricted	to	specific	cell	types	
IL-6R	expression	is	restricted	to	several	cell	types,	such	as	lymphoid	cells	(megacaryocytes,	
neutrophils,	 monocytes/macrophages,	 leukocytes,	 certain	 lymphocytes),	 hepatocytes	 and	
airway	epithelial	cells	[146]	[246]	[247]	[248].	Cells	that	do	not	express	IL-6R,	but	do	express	
gp130	 can	 still	 transduce	 IL-6	 signals	 via	 binding	 of	 IL-6/sIL-6R	 complexes.	 Many	 cells	
including	smooth	muscle	cells	 [249]	and	endothelial	cells	 [250]	are	only	responsive	to	 IL-6	
through	IL-6/sIL-6R	trans-signaling	[249]	[250]	(Figure	6).		
	
The	role	of	IL-6R	in	inflammation	and	remodeling	
Bacterial	toxins,	bacterial	metalloproteinases	and	apoptosis	are	known	to	stimulate	release	
of	sIL-6R.	It	has	been	shown	that	in	polarized	airway	epithelial	cell	lines	bacterial	treatment	
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induces	 shedding	of	 sIL-6R	 [248].	Expression	of	 IL-6	and	 sIL-6R	 is	 increased	 significantly	 in	
serum	 and	 lung	 biopsies	 from	 adenocarcinoma	 patients	 [243].	 Further,	 in	 an	
adenocarcinoma	mouse	model	blocking	of	the	sIL-6R	mediated	trans-signaling	with	an	anti-
IL-6R	 antibody	 or	 the	 inhibitor	 sgp130Fc	 alleviates	 lung	 cancer	 pathogenesis	 showing	 the	
importance	of	IL-6R	signaling	in	tumour	signaling	[243],	proliferation	and	migration	[251].	
	
	
Figure	6	Classic	and	trans-signal	activation	of	 IL-6R	signaling.	 In	classic	signaling	membrane	bound	
IL-6R	 stimulated	 with	 autocrinally	 or	 paracrinally	 secreted	 IL-6	 associates	 with	 the	 homodimer	 of	
signal	 transducing	 glycoprotein,	 gp130	 to	 activate	 downstream	 molecules,	 like	 STAT-3.	 In	 trans-
signaling	soluble	form	of	IL-6R	(sIL-6R)	generated	either	by	ADAM17	or	by	alternative	splicing	binds	
to	 IL-6	 and	 this	 IL-6/IL-6R	 complex	 activates	 gp130	 on	 the	 airway	 epithelial	 cells	 (autocrine	 IL-6R	
trans-signaling)	 or	 underlying	 fibroblasts/myoblasts/smooth	muscle	 cells	 that	 do	 not	 express	 IL-6R	
(paracrine	IL-6R	trans-signaling),	but	express	gp130	to	evoke	activation	of	downstream	molecules,	for	
instance	STAT-3	signaling.	
	
However,	the	role	of	IL-6R	in	CF	and	COPD	has	not	been	studied	in	detail.	In	COPD	patients,	
elevated	 levels	 of	 IL-6R	 have	 been	 observed	 in	 peripheral	 blood	 leukocytes	 [252]	 and	
sputum	 samples	 [189].	 Recently,	 genetic	 variants	 of	 IL-6R	 have	 been	 linked	 with	 lung	
function	 [253]	 and	 COPD	 severity	 [254].	 Elevated	 levels	 of	 IL-6R	 were	 also	 detected	 in	
protein	lysates	from	lungs	of	the	patients	with	idiopathic	pulmonary	fibrosis	(IPF),	which	is	a	
lethal	 lung	 disease	 with	 progressive	 fibrosis	 [255].	 In	 contrast	 to	 elevated	 IL-6R	 levels	 in	
sputum	of	 COPD	patients	 [189]	 and	 in	 bronchoalveolar	 lavage	 fluids	 (BALF)	 from	patients	
with	allergic	asthma	[256],	the	levels	of	sIL-6R	in	BALF	form	CF	patients	were	not	different	in	
comparison	 to	 control	 [257].	 This	 was	 explained	 by	 enhanced	 degradation	 of	 sIL-6R	 by	
serine	 proteases.	 Furthermore,	 it	 is	 not	 evident	what	 the	 impact	 of	 luminal	 IL6-R	 on	 the	
activity	of	the	sub-epithelial	tissue	is,	which	is	separated	from	the	lumen	by	tight	junctions.		
	 31	
Shedding	 of	 IL6-R	 from	 epithelial	 cells	 occurs	 mainly	 towards	 the	 basal	 side	 (Chapter	 2)	
[248].	 Importantly,	 in	 bleomycin	 challenged	 murine	 lungs	 inhibition	 of	 sIL-6R	 by	
intraperitoneal	injection	of	a	recombinant	decoy	receptor	(gp130Fc)	attenuates	pulmonary	
fibrosis	 observed	 as	 reduction	 in	 myofibroblasts,	 fibronectin,	 and	 collagen,	 whereas	
activation	 of	 IL-6	 trans-signaling	 in	 cell	 lines	 enhances	 fibroblast	 proliferation	 and	
extracellular	 matrix	 protein	 production	 [255],	 which	 are	 the	 hallmarks	 of	 the	 pulmonary	
fibrosis	progression.		
Together	these	data	show	the	importance	of	IL-6R	trans-signaling	in	inflammation	and	lung	
remodeling	[24].	We	focused	our	studies	on	the	mechanism	regulating	the	IL-6R	mRNA	and	
protein	shedding	from	COPD	airway	epithelial	cells	(Chapter	2).		
Species	specificity	of	IL-6R	signaling		
IL-6R	 is	a	 substrate	 for	both	ADAM17	and	 its	close	 relative	ADAM10	 [229].	 IL-6R	needs	 to	
bind	IL-6	to	evoke	downstream	signaling,	neither	IL-6R	alone	nor	IL-6	has	affinity	for	gp130	
[258].	 Species	 differences	 in	 IL-6R	 mediated	 signaling	 have	 been	 observed.	 Human	 IL-6	
stimulates	 human	 and	 murine	 cells,	 whereas	 murine	 IL-6	 only	 stimulates	 murine	 IL-6R	
signaling	[259].	Because	of	this	species	specificity	transgenic	mice	expressing	human	sIL-6R	
from	a	liver	promotor	did	not	bind	the	endogenous	murine	IL-6,	and	as	a	consequence	the	
transgenic	animals	do	not	have	a	 transgene	specific	phenotype	 [259]	 [260].	Garberts	et	al	
for	 the	 first	 time	 questioned	 the	 species	 specificity	 of	 IL-6R	 shedding	 by	 showing	 that	
human	 IL-6R	 is	 a	 substrate	of	human	ADAM17,	but	murine	 IL-6R	 is	 a	 substrate	of	murine	
ADAM10	[261].	Subsequently,	Schumacher	et	al.	revealed	that	trigger-induced	shedding	of	
both	human	and	mouse	IL-6R	is	mediated	by	murine	ADAM17,	but	constitutive	release	of	IL-
6R	is	largely	mediated	by	ADAM10	in	mice	[230].	Additionally,	 in	humans,	but	not	in	mice,	
the	sIL-6R	can	be	generated	by	translation	from	an	alternatively	spliced	mRNA	[262]	[230].	
Of	 note,	 the	 soluble	 gp130	 form,	 which	 circulates	 in	 human	 plasma,	 blocks	 IL-6R	 trans	
signaling	 responses	 and	 does	 not	 show	 species	 specificity,	meaning	 that	 it	 interacts	 with	
human	and	mouse	sIL-6R	complexes	[263].	All	of	this	has	implications	in	the	extrapolation	of	
IL-6R	data	obtained	in	mouse	models	to	human.	Thus,	to	provide	clinically	relevant	data,	we	
focused	our	studies	on	primary	and	immortalized	human	cells	from	COPD	and	CF	patients.	
	
1.8	 IS	 ADAM17	 PHOSPHORYLATION	 IMPORTANT	 FOR	 CS-INDUCED	 AREG	 AND	 IL-6R	
SHEDDING?		
The	 serine-	 and	 threonine-rich	 ADAM17	 cytoplasmic	 tail	 [130]	 has	 three	 phosphorylation	
sites	that	have	been	proposed	to	activate	ADAM17:	Thr735,	Ser791	and	Ser819	(Figure	2).	
Phosphorylated	ADAM17	is	detected	under	basal	conditions	[264].	Stimulation	of	ADAM17	
further	 increases	 its	phosphorylation,	without	changing	 the	total	protein	 level	 [130]	 [264],	
suggesting	that	phosphorylation	plays	a	role	 in	the	regulation	of	the	proteolytic	activity	of	
ADAM17.	 However,	 mutation	 of	 the	 phosphorylation	 sites	 individually	 or	 in	 combination	
and	 even	 removal	 of	 the	 whole	 cytoplasmic	 tail	 has	 no	 significant	 effect	 on	 stimulated	
shedding	suggesting	that	phosphorylation	may	be	an	additional	but	not	a	crucial	regulatory	
mechanism	of	ADAM17	proteolytic	 activity,	which	does	not	exclude	 that	 it	 plays	a	 role	 in	
transport,	processing,	and	maturation	[130]	[138]	[185]	[265]	[266].	
Different	 stimuli	 affect	 distinct	 phosphorylation	 sites	 on	 the	ADAM17	molecule.	 Cigarette	
smoke	extract	 increases	phosphorylation	of	Ser	and	Thr,	but	not	Tyr	residues	on	ADAM17	
molecule	in	a	PKC-ε	dependent	manner.	ADAM17	Ser819	residue,	but	not	on	Thr	or	Tyr,	is	
phosphorylated	when	ERK/MAP	kinase	signaling	pathway	 is	 induced	by	growth	factor	 (GF)	
stimulation	[130].	However,	an	ADAM17-Ser819	mutant	does	not	lose	its	proteolytic	activity	
when	 simulated	 with	 fibroblast	 growth	 factor	 (FGF)	 [130],	 suggesting	 that	 this	
phosphorylation	 is	 not	 required	 for	 ADAM17	 proteolytic	 activity.	 To	 date,	 the	 kinase	
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responsible	 for	 phosphorylation	 of	 this	 site	 has	 not	 been	 identified.	 Another	
phosphorylation	residue	on	ADAM17	molecule,	a	Ser791	 is	phosphorylated	in	resting	cells,	
whereas	 in	 response	 to	 GF	 stimulation	 Ser791	 undergoes	 dephosphorylation,	 which	 is	
independent	of	the	ERK/MAPK	pathway	[130].	Pro-ADAM17	and	mature	ADAM17	are	also	
phosphorylated	at	Thr735	under	resting	condition.	Phorbol	esther	(PMA)	treatment	further	
increases	phosphorylation	at	this	site	[264].	ERK	1/2	co-immunoprecipitates	with	ADAM17	
and	 directly	 phosphorylates	 it	 at	 Thr735	 [143]	 [264]	 [267],	 providing	 evidence	 that	 it	
regulates	ADAM17	maturation,	 trafficking	 to	 the	 cell	 surface	 and	 activation.	Also	p38	has	
been	shown	to	phosphorylate	Thr735	on	ADAM17	[264]	[267].	Stimulation	of	ERK	and	PKC	
with	 PMA	 also	 activates	 ADAM17,	 leading	 to	 shedding	 of	 IL-6R	 [143].	 P38α	 MAP	 kinase	
interacts	 with	 the	 cytoplasmic	 domain	 of	 ADAM17	 and	 phosphorylates	 it	 on	 Thr735	
resulting	in	release	of	TGF-α	and	enhanced	cell	proliferation	[143],	which	is	likely	dependent	
on	the	association	of	ERK	and	ADAM17	[264].		
	
Taken	together,	 some	studies	show	that	GF	stimulation	 induces	ADAM17	phosphorylation	
at	 Thr735	 [264],	while	 others	 find	 contradicting	 data	 [130],	which	may	 be	 cell	 or	 context	
dependent.	In	Chapter	2	we	addressed	the	association	of	Thr735	phosphorylated	ADAM17	
with	its	substrates	(IL-6R	and	AREG)	in	CS	treated	airway	epithelial	cells,	and	correlated	this	
with	ADAM17	shedding	activity.	
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1.9	Murine	models	to	study	activity	of	ADAM17	in	airway	epithelia	
Inactivation	 of	 ADAM17	 by	 deletion	 of	 the	 zinc	 binding	 domain	 through	 homologous	
recombination	 in	 mice	 led	 to	 severely	 hypoplastic	 lungs	 at	 birth,	 reduced	 branching	
morphogenesis	 and	 alveolar	 development,	 impaired	 epithelial	 cell	 proliferation	 and	
differentiation	 and	delay	 in	 vasculogenesis	 [268].	Due	 to	 the	 early	mortality	 of	 ADAM-KO	
mice,	 several	 alternative	 ADAM17	 mouse	 models	 have	 been	 developed,	 with	 reduced	
activity	 (hypomorphic)	 or	 conditional	mutants	 [132].	 Conditional	 knockout	 ADAM17	mice	
can	 serve	 as	 a	model	 to	 investigate	 the	 role	 of	ADAM17	 in	 organogenesis,	 in	 specific	 cell	
types,	and	in	inflammatory	responses	and	tissue	remodeling.		
Induced	 dysfunction	 of	 ADAM17	 (ADAM17flox/flox	 SPC-rtTA	 TetO-Cre)	 in	 developing	 lung	
epithelial	 cells	 reduced	 saccular	 formation,	 decreased	 cell	 proliferation	 and	 reduced	 lung	
epithelial	 cell	 differentiation,	 but	 the	mice	were	 born	without	 severe	 respiratory	 distress	
[152].	 Phenotypic	 differences	 were	 reduced	 after	 alveolarisation	 of	 the	 immature	 lung	
(P14).	Knocking	out	 the	gene	 in	mesenchymal	 cells	using	a	Dermo1-Cre	 transgene	did	not	
produce	a	detectable	phenotype	[152].	This	suggests	that	epithelial,	but	not	mesenchymal	
ADAM17	plays	a	prominent,	but	not	decisive	role	in	lung	development.	
Conditional	 knockout	mice	 in	 the	 hematopoietic	 system	 (Adam17flox/ΔZn	 driven	 by	 Vav-
Cre)	treated	with	LPS	have	significantly	reduced	LPS-induced	alveolar	TNF-α	and	L-selectin	
levels,	but	IL-6R	levels	are	reduced	by	only	25%	[269],	consistent	with	reports	that	in	mice	
IL-6R	is	a	preferred	substrate	of	ADAM10,	but	not	ADAM17	as	in	human	[261]	[230].	In	the	
mutant	 mice	 alveolar	 neutrophil	 counts	 are	 reduced	 after	 LPS	 challenge,	 but	 initial	
infiltration	 of	 neutrophils	 occurs	 quicker,	 in	 comparison	 to	 control	 animals	 [269].	 Other	
studies	 show	 that	 conditional	 knockout	 mice	 (ADAM17flox/flox	 with	 R26Cre	 ER)	 treated	
with	 human	 neutrophil	 elastase	 have	 attenuated	 goblet	 cell	metaplasia	 in	 comparison	 to	
the	wild-type	mice	[270],	suggesting	that	ADAM17	is	involved	in	the	airway	metaplasia.	
In	our	 laboratory	we	took	an	effort	 to	generate	CF	ADAM17	conditional	knockout	mice	 in	
lung	 epithelial	 cells	 (SPC-rtta/Tet-O-Cre/Adam17flox/flox),	 which	 can	 serve	 as	 a	model	 of	
inflammatory	 and	 repair	 responses	 in	 normal	 and	 CF	 airway	 epithelial	 cells,	 by	 crossing	
Cftrtm1EUR	 F508del	 CFTR	 mutant	 mice	 with	 ADAM17flox/flox	 [271]	 and	 SPC-rtTA/tetO-cre	
[272].	
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HYPOTHESIS:		
ADAM17	 is	hyperactive	 in	CF	and	COPD,	promoting	 inflammation	and	tissue	remodeling	
by	 shedding	 of	 EGFR	 binding	 growth	 factor	 AREG	 and	 the	 cytokine	 receptor	 IL-6R	 from	
airway	epithelial	cells	
	
We	hypothesized	that	both	CF	and	COPD	lung	disease	are	associated	with	hyperactivity	of	
the	 EGFR/ADAM17	 signaling	 cascade	 in	 airway	 epithelial	 cells,	 causing	 enhanced	 or	
sustained	 release	 of	 growth	 factors,	 pro-inflammatory	 cytokines	 and	 cytokine	 receptors.	
This	may	contribute	to	epithelial	metaplasia,	 fibroblast	and	smooth	muscle	cell	activation,	
and	 net	 deposition	 of	 extracellular	 matrix.	 Interventions	 in	 this	 pathway	 may	 therefore	
reduce	CF	and	COPD	lung	pathology.	
	
We	 focused	 our	 studies	 on	 two	 ADAM17	 substrates:	 growth	 factor	 AREG	 and	 pro-
inflammatory	 IL-6	 receptor	 (IL-6R).	 AREG,	 a	 type	 I	 trans-membrane	 protein	 [273],	
proteolytically	cleaved	by	ADAM17	from	airway	epithelial	cells,	activates	EGFR	not	only	on	
the	 airway	 epithelial	 cells,	 but	 also	 on	 the	 underlying	 fibroblasts.	 IL-6R	 trans-signaling	
requires	ADAM17-mediated	shedding	of	the	extracellular	domain	[228]	[230]	or	alternative	
mRNA	splicing	[232]	[233]	[234].	The	shed	form	and	alternatively	spliced	form	bind	to	IL-6	
creating	 IL-6/IL-6R	 complexes	 that	 dimerize	 and	 trans-activate	 gp130	 on	 the	 underlying	
myofibroblasts	 [232]	 [235]	 [236].	 gp130	 is	ubiquitously	expressed,	meaning	 that	 cells	 that	
do	not	express	IL-6R,	but	do	express	gp130	can	still	transduce	IL-6R	signal	by	binding	IL-6/IL-
6R	 complexes.	Many	 cells	 including	 smooth	muscle	 cells	 [249]	 and	 endothelial	 cells	 [250]	
are	only	responsive	to	IL-6	through	IL-6/IL-6R	trans-signaling.		
	
Taken	 together,	 we	 hypothesised	 that	 pathology	 driven	 trans-signaling	 at	 least	 in	 part	
depends	on	airway	epithelial	AREG	and	IL-6R	shedding.	 Importantly,	signals	transduced	by	
shed	 AREG	 and	 IL-6R	 from	 airway	 epithelial	 cells	 may	 converge	 in	 activation	 of	 the	
transcription	 factor	 STAT3	 in	 lung	 fibroblasts,	 myofibroblasts	 and	 smooth	 muscle	 cells	
(Figure	7),	which	is	involved	in	fibrotic	responses	and	inflammatory	lung	disease	[274].	This	
aspect	has	not	been	investigated	during	the	course	of	this	thesis;	however,	it	is	the	subject	
of	ongoing	investigations	in	our	institute.		
	
Considering	the	similarity	of	the	pathology	of	COPD	and	CF,	we	investigated	the	influence	of	
COPD	 disease	 on	 the	 basal	 and	 CS-induced	 EGFR/ADAM17	 signaling	 in	 differentiated	
primary	 bronchial	 epithelial	 cells.	 Furthermore,	 by	 using	 CFBE41o-	 cells	 with	 inducible	
expression	 of	 CFTR,	 we	 aimed	 to	 establish	 whether	 CFTR	 deficiency	 hyper-activates	
EGFR/ADAM17	 signaling	 as	 a	 cell-autonomous	 defect.	 Finally,	 we	 aimed	 to	 define	 the	
druggable	 targets	 in	 the	 EGFR/ADAM17	 signaling	 pathway,	 which	 could	 be	 applied	 in	
management	of	COPD	and	as	an	early	intervention	CF	lung	therapy.	
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Figure	7	Is	ADAM17/EGFR	signaling	an	important	player	in	CF	and	COPD	lung	disease?		
We	 hypothesized	 that	 both	 CFTR	 deficiency	 and	 cigarette	 smoke	 exposure	 are	 associated	 with	
hyperactivity	of	ADAM17/EGFR	signaling	cascade	in	airway	epithelial	cells,	causing	enhanced	release	
of	 pro-inflammatory	 cytokines	 and	 growth	 factors.	 We	 focused	 our	 studies	 on	 two	 ADAM17	
substrates:	 pro-inflammatory	 IL-6	 receptor	 (IL-6R)	 and	 growth	 factor	 AREG.	 AREG	 proteolytically	
cleaved	by	ADAM17	from	airway	epithelial	cells	activates	EGFR	autocrinally	 in	 the	airway	epithelial	
cells	and	paracrinally	on	the	underlying	fibroblasts.	IL-6R	trans-signaling	requires	ADAM17-mediated	
shedding	of	the	extracellular	domain	or	alternative	mRNA	splicing.	The	alternatively	spliced	and	shed	
form	 binds	 to	 IL-6	 creating	 IL-6/IL-6R	 complexes	 to	 dimerize	 and	 trans-activate	 gp130	 on	 the	
underlying	myofibroblasts.	 Signals	 transduced	 by	 shed	AREG	 and	 IL-6R	 from	 airway	 epithelial	 cells	
may	 converge	 in	 activation	 of	 a	 transcription	 factor	 STAT3	 in	 lung	 fibroblasts,	myofibroblasts	 and	
smooth	muscle	cells,	which	is	involved	in	fibrotic	responses	and	inflammatory	lung	disease.	Enhanced	
ADAM17/EGFR	signaling	may	contribute	to	hyper-inflammation	and	epithelial	metaplasia,	fibroblast	
and	 smooth	 muscle	 cell	 activation,	 and	 net	 deposition	 of	 extracellular	 matrix	 (tissue	 remodeling)	
leading	to	lung	pathology	observed	in	COPD	and	CF.		
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Abstract
Aberrant activity of a disintegrin and metalloprotease 17 (ADAM17), also
known as TACE, and epidermal growth factor receptor (EGFR) has been sug-
gested to contribute to chronic obstructive pulmonary disease (COPD) devel-
opment and progression. The aim of this study was to investigate the role of
these proteins in activation of primary bronchial epithelial cells differentiated
at the air–liquid interface (ALI-PBEC) by whole cigarette smoke (CS), com-
paring cells from COPD patients with non-COPD. CS exposure of ALI-PBEC
enhanced ADAM17-mediated shedding of the IL-6 receptor (IL6R) and the
EGFR agonist amphiregulin (AREG) toward the basolateral compartment,
which was more pronounced in cells from COPD patients than in non-COPD
controls. CS transiently increased IL6R and AREG mRNA in ALI-PBEC to a
similar extent in cultures from both groups, suggesting that posttranslational
events determine differential shedding between COPD and non-COPD cul-
tures. We show for the first time by in situ proximity ligation (PLA) that CS
strongly enhances interactions of phosphorylated ADAM17 with AREG and
IL-6R in an intracellular compartment, suggesting that CS-induced intracellu-
lar trafficking events precede shedding to the extracellular compartment. Both
EGFR and ADAM17 activity contribute to CS-induced IL-6R and AREG pro-
tein shedding and to mRNA expression, as demonstrated using selective inhi-
bitors (AG1478 and TMI-2). Our data are consistent with an autocrine-
positive feedback mechanism in which CS triggers shedding of EGFR agonists
evoking EGFR activation, in ADAM17-dependent manner, and subsequently
transduce paracrine signaling toward myeloid cells and connective tissue.
Reducing ADAM17 and EGFR activity could therefore be a therapeutic
approach for the tissue remodeling and inflammation observed in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disorder characterized by irreversible airflow
obstruction due to airway inflammation, infection, and
tissue remodeling (Vestbo et al. 2013). Airway epithelial
cells play a central role in the pathogenesis of COPD
through a variety of mechanisms, including production of
inflammatory mediators, antimicrobial peptides, and
growth factors (Hiemstra et al. 2015). Exposure of the
lung tissue to triggers like cytotoxic particles and gasses,
including cigarette smoke, microbes, and innate immune
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2016 | Vol. 4 | Iss. 16 | e12878
Page 1
Physiological Reports ISSN 2051-817X
	 63		
mediators (Koff et al. 2008; Kim et al. 2011) (Lemjabbar-
Alaoui et al. 2011) (Shao 2004) (Zhou et al. 2012)
activate various matrix metalloproteinases (MMPs) and a
disintegrin and metalloproteinases (ADAMs) expressed by
airway epithelial cells (Dijkstra et al. 2009; Paulissen et al.
2009). The activity of MMPs and ADAMs contributes not
only to proteolytic degradation of lung tissue, but also to
regulation and processing of numerous receptor activating
proteins (Richter et al. 2002; Gomez et al. 2005; Bell et al.
2007; Baumgart et al. 2010). Through these various activi-
ties, MMPs and ADAMs are implicated in a broad spec-
trum of processes ranging from inflammatory responses
to airway epithelial repair. It has been proposed that their
aberrant activity might lead to chronic inflammation and
abnormal tissue remodeling in the lungs of COPD
patients (Paulissen et al. 2009).
One of the ADAMs, a ubiquitously expressed Zn2+-
dependent disintegrin and metalloprotease 17 (ADAM17),
formerly known as TNFa converting enzyme (TACE), is
recognized as an important regulator of pulmonary
inflammation, cell proliferation, and epithelial barrier
function (Gooz 2010; Lemjabbar-Alaoui et al. 2011). In
bronchial epithelial cells, ADAM17 modulates these pro-
cesses by cleaving membrane-bound cytokines (TNFa),
several EGF receptor (EGFR) agonists (TGF-a, amphireg-
ulin, epiregulin, HB-EGF), cytokine receptors (IL6R,
TNF-R), growth factor receptors (NOTCH receptors),
and adhesion proteins (L-selectin, ICAM-1, E-cadherin)
(Gomez et al. 2005; Bell et al. 2007; Baumgart et al. 2010;
Gooz et al. 2012). Moreover, ADAM17 phosphorylation
and activity is enhanced in airway epithelial cell lines and
in undifferentiated primary cells upon exposure to cigar-
ette smoke extract (Lemjabbar et al. 2003; Shao 2004;
Lemjabbar-Alaoui et al. 2011).
Our studies focus on two ADAM17 substrates impli-
cated in COPD pathogenesis: the IL-6 cytokine receptor
(IL6R) and the growth factor amphiregulin (AREG),
one of the EGFR agonists produced by bronchial
epithelial cells (Richter et al. 2002). Elevated levels of
IL6R have been observed in peripheral blood leukocytes
of COPD patients (Edmiston et al. 2010), and recently
genetic variants of IL6R have been linked with COPD
severity (P!erez-Rubio et al. 2016). However, the regula-
tion of shedding of IL6R and AREG from COPD air-
way epithelium has not been studied. Upon shedding
from epithelial cells, IL6R and AREG activate the
shared interleukin receptor gp130 and EGFR, respec-
tively, on epithelial cells (autocrine), as well as on
underlying myofibroblasts and myeloid cells (paracrine)
(Burgel and Nadel 2008; Nechemia-Arbely et al. 2008;
Kasina et al. 2009; Rose-John 2012). Both IL6/IL6R/
gp130 and AREG/EGFR/ERK pathways are involved in
the resolution of lung inflammation and repair of
injury, but also in progression of subepithelial fibrosis
and collagen deposition (Zhou et al. 2012). These sig-
naling pathways involve the JAK kinase and/or MAP
kinase pathway, which are druggable targets in COPD
pathology (Barnes 2013). Excessive ligand-mediated
EGFR activation results in epithelial hyperproliferation
and increased production of the inducible mucin
MUC5AC, processes observed in smokers with or with-
out COPD (Lemjabbar et al. 2003; Shao 2004; Desh-
mukh et al. 2005; Kasina et al. 2009; Lemjabbar-Alaoui
et al. 2011; Li et al. 2011; Zhang et al. 2014). Moreover,
EGFR activation results in subsequent transcriptional
regulation of inflammatory mediators such as IL-8
(Richter et al. 2002), a chemokine that has been impli-
cated in COPD development.
So far, studies on the effect of cigarette smoke on
epithelial ADAMs activity has largely relied on the use
of airway epithelial cell lines or undifferentiated primary
cell cultures, stimulated with an aqueous extract of cigar-
ette smoke. However, whole cigarette smoke exposure
and primary differentiated airway cell cultures represent
more relevant physiological conditions. Firstly, fresh
whole cigarette smoke (CS) contains unstable active
components and particulate matter that are largely
absent from extracts. Furthermore, immortalized epithe-
lial cells are poor models of bronchial epithelium in situ,
since they are frequently karyotypically unstable and
heterogeneous, do not show characteristic features of dif-
ferentiation and inherently carry multiple mutations in
pathways essential for growth, differentiation, cell-cell
interaction, and polarization. Furthermore, submerged
cultures of primary airway epithelial cells fail to differen-
tiate. Finally, using cell lines does not allow a compar-
ison of patient populations. Therefore, we examined the
effect of whole CS exposure on shedding of the soluble
interleukin-6 receptor (sIL6R) and the EGFR-ligand
amphiregulin (AREG) by well-differentiated, air–liquid
interface cultured human primary bronchial epithelial
cells (ALI-PBEC).
This allowed us to compare CS-induced ADAM17-
mediated protein shedding and mRNA expression of
sIL6R and AREG in well-differentiated ALI-PBEC from
COPD and non-COPD (ex)smokers. Moreover, we estab-
lished in this model the involvement of both EGFR and
ADAM17 not only in shedding of ADAM17 substrates,
but also in the regulation of mRNA levels of ADAM17
substrates and IL-8. Finally, for the first time, we
observed intracellular CS-induced phosphorylated
ADAM17-substrate interaction via an in situ proximity
ligation assay. Overall, our results provide novel insights
into the activation of airway epithelial cells by cigarette
smoke in COPD, and highlight a possible role of ADAMs
and EGFR in COPD pathology.
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Materials and Methods
Air–liquid interface cell culture of human
primary bronchial epithelial cells
Human airway epithelial cells were obtained from macro-
scopically normal, anonymous bronchial tissue obtained
from lung cancer patients undergoing resection surgery
for lung cancer at LUMC. This material was be used for
research according to the “Code of Conduct for Responsi-
ble Use” (FEDERA code) based on the condition that the
patient has no objection against such use. Primary bron-
chial epithelial cells (PBEC) were isolated from tumor-
free lung resection material (Wetering et al. 2000), and
passage 2 expanded cells were cultured at the air–liquid
interface (ALI) to achieve mucociliary differentiation as
previously described (Amatngalim et al. 2015). Briefly,
40,000 cells were seeded on 0.65 cm Transwell inserts
(Corning Costar, Cambridge, MA) with a 0.4 lm pore
size, which were coated with 30 lg/mL PureCol
(Advanced BioMatrix, San Diego, CA), 10 lg/mL Bovine
serum albumin (Sigma-Aldrich, St. Louis, MO), and
10 lg/mL Fibronectin (isolated from plasma). Cells were
cultured in Bronchial epithelial growth medium (BEGM)
(Lonza, Verviers, Belgium) and Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Bleiswijk, The Nether-
lands) (1:1 mixture) containing 1 mmol/L Hepes (Lonza)
and supplemented with SingleQuot supplements and
growth factors according to the manufacturer’s instruc-
tions (bovine pituitary extract, hydrocortisone, human
epidermal growth factor, epinephrine, transferrin, insulin,
T3 and retinoic acid; all from Lonza), additional 15 ng/
mL retinoic acid (Sigma–Aldrich), 1 mg/mL BSA (Sigma–
Aldrich), 100 U/mL penicillin, and 100 lg/mL strepto-
mycin (Lonza). PBEC were initially cultured on inserts in
submerged conditions until cell layers were confluent.
Next, apical medium was removed and cells were cultured
at air-exposed conditions for at least 2 weeks to allow
mucociliary differentiation. Clinical history and lung
function data were obtained from anonymized patients
(Table 1), and COPD disease status was based on lung
function data according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) classification
(Vestbo et al. 2013). Donor cells were randomly allocated
to experimental groups.
Cigarette smoke exposure
Air–liquid interface cultured human primary bronchial
epithelial cells were exposed to whole cigarette smoke (CS)
in an exposure model, adapted from (Beisswenger et al.
2004) and previously described in more detail (Amatn-
galim et al. 2015). In this model, ALI-PBEC cultures were
placed in either a CS- or air (negative control) exposure
chamber located in a tissue incubator at 37°C and 5%
CO2. Smoke derived from one cigarette (3R4F reference
cigarettes [University of Kentucky, Lexington, KY]) was
infused into the exposure chamber by a mechanical pump
with a constant flow of 1 L/min, and equally distributed
by a ventilator inside the chamber. After infusion (approx-
imately 4–5 min), residual smoke was removed by infu-
sion of air from the tissue incubator for 10 min. Directly
after CS exposure, the basal medium of the cell cultures
was refreshed and cells were incubated for the indicated
periods of time. Untreated cells used as controls were sub-
jected to the same procedure omitting the smoke (AIR).
Inhibitors
TMI-2 (1 lmol/L; PF-5480090), a highly selective inhibi-
tor of ADAM17 activity (Zhang et al. 2004), was obtained
from Wyeth inc. (Philadelphia, Pennsylvania) and the
selective EGFR inhibitor AG1478 (1 lmol/L) was from
Sigma Aldrich. Cells were preincubated for 1 h with inhi-
bitors before CS exposure, and directly after CS exposure
media were replaced and inhibitors were freshly added.
ELISA
ALI-PBEC conditioned culture media were collected from
the basolateral side of the inserts (1 mL), and apical
washes were obtained by washing the apical surface with
100 lL PBS at different time points, dependent on the
experiment. Collected samples were diluted 1:1 with
BEGM media and analyzed for IL6R and AREG by
human IL6R or AREG ELISA kit, R&D. Further steps
were performed according to the manufacturer’s protocol.
Data were corrected for the dilution factor and insert size,
and the amount of the shed IL6R and AREG was
expressed as pg/mL per cm2.
Table 1. COPD and non-COPD patient characteristics.
COPD non-COPD P-value
Number of donors 15 11
Gender (females/males) 4/11 2/9
Age, years 70 ! 8 66 ! 6 0.1667
FEV1, % predicted 65 ! 16 81 ! 16 <0.01
FEV1/FVC % 55 ! 9 79 ! 9 <0.0001
Characteristics of PBEC donors. Age in years, and lung function as
FEV1 (% predicted) and FEV1/FVC are shown as means ! SD. The
mean differences were compared using the nonparametric Mann–
Whitney test. COPD, chronic obstructive pulmonary disease,
FEV1, Forced expiratory volume in one-second, FVC, forced vital
capacity.
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RNA isolation and quantitative real-time
PCR
RNA was isolated using the miRNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions, and cDNA
was synthesized by reverse-transcription PCR using oligo
(dT) primers (Qiagen) and Moloney murine leukemia
virus (M-MLV) polymerase (Promega, Leiden, The
Netherlands). mRNA expression was determined by quan-
titative real-time PCR as described previously (Amatn-
galim et al. 2015) with primer pairs presented in Table 2.
mRNA expression was quantified using the standard
curve method (Larionov et al. 2005), in which arbitrary
expression levels were normalized to the housekeeping
genes RPL13A and ATP5B. The housekeeping genes were
selected based on stable expression using the “Genorm
method” (Vandesompele et al. 2002).
Proximity ligation assay
Chronic obstructive pulmonary disease ALI-PBEC were-
fixed with 4% paraformaldehyde and permeabilized with
0.5% Triton-X100 in PBS twice for 15 min, blocked with
1% BSA and 0.15% glycine. Next, they were incubated
overnight in 4°C with two different first antibodies simul-
taneously: against ADAM17 (rabbit polyclonal, C-terminal
ADAM17, 25 lg/mL, ab78162, Abcam) or ADAM17PT735
(rabbit polyclonal, phospho-ADAM17 in position T735,
25 lg/mL, ab60996, Abcam) and IL6R (goat anti-human
IL6R recognizing extracellular domain, 20 lg/mL, AF-
227-NA, R&D) or AREG (polyclonal goat anti-human
Areg, 25 lg/mL, AF-262, R&D). All washing steps were
repeated three times with 0.5% Triton-X100 in PBS
(Sigma-Aldrich). Further steps were performed according
to the DuoLink manufacturer’s protocol. Briefly, Proxim-
ity ligation assay (PLA) probes for anti-goat PLUS and
anti-rabbit MINUS were incubated at 37°C for 1 h. Liga-
tion and amplification steps were performed with Detec-
tion Red Reagent. Finally, inserts with ALI-PBEC were
cut out and mounted on the slides with DAPI (Vec-
tashield mounting medium for fluorescence with DAPI,
H-1200). z-stacks were acquired using confocal micro-
scopy (Leica604).
PLA image analysis
The number of dots was counted in the whole z-stack
with Image J software. The threshold values were adjusted
with the Intermodes algorithm (the filter size set between
10 and 437 microns to exclude the small and large dots,
which were in the range of 10% of the total dot count).
The objects on the edges of the culture inserts were
excluded from the analysis. The number of nuclei was
counted in each z-stack by hand to express the number of
dots per nucleus.
Statistical analysis
Data were analyzed with GraphPad Prism Software, using
the appropriate statistical test, as indicated underneath
each figure. Cells from various donors (number indicated
by n in the legends of figures) were used for each experi-
ment, samples were collected from two or three wells
from a single donor, averaged and represented as a single
dot in the figure. Statistical analysis was performed on the
averaged data. Values are presented as mean with SEM
values. Differences at P-values <0.05 were considered to
be statistically significant. ns > 0.05, *P < 0.05,
**P < 0.01, **P < 0.001, ****P < 0.0001.
Results
CS induces shedding of IL6R and AREG by
ALI-PBEC into basolateral medium, but not
apical
We first examined the effect of cigarette smoke (CS)
exposure on the release of sIL6R and AREG by ALI-PBEC
Table 2. Quantitative-PCR primers.
Primer name [ref]
IL8 FW 50-CAGCCTTCCTGATTTCTG-30 Amatngalim et al. (2015)
RV 50-CACTTCTCCACAACCCTCTGC-30
AREG FW 50GTGGTGCTGTCGCTCTTGATA 30 Clarke et al. (2013)
REV 50ACTCACAGGGGAAATCTCACT30
IL6R full-length
form (full-IL6R)
FW 50GCTGTGCTCTTGGTGAGGAAGTTT30 Rath et al. (2010)
REV 50CTGAGCTCAAACCGTAGTCTGTAGAAA30
IL6R alternatively spliced
variant (spliced IL6R)
FW 50GCGACAAGCCTCCCAGGTT30 Rath et al. (2010)
REV 50CCGCAGCTTCCACGTCTTCTT30
FW, Forward primer; REV, Reversed primer.
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at the apical surface and in the basal medium, which con-
tains a maintenance level of EGF, associated with a basal
level of EGFR activity. This was done, using a previously
described whole CS exposure model (Amatngalim et al.
2015), in which CS caused a transient disruption in the
airway epithelial barrier integrity, accompanied by minor
cytotoxic effects measured at the apical surface. Both
sIL6R and AREG were barely detectible in the apical
washes collected from ALI-PBEC of 17 COPD donors at
different stages of disease, following exposure to either CS
or air (Fig. 1A and B). In contrast, sIL6R and AREG were
markedly released into the basal medium in both condi-
tions. CS significantly increased release of sIL6R into the
basal medium at 12 h postexposure, while AREG levels
were increased at 12 and 24 h after CS exposure. These
results demonstrate that shedding of sIL6R and AREG by
ALI-PBEC occurs mainly to the basolateral compartment,
and is enhanced by CS exposure.
CS significantly induces shedding of IL6R
and AREG in COPD ALI-PBEC but not in non-
COPD ALI-PBEC
Next, we explored whether shedding of sIL6R and AREG
differs between ALI-PBEC isolated from COPD patients
and non-COPD (ex)-smokers upon CS and air exposure.
Based on the previous result, the release was only deter-
mined in the basal medium 24 h after exposure. Shedding
of sIL6R and AREG did not differ between COPD and
non-COPD ALI-PBEC exposed to air (Fig. 2A and B),
indicating no differences at baseline conditions. In
contrast, shedding of sIL6R (Fig. 2A) and AREG (Fig. 2B)
was significantly higher after CS exposure only in COPD
ALI-PBEC, and not in non-COPD ALI-PBEC. These data
show that CS-induced release of sIL6R and AREG was
more pronounced in airway epithelial cells from COPD
in comparison to non-COPD donors.
CS-induced IL6R and AREG mRNA expression
is lower in COPD ALI-PBEC compared to non-
COPD cultures
We further determined mRNA expression of IL6R and
AREG in CS and air exposed ALI-PBEC cultures from
COPD and non-COPD patients. The soluble form of
IL6R can be generated either by shedding of the mem-
brane anchored form or by de novo synthesis of the alter-
natively spliced isoform that differs at the C-terminus
(Rose-John 2012). Therefore, we determined mRNA
expression levels of both IL6R variants: the membrane-
anchored (full-IL6R mRNA) and the alternatively spliced
(spliced-IL6R mRNA) variant.
Time-course analysis revealed that CS increased full-
IL6R mRNA 3 h after exposure, but not at later time
points (Fig. 3A). In contrast, baseline expression of
spliced-IL6R mRNA did not differ from the expression
after CS treatment (Fig. 3B), suggesting that the increase
in sIL6R protein levels in culture supernatants did not
result from alternative splicing. Similar to full-IL6R
mRNA, CS significantly induced AREG mRNA expression
3 h after exposure, but not at later time points (Fig. 3C).
These findings suggest that the CS-induced increase in
Figure 1. Cigarette smoke induces shedding of IL6R and AREG by ALI-PBEC into basolateral medium. IL6R (A) and AREG (B) were mainly shed
to the basolateral compartment in ALI-PBEC (COPD donors at different stages, n = 12 for IL6R and n = 5 for AREG). Basolateral media
(basolateral) were collected and apical PBS washes (apical) were performed 12 h and 24 h after CS or air exposure. Both IL6R and AREG were
readily detectable in the basolateral compartment, and barely present in the apical washes. The response of cells from each donor was
analyzed within one experiment using duplicate or triplicate inserts. Statistical analysis was performed by two-way ANOVA (Bonferroni) on the
averaged data from each donor, comparing apical versus basolateral shedding at air and CS exposure, and basolateral shedding at air versus CS
exposure.
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IL6R and AREG shedding is mediated at least in part via
regulation of their mRNA expression levels.
Baseline expression of full-IL6R and AREG mRNA did
not differ between COPD and non-COPD ALI-PBEC
(Fig. 3D and F). After CS exposure, full-IL6R and AREG
mRNA were expressed at higher levels in both non-
COPD and COPD ALI-PBEC. Interestingly, after CS
induction, COPD cells expressed full-ILR and AREG at
lower levels on average but this did not reach statistical
significance (Fig. 3D and F). Spliced-IL6R mRNA expres-
sion did not differ between investigated groups either
after CS or air exposure (Fig. 3E). These findings suggest
that COPD patients may have impaired transcriptional or
posttranscriptional responses to inflammatory and tissue
regenerative triggers. The apparent contrast with the
more pronounced shedding from COPD cells after CS
challenge (Fig. 2) suggests that posttranslational mecha-
nisms determine shedding rate, rather than substrate
mRNA levels.
ADAM17 is required for CS-induced release
of IL6R and AREG in ALI-PBEC
To confirm the previously established involvement of
ADAM17 in the shedding process of IL6R and AREG in
our model, we used the selective ADAM17 inhibitor
TMI-2 (Wyeth) (Zhang et al. 2004). TMI-2 only partially
decreased baseline IL6R release at all investigated time
points (Fig. 4A), plausibly because release of the product
of spliced-IL6R mRNA, which cannot be distinguished
from shed IL-6R with the available antibodies, is not sen-
sitive to inhibitors of ADAMs (Vermes et al. 2012). In
contrast, TMI-2 significantly decreased baseline AREG
shedding at all time points (Fig. 4B). Importantly, CS-
induced shedding of IL6R and AREG was significantly
inhibited by TMI-2 at all time points after CS exposure,
indicating that ADAM17 activity is involved in CS-
induced ADAM17 substrate release (Fig. 4).
ADAM17- and ADAM17P-substrate
interactions are increased after CS exposure
in an intracellular compartment of ALI-PBEC
Next, we explored the interactions of IL6R or AREG with
ADAM17 3 h after CS treatment in ALI-PBEC with an
in situ proximity ligation assay (PLA) (Fredriksson et al.
2002), using antibodies against ADAM17 phosphorylated
at Thr735 (ADAM17-PT735) or total ADAM17. Protein
IL6R/AREG-ADAM17 and IL6R/AREG-ADAM17-PT735
interactions were visualized as fluorescent red dots in x-y
confocal sections (representative confocal pictures shown
in Fig. 5A and B). In air-exposed cells, PLA signals were
largely confined to the basal region, as in the control
incubations, and not significantly higher than background
(data not shown), as indicated by red lines in Figure 5C–
F (relevant control data are shown in Figure S1). Interest-
ingly, CS exposure significantly increased the total num-
ber of PLA signals for interactions of IL6R or AREG with
ADAM17 (Fig. 5C and E). We observed that CS strongly
enhanced interactions of IL6R or AREG with ADAM17-
PT735 (Fig. 5D and F), which further extends previous
findings showing that ADAM17 is phosphorylated after
smoke extract (CSE) exposure in submerged immortalized
NCI-H292 cells (Lemjabbar-Alaoui et al. 2011). CS-
induced PLA signals of substrate-ADAM17 and substrate-
ADAM17-PT735 were primarily detected in the apical
Figure 2. Cigarette smoke significantly induces shedding of IL6R and AREG into basolateral medium by COPD ALI-PBEC. Soluble forms of IL6R
(A) and AREG (B) shed into the basolateral compartment were detected 24 h after CS or air exposure in ALI-PBEC derived from non-COPD and
COPD donors (Table 1). (A) IL6R levels were significantly increased 24 h after CS treatment in COPD-ALI-PBEC (n = 15), but this increase was
not significant in the non-COPD group (n = 11 donors). (B) Similarly, CS exposure significantly increased AREG levels in ALI-PBEC cells derived
from COPD donors (n = 10), but not in non-COPD ALI-PBEC (n = 8 donors). Statistical analysis: paired t-test. n refers to the number of donors,
duplicate or triplicate data were averaged per donor. Statistical analysis was performed on the averaged data from each donor.
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region of the cells and were not confined to a lateral
membrane pattern suggesting an intracellular vesicular
localization of protein complexes in ALI-PBEC. These
data for the first time demonstrate that CS exposure
strongly increases the interaction of ADAM17 and
ADAM17-PT735 with IL6R or AREG in an intracellular
vesicular compartment of ALI-PBEC, suggesting a CS
induced effect on protein trafficking.
Figure 3. CS exposure transiently enhances IL6R and AREG mRNA expression in COPD and non-COPD ALI-PBEC. mRNA levels of the IL6R full-
length variant (full-IL6R) (A), the IL6R splice variant (spliced-IL6R) (B) and AREG (C) were determined by qPCR 3, 12, and 24 h after CS (black
bars) or air exposure (open bars) (n = 14 unspecified donors). A transient induction of full-IL6R (A) and AREG (C), but not spliced-IL6R (B) was
observed at 3 h after CS exposure. In COPD (n = 7) and non-COPD (n = 8) ALI-PBEC, mRNA of full-IL6R (D), spliced-IL6R (E), and AREG (F)
were determined 3 h after CS exposure. mRNA expression of full-IL6R and AREG, was lower on average but not statistically significant in COPD
compared to non-COPD donors. Data were normalized for expression against two reference genes (ATP5B and RPL13A). n refers to the
number of donors. The response of cells from each donor was analyzed within one experiment using duplicate inserts and data were averaged
per donor. Statistical analysis was performed on the averaged data from each donor. Statistical analysis: Two-way ANOVA With Tukey’s
multiple comparison test.
Figure 4. ADAM17 is involved in the release of soluble IL6R and AREG in ALI-PBEC. The selective ADAM17 inhibitor, TMI-2 (Zhang et al. 2004)
decreases basal and CS-induced IL6R (A,B) and AREG (C,D) shedding in ALI-PBEC cells (n = 3 COPD donors) at 3, 6 (A,C), 12, and 24 h time
points (B,D). n refers to the number of donors. The response of cells from each donor was analyzed within one experiment using duplicate or
triplicate inserts and data were averaged per donor. Statistical analysis was performed on the averaged data from each donor, by two-way
ANOVA (Bonferroni), confirming first the effect of CS on IL6R and AREG shedding at different time points, and second the effect of TMI-2 on
shedding during air and CS exposure.
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EGFR is required for basal and induced
AREG shedding in ALI-PBEC
ADAM17-dependent shedding of EGFR ligands such as
AREG results in activation of EGFR through an autocrine
feedback loop, which modulates basal EGFR activity
(DeWitt et al. 2001). This mechanism was shown to be
activated by CS extract in submerged cultured PBEC and
in cell lines (Lemjabbar et al. 2003). In our experimental
set-up, we have previously shown that CS enhances basal
EGFR activity by increasing its phosphorylation (Amatn-
galim et al. 2015). To illustrate the involvement of EGFR
in CS-induced ADAM17-related shedding in ALI-PBEC,
we assessed sIL6R and AREG shedding after starvation for
A
B
C D E F
Figure 5. CS increases substrate-ADAM17 and substrate-ADAM17-PT735 interactions in pseudostratified COPD ALI-PBEC cells. The proximity
ligation assay (PLA) signal in COPD- ALI-PBEC exposed to CS or air was performed for the following interactions: IL6R-ADAM17, IL6R-
ADAM17PT735, AREG-ADAM17, and AREG-ADAM17-PT735. Relevant control data are shown in Figure S1. Here, we show a representative
figure of IL6R-ADAM17PT735 3 h after air (A) and CS exposure (B). Left panels show merged signals of nuclei (blue) and PLA (red) in the x–y
sections of the confocal z-stack and right panel presents PLA signal in the apical region (red dots). The number of PLA interactions was counted
for all interactions as described in the methods section and expressed per nucleus 3 h after CS or air exposure in the whole z-stack of the ALI-
PBEC (C–F). The red lines on the graphs indicate the maximal dot count in the PLA assay controls, in which one of the antibodies for the
interaction was omitted (background staining not shown). For each interaction, cells from one donor were analyzed. Different filters (n = 4)
were used to show distinct interactions. Statistical analysis: unpaired t-test.
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growth factors, using medium devoid of EGF and bovine
pituitary extract (BPE). Removing these factors from the
medium substantially reduced baseline shedding of IL6R
and AREG (Fig. 6), when compared to standard culture
conditions including EGF and BPE (Fig. 4A and C). Both
sIL6R and AREG release were significantly increased at 3 h
after CS exposure. The selective ADAM17 inhibitor TMI-2
and the EGFR tyrosine kinase inhibitor (AG1478) added
prior to CS exposure, partially inhibited sIL6R shedding,
consistent with a substantial contribution of the ADAM-
insensitive splice variant sIL-6R levels in the basal medium
(Fig. 6A). AG1478 strongly impaired AREG shedding, to a
similar extent as TMI-2 (Fig. 6B). These findings together
demonstrate a critical role of EGFR activation in ADAM17-
mediated basal and CS-induced shedding activity.
EGFR and ADAM17 are required for CS-
induced IL6R and AREG mRNA expression
We previously observed that EGFR activation is involved in
CS-induced expression of several genes in ALI-PBEC
(Amatngalim et al. 2015). The molecular mechanism by
which CS activates EGFR are not known. Here, we explored
the effect of ADAM17 and EGFR inhibition on CS-induced
IL6R and AREG mRNA levels in ALI-PBEC. At 3 hours
after CS exposure in the absence of EGF in the medium,
both TMI-2 and AG1478 significantly impaired CS-induced
expression of full-L6R mRNA (Fig. 7A), but not the splice
variant (Fig. 7B). Both inhibitors strongly diminished CS-
induced AREG mRNA levels (Fig. 7C) as well as IL-8
Figure 6. IL6R and AREG shedding depends on ADAM17 and
EGFR activity in COPD-ALI-PBEC. COPD ALI-PBEC (n = 3 donors)
were starved for growth factors for 48 h prior to CS or air
exposure. Three hours after CS exposure, IL6R (A) and AREG (B)
shedding were significantly increased compared to air. The
ADAM17 inhibitor (1 lmol/L TMI-2) and the EGFR inhibitor
(1 lmol/L AG1478) significantly reduced AREG, but IL6R shedding
to a lesser extent. The response of cells from each donor was
analyzed within one experiment using triplicate inserts and data
were averaged per donor. Statistical analysis was performed on the
averaged data from each donor by one way ANOVA (Tukey
multiple comparison test), only relevant comparisons are shown, air
versus CS-treated cells and the effect of inhibitors in CS-treated
cells.
Figure 7. IL6R and AREG mRNA expression are regulated by
ADAM17 and EGFR activity in ALI-PBEC. ALI-PBEC (n = 3 donors)
were starved for growth factors for 48 h prior to CS exposure. At
3 h, CS-induced mRNA levels of full-length IL6R (A), AREG (C), and
IL8 (D) were diminished upon ADAM17 (1 lmol/L TMI-2) and EGFR
(1 lmol/L AG1478) inhibition, whereas that of the alternatively
spliced form of IL6R was not affected (B). n refers to the number of
donors. The response of cells from each donor was analyzed within
one experiment using triplicate inserts and data were averaged per
donor. Statistical analysis was performed on the averaged data
from each donor, by one-way ANOVA (Tukey multiple comparison
test), only relevant comparisons are shown, air versus CS-treated
cells and the effect of inhibitors in CS-treated cells.
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mRNA expression (Fig. 7D). Overall, these findings for the
first time demonstrate that ADAM17, next to EGFR, is
essential in the CS-induced mechanism regulating not only
the mRNA of ADAM17 substrates (IL6R and AREG), but
also IL-8 in ALI-PBEC.
Discussion
Many studies have demonstrated that airway epithelial cells
are activated by exposure to environmental triggers like
cigarette smoke, which contributes to COPD pathology
(Rusznak et al. 2000; Schulz et al. 2004; Heijink et al.
2012; Amatngalim et al. 2015). In contrast to most studies,
we used fresh whole cigarette smoke instead of (aged)
cigarette smoke extract, and ALI-differentiated PBEC from
COPD and non-COPD donors instead of submerged cul-
tures of nondifferentiated primary cells or cell lines.
While the obvious advantage of this approach is that we
can study well-differentiated primary cells from different
patient populations, a limitation is that confirmation of
data obtained with experimental pharmaceutics by, for
example, gene editing or RNAi technology is not feasible in
this context. Aside from efficiency issues and off-target
effects in primary cells, knocking down EGFR or ADAM17
likely affects the growth and differentiation of primary
bronchial epithelial cells, which essentially defeats our pur-
pose. However, the two inhibitors that we apply here to
inhibit EGFR (AG1478) and ADAM17 (TMI-2), respec-
tively are widely used and are known to be highly selective.
Importantly, our data demonstrate for the first time that
CS triggered increase of basal shedding of IL6R and AREG
into the basal medium, in the presence of EGF in the
growth medium providing basal EGFR activity, was more
pronounced in ALI-PBEC derived from COPD patients
compared to non-COPD controls. We further report the
ability of CS to increase mRNA expression of these genes in
an EGFR- and ADAM17-dependent way in ALI-PBEC cells,
under these conditions, with a lower tendency to induction
in the COPD group. These results extend previous studies
showing dysregulated responses of COPD airway epithelial
cells to cellular stress, and provide novel evidence for the
mechanism of CS-induced and COPD-related proinflam-
matory and profibrotic responses (Fig. 8).
The differential effect of CS on sIL6R and AREG
release between COPD and non-COPD ALI-PBEC might
be related to differences in epithelial barrier function as
previously described (Heijink et al. 2014). Using the cur-
rent CS exposure system, we have previously shown that
CS causes a transient decrease in epithelial barrier func-
tion (Amatngalim et al. 2015). However, in contrast to
Heijink et al., we did not observe differences between
COPD and non-COPD cultures at baseline conditions
and upon CS exposure (G.D. Amatngalim et al., unpubl.
data), which may be explained by the fact that Heijink
et al. focused on severe (GOLD stage IV) COPD. Another
explanation might be differences in epithelial cell differen-
tiation, as it has been shown that COPD epithelial cells
display a more mesenchymal phenotype due to enhanced
autocrine expression of TGF-b1 (Gohy et al. 2015).
As previously shown, the EGFR-ADAM17 pathway is
essential for IL-8 release from a bronchial epithelial cell
line exposed to particulate air pollution (Ovrevik et al.
2011) and implicated in CS extract-induced expression of
the mucin MUC5AC (Shao 2004). Further, autocrine pro-
duction of EGFR ligands is involved in CS-induced IL-8
release from airway epithelial cells (Richter et al. 2002).
Our studies extend these observations by showing the
involvement of the ADAM17-EGFR pathway in the
release of IL6R and AREG upon CS exposure of differen-
tiated PBEC, both in the presence (Fig. 4), and absence
(Fig. 6) of EGFR ligand (EGF) in the basal medium
respectively. Notably, the basal shedding rates are consid-
erably lower in cells preincubated in medium lacking
EGF, resulting in a much larger ADAM17- and EGFR-
dependent stimulation effect of CS (compare Figs 4 and
6). Which of these extreme conditions of basal EGFR
activation apply in normal and COPD lungs in situ, and
to what extent autocrine feedback signaling through
ADAM-dependent EGFR ligand shedding determines
EGFR activity (Fig. 8) remains to be established.
Additionally, EGFR and ADAM17 were both essential
for CS-induced IL6R and AREG mRNA expression
(Fig. 7). These results provide novel insights into the
mechanisms of airway epithelial cell activation by cigar-
ette smoke in COPD, and highlight a role of ADAMs and
EGFR in this process (Fig. 8).
We further found that CS increases shedding of IL6R
and AREG to the basal medium, but not to the apical
side (Fig. 1). This is in line with report in polarized
Madin-Darby canine kidney cells (MDCK cells) showing
that newly synthetized AREG is directly delivered to the
basolateral surface with >95% efficiency (Brown et al.
2001). However, this is in contrast to the secretion of the
innate immune mediators IL-8 and ribonuclease 7, which
were also detected at the apical surface (Amatngalim et al.
2015). A polarized ADAM17-mediated secretion toward
underlying tissue may be relevant for lung tissue remodel-
ing through autocrine, paracrine, extracrine (exosomal
targeted receptor activation) pathways in COPD (Booth
et al. 2007; Zhou et al. 2012). Further examination of this
phenomenon in epithelial–mesenchymal co-culture sys-
tems is in progress.
Amphiregulin release and phosphorylation of ADAM17
after CS extract treatment in ALI-PBEC has been previ-
ously detected by ELISA or western Blotting (Lemjabbar-
Alaoui et al. 2011). Our proximity ligation assay (PLA)
2016 | Vol. 4 | Iss. 16 | e12878
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data show for the first time that CS-induced shed-
ding involves an intracellular interaction between
phosphorylated ADAM17 and its substrates (Figs 5 and
8), whereas the majority of the literature suggests that
shedding occurs mainly at the plasma membrane surface.
This interaction likely takes place in intracellular
ADAM17
Full-IL6R                sIL6R
IL6
Full-AREG               AREG
gp130 in complex 
with IL6R and IL6
EGFR EGFR-P
• Inflamma!on  
P-STAT3
Transac!va!on
Autocrine ac!va!on
STAT3 P-STAT3
IL6R AREG 
IL8 mRNA
• Tissue remodeling
1. Air: basal ac!vity 2. CS: ac!va!on 3. Secre!on/transac!va!on
Cigare"e smoke exposure
Figure 8. Cigarette smoke exposure activates EGFR-ADAM17 axis in airway epithelial cells. Under basal conditions, there is ADAM17 related
AREG and IL6R shedding activity, depending on the level of EGFR activity (compare Figs 4 and 6). Cigarette smoke exposure (CS) initiates an
interaction of the phosphorylated form of ADAM17 (ADAM17-P) with the full-length transmembrane forms of IL6R and AREG in an
intracellular compartment of the airway epithelial cell (Fig. 5), resulting in proteolysis and subsequent secretion (shedding) of the soluble active
domains of IL6R and AREG toward the basolateral compartment. This involves both ADAM17 and EGFR activity (Figs 4 and 6). CS exposure
also affects IL6R and AREG gene expression or mRNA stabilization in airway epithelial cells through ADAM17 and EGFR activation. sAREG and
sIL6R secreted towards the basolateral compartment may change the level of activity of EGFR and the interleukin receptor IL6st/gp130 on the
airway epithelial cells (autocrine). This may contribute to the activity of the EGFR/ADAM17 axis (positive feedback), which is likely kept in check
by inactivation of internalized EGFR. Paracrine activity of sAREG and sIL6R may further transactivate EGFR and the interleukin receptor IL6st/
gp130 on the underlying myofibroblasts, and myeloid cells, activating downstream pathways, including STAT3, involved in inflammation,
collagen deposition, and myofibroblast proliferation.
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membranes that sequester active phosphorylated
ADAM17 and its transmembrane substrates upon activa-
tion. This process may relate to the transient change in
barrier function upon CS treatment in our system and
the subsequent activation of EGFR (Amatngalim et al.
2015). Our observation is supported by other reports
showing the presence ADAM17 or its substrates in a
vesicular compartment in lysosomes (Ebsen et al. 2015),
endosomes (Gephart et al. 2011; Dombernowsky et al.
2015), and exosomes negative for the ER marker calretic-
ulin (Higginbotham et al. 2011). Moreover, Gutwein et al.
demonstrated that ADAM10-mediated L1 migration fac-
tor cleavage occurs in Golgi-derived vesicles in tumor
cells (Gutwein et al. 2002). This was further supported by
a recent paper suggesting that also ADAM10/ADAM17-
mediated release of soluble FasL occurs from an intracel-
lular vesicular pool of secretory lysosomes in stimulated T
lymphocytes (Ebsen et al. 2015).
Moreover, after ligand binding, EGFR traffics in endo-
somes from the plasma membrane to an intracellular
compartment to continue its signaling (Vieira et al. 1996;
Teis et al. 2006). EGF-dependent MAPK signaling occurs
from late endosomes and lysosomes (de Araujo et al.
2013). Interestingly, the MAPK/ERK pathway regulates
trafficking of ADAM17 phosphorylated at Thr735 from
the endoplasmic reticulum toward the plasma membrane
(Soond 2005; Hilliard et al. 2011), which can be also acti-
vated through ligand binding to EGFR. Higginbotham
et al. showed that AREG containing exosomes are rapidly
internalized by recipient cells in an EGFR-dependent
manner (Higginbotham et al. 2011), enhancing invasion
of LM2-4175 cells through Matrigel and wound healing.
In our ALI-PBEC system, we observed a predominantly
lateral localization of EGFR under basal culture condi-
tions. After exposure to CS, we observed a more cytoplas-
mic localization, consistent with EGFR activation
(Figure S2). Therefore, in line with these and published
observations, our findings suggest that in HBEC-ALI, CS
triggers EGFR-mediated trafficking of ADAM17 and its
substrates to a common subcellular compartment to allow
proteolysis and subsequent secretion of soluble products
(Fig. 8). At this time, we cannot establish to what extent
autocrine signaling through shed ADAM substrates deter-
mine this response, or whether alternative mechanisms
such as transactivation by intracellular kinases or oxida-
tion or the extracellular receptor domain plays a role.
Additional studies of triggered trafficking of EGFR,
ADAM17-P, and its substrates in polarized airway cells
are required to further establish this mechanism.
In addition to CS-enhanced release through ADAM17
enzymatic activity, we observed transiently enhanced
mRNA expression of both AREG and full-IL6R in ALI-
PBEC upon CS exposure (Figure 3). CS did not affect
the level of the alternatively spliced form of IL6R, so we
conclude that alternative splicing unlikely contributes to
CS-enhanced release of IL6R. Previously, we observed
upregulated IL-8 mRNA expression in ALI-PBEC
exposed to CS as a result of enhanced EGFR phosphory-
lation and activation of the downstream MAPK/ERK1/2
signaling pathway (Amatngalim et al. 2015). Here, we
report that CS-induced IL6R and AREG mRNA expres-
sion was also reduced upon EGFR inhibition. In addi-
tion, we show here for the first time that inhibition of
ADAM17 has the same effect on these mRNA levels
(Fig. 7). Therefore, our data suggest that CS enhances
factors common for activation of IL6R, AREG, and IL-8
mRNA expression likely via an autocrine ADAM17-
EGFR axis (Fig. 8).
The transcriptional and posttranscriptional regulation
of these genes upon inhaled toxic substances has not
been fully elucidated. Induced EGFR signaling is able to
activate transcription of target genes. In addition, it has
been shown that CS extract enhances HuR-mediated IL-
8 mRNA stability in airway epithelial cells (Hudy and
Proud 2013). Moreover, UV-exposure of keratinocytes
enhances mRNA HuR-mediated stability of AREG, in an
EGFR-dependent manner (Nakayama et al. 2013). These
observations suggest that CS-induced activation of EGFR
enhances sIL6R, AREG, and IL8 mRNA stability in ALI-
PBEC. Furthermore, mRNA regulation may be altered in
cultured airway epithelial cells from COPD patients
(Steiling et al. 2013). CS-treated COPD ALI-PBEC
expressed lower AREG and IL6R mRNA levels on aver-
age compared to non-COPD controls, but this difference
was not statistically different (Fig. 3). Further studies on
mRNA stability in this system are required to establish
this. Nevertheless, this observation contrasts with the
shedding data (Fig. 2) and suggests that ADAM17-
dependent AREG and sIL6R output is not primarily reg-
ulated on the mRNA level, but involves posttranslational
regulation.
Our data support the relevance of the ADAM17/EGFR
pathway in COPD development and progression. Selective
inhibitors of ADAM17, EGFR, and other components of
this signaling pathway such as JAK and MAPK potentially
expand therapeutic possibilities. The development of
ADAM inhibitors for clinical use has been studied inten-
sively (Moss et al. 2008; Duffy et al. 2011; Dreymueller
et al. 2015). In cellular and animal tumor models, positive
results were recorded (Witters et al. 2008). An ADAM17
inhibitor, TAPI-0, reduced bleomycin-induced lung
inflammation (Lee et al. 2012). The selective inhibitor
TMI-2 used in this study, reduced LPS-induced inflamma-
tion in vivo (Zhang et al. 2004). However, due to a lack of
target specificity of available compounds, and side effects
associated with the various other biological functions of
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ADAMs, chronic and systemic application of these com-
pounds in humans is so far prohibited (Arribas and Esse-
lens 2009). Clearly, more advanced intervention tools are
required. Our data offer new insights in the regulation of
mRNA expression, secretion, and release of ADAM17 sub-
strates in airway epithelial cells upon triggering, which in
combination with state of the art molecular design and
advanced organotypic cellular modeling of airways could
allow development of more selective inhibitors, targeted to
specific cells and subcellular domains.
In summary, this study provides evidence that
ADAM17-mediated release and shedding of IL-6R and
AREG is highly enhanced in airway epithelial cells in
response to CS-induced injury. Next to ADAM17, we
highlight the importance of EGFR in the regulation of
IL6R and AREG release and mRNA expression. Moreover,
CS-induced ADAM17-mediated shedding of IL6R and
AREG is especially high in COPD ALI-PBEC, suggesting
that reducing ADAM17 activity in COPD might be a
potential therapeutic approach.
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Abstract	
A	disintegrin	and	metalloprotease	17	(ADAM17)	activity	is	involved	in	chronic	inflammation	
and	tissue	remodeling.	Since	these	are	hallmarks	of	CF	 lung	disease	we	aimed	to	establish	
whether	 CFTR	 deficiency	 affects	 ADAM17	 in	 polarized	 CFBE41o-	 cells	 lacking	 functional	
CFTR	(iCFTR-)	compared	to	cells	with	induced	CFTR	expression	(iCFTR+).	We	found	enhanced	
ADAM17-mediated	shedding	of	an	EGFR	ligand,	amphiregulin	(AREG)	in	iCFTR-	compared	to	
iCFTR+	 cells.	 This	 difference	 was	 observed	 at	 air-liquid	 interface,	 but	 not	 in	 submerged	
culture.	 Expression	 of	 the	 G551D	 mutant	 form	 of	 CFTR	 does	 not	 have	 this	 effect.	 As	
previously	 reported,	 ADAM17-mediated	 AREG	 shedding	 is	 tightly	 regulated	 by	 tyrosine	
kinases	 and	 phosphatases,	 particularly	 by	 EGFR/MAPK	 and	 SRC.	 iCFTR-	 cells	 displayed	
enhanced	apical	 presentation	of	 the	basolateral	marker	 EGFR	 compared	 to	 iCFTR+,	which	
suggests	 its	 abnormal	 trafficking	 in	 CFTR	 deficient	 cells.	 Furthermore,	 AREG	 shedding	 is	
controlled	 by	 extracellular	 redox	 potentials,	 since	 the	 non-permeant	 natural	 antioxidant	
glutathione	 (GSH),	 but	 not	 its	 permeant	 precursor	 GSH	 ester,	 significantly	 inhibits	 AREG	
release.	The	apical	extracellular	redox	state	measured	with	a	fluorescent	ROS	probe	(Grx1-
roGFP-GPI)	 indicated	 enhanced	 oxidation	 of	 the	 apical	 surface	 fluid	 (ASL)	 in	 iCFTR-	
compared	to	 iCFTR+	cells.	 In	contrast,	an	 intracellular	 fluorescent	ROS	probe	(Grx1-roGFP)	
did	not	reveal	a	difference	between	 iCFTR-	and	 iCFTR+	cells.	 In	summary	our	data	suggest	
that	 in	 iCFTR-	 cells	 a	hyper-oxidized	 state	of	 the	extracellular	membrane,	 likely	 caused	by	
defective	GSH	 secretion,	 results	 in	 enhanced	 activity	 of	 the	 EGFR/ADAM17	 signaling	 axis.	
This	may	contribute	to	the	development	of	CF	lung	pathology,	which	should	be	investigated	
in	future	studies.	
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INTRODUCTION	
More	 than	 2000	 different	 mutations	 in	 the	 cystic	 fibrosis	 transmembrane	 conductance	
regulator	gene	(CFTR)	have	been	identified.	Most	of	these	mutations	impair	the	function	of	
the	 CFTR	 protein	 (68)	 (76),	 an	 anion	 channel	 involved	 in	 fluid	 homeostasis	 in	 multiple	
secretory	epithelia	(19)	(46),	leading	to	a	recessive	inherited	disease	Cystic	Fibrosis	(CF).	The	
morbidity	and	mortality	of	CF	patients	 is	mainly	due	to	chronic	 lung	disease	characterized	
by	 mucus	 plugging,	 chronic	 inflammation,	 recurrent	 bacterial	 infections,	 and	 tissue	
remodeling	(11).		
	
So	 far,	 the	 results	 of	 gene	 therapy	 and	 small	molecule	 therapies	 aimed	 at	 correcting	 the	
activity	of	mutant	CFTR	are	promising,	but	not	sufficiently	effective	to	correct	CFTR	function	
to	 the	WT	 level	 in	 CF	 patients	 (16).	 Therefore,	 additional	 therapeutic	 strategies	 targeting	
downstream	 effects	 of	 CFTR	 deficiency	 are	 required	 to	 prevent	 or	 reduce	 loss	 of	 lung	
function,	 preferably	 as	 early	 intervention	 (44).	 This	 requires	 in	 depth	 knowledge	 of	 the	
relationship	 between	 the	 primary	 functional	 CFTR	 defect	 and	 disease	 pathology.	 In	 the	
present	 study	 we	 focused	 on	 the	 effect	 of	 CFTR	 dysfunction	 on	 airway	 epithelial	 pro-
inflammatory	and	pro-fibrotic	signaling	through	the	EGFR/ADAM17	axis.	
	
The	 transmembrane	 protease	 A	 Disintegrin	 And	 Metalloprotease	 17	 (ADAM17;	 formerly	
known	as	TACE)	is	likely	involved	in	CF	lung	disease	(17).	ADAM17	function	is	closely	linked	
to	 Epithelial	 Growth	 Factor	 Receptor	 (EGFR)	 activity.	 An	 activated	 ADAM17	 releases	 a	
soluble	 EGFR	 binding	 domain	 of	 transmembrane	 growth	 factors	 and	 cytokines	 into	 the	
extracellular	 space	 in	 a	 process	 called	 shedding.	 This	 allows	 both	 autocrine	 signaling	
towards	 the	 epithelial	 cells	 and	 paracrine	 epithelial-mesenchymal	 trans-signaling	 (6)	 (8)	
(61).	 Inhibition	 of	 either	 ADAM17	 or	 EGFR	 affect	 ADAM17-mediated	 release	 of	 EGFR	
ligands,	suggesting	that	the	EGFR/ADAM17	axis	 is	established	by	a	positive	feedback	 loop,	
likely	involving	the	MAPK	pathway	(5)	(35)	(61)	(66)	(64)	(79).	
	
In	 the	 lungs,	 the	 ADAM17/EGFR	 pathway	 is	 activated	 during	 inflammation	 and	 bacterial	
infections	 (9).	EGFR	and	ADAM17	activities	are	 involved	 in	 cytokine	 (e.g.	 IL-8)	and	growth	
factor	 (e.g.	TGFα)	 release	and	 in	 regulation	of	 their	mRNA	expression	 levels	 	 (2)	 (51)	 (69).	
Among	 other	 substrates,	 ADAM17	 sheds	 most	 of	 the	 epidermal	 growth	 factor	 receptor	
(EGFR)	ligands	(64),	including	amphiregulin	(AREG).	AREG	autocrine	signaling	affects	mucus	
expression	 (75)	 (21)	 and	 cytokine	 secretion	 (12),	whereas	 its	paracrine	 signaling	has	been	
linked	 to	 airway	 smooth	 muscle	 cell	 proliferation	 (15)	 and	 TGFβ	 induced	 fibrosis	
characterized	 by	 fibroblast	 proliferation,	 enhanced	 α-smooth	 muscle	 actin	 and	 collagen	
expression	(88).	
	
ADAM17/EGFR	signaling	is	also	involved	in	regulation	of	mucus	production.	Its	hyperactivity	
leads	to	mucus	plugging	of	distal	airways,	as	frequently	observed	in	CFTR	deficient	subjects	
(71)	 (85)	 (87).	 Importantly,	 the	 hyperactivity	 may	 also	 contribute	 not	 only	 to	 excessive	
inflammation	 and	 mucus	 secretion,	 but	 due	 to	 paracrine	 signaling	 also	 to	 lung	 tissue	
remodeling	 in	CF	 lung	disease.	EGFR/ADAM17	activity	regulates	tissue	repair	by	 increasing	
epithelial	proliferation	and	differentiation	(8)	(10)	(40)	(53).	Conversely,	inhibition	of	either	
AREG	or	EGFR	diminishes	proliferation	of	TGF-β-stimulated	lung	fibroblasts,	expression	of	α-
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smooth	 muscle	 actin	 and	 collagen	 (88)	 suggesting	 that	 hyperactivation	 of	
ADAM17/AREG/EGFR	signaling	may	contribute	to	pulmonary	fibrosis.		
	
Altered	epithelial	EGFR	expression	and	signaling	have	been	observed	in	CF	lung	disease	(55)	
(34),	but	its	cross-talk	with	ADAM17	has	not	been	studied	in	detail.	We	recently	found	that	
cigarette	 smoke	 (CS)	 leads	 to	 a	 more	 pronounced	 increase	 in	 EGFR	 dependent	 ADAM17	
activity	in	differentiated	primary	epithelial	cells	from	COPD	patients	in	comparison	to	non-
COPD	controls,	suggesting	that	chronic	inflammation	changes	the	EGFR/ADAM	signaling	axis	
(69).	An	inhibitory	effect	of	CS	on	CFTR	activity	has	recently	been	reported	(13)	(67),	which	
raises	 the	possibility	 that	 lack	 of	 functional	 CFTR	 is	 a	 contributing	 factor	 to	 the	 increased	
EGFR/ADAM17	signaling.		
	
The	EGFR/ADAM17	signaling	pathway	is	sensitive	to	oxidative	stress	(ROS),	which	activates	
the	PKC	and	MAPK	pathways	(52).	ROS	is	also	a	direct	regulator	of	both	ADAM17	and	EGFR	
activity	 by	 oxidizing	 or	 rearranging	 their	 cysteine	 residues	 (18)	 (81)	 (31).	 In	 CF	 bronchi	
proper	 oxidant/antioxidant	 homeostasis	 (25)	 is	 disrupted	 and	 increased	 concentration	 of	
reactive	 oxygen	 species	 (ROS),	 lower	 levels	 of	 glutathione	 (GSH)	 and	 reduced	 nitric	 oxide	
(NO)	 have	 been	 reported	 (25)	 (89).	 This	 abnormal	 redox	 signaling	 is	 possibly	 linked	 to	
impaired	 proteostasis	 and	 autophagy	 in	 CF	 epithelial	 cells	 (45)	 (74),	 and	 may	 enhance	
EGFR/ADAM17	responses	in	CFTR	deficient	airway	epithelial	cells.		
To	 test	 this	 hypothesis	 we	 have	 investigated	 the	 ADAM17	 activity	 in	 a	 CF	 cell	 model	 of	
airway	 epithelium	 that	 allows	 inducible	 expression	 of	 CFTR	 (77).	We	 observed	 that	 CFTR	
deficiency	 in	airway	epithelial	cells	enhances	ADAM17	dependent	growth	factor	shedding.	
This	 activity	 is	 regulated	 by	 EGFR,	 MAPK	 and	 SRC.	 Ratiometric	 measurements	 of	 redox	
potentials	show	that	the	enhanced	ADAM17/EGFR	responses	in	CFTR	deficient	cells	are	not	
related	to	a	substantial	change	in	intracellular	redox	potential,	but	can	instead	be	attributed	
to	an	increased	oxidation	state	of	the	extracellular	fluid.	Oxidation	of	the	apical	lining	fluid	
in	CFTR	deficient	condition	may	be	caused	by	defective	glutathione	transport	(25)	(38)	(89).	
Overall,	our	study	provides	novel	 insights	 in	the	 involvement	of	 the	EGFR/ADAM17	axis	 in	
CF	 pathology	 and	 suggests	 that	 intervention	 in	 this	 pathway	 may	 be	 beneficial	 for	 CF	
patients.	
	
RESULTS	
Absence	of	CFTR	expression	enhances	AREG	release	in	human	CF	bronchial	epithelial	cells.	
We	 used	 the	 immortalized	 CF	 bronchial	 epithelial	 cell	 line	 CFBE41o-	 (CFBE)	 to	 study	 the	
effect	 of	 functional	 CFTR	 expression	 on	 the	 release	 of	 amphiregulin	 (AREG),	 an	 autocrine	
and	 paracrine	 factor	 for	 EGFR	 activation	 that	 is	 involved	 in	 lung	 morphogenesis,	 tissue	
repair	following	infection	or	injury,	and	the	resolution	of	inflammation	(83).	CFBE	cells	have	
a	 CFTR	 F508del/F508del	 genotype	 with	 no	 detectable	 endogenous	 F508del	 CFTR	 protein	
expression	 (20).	 These	 cells	 were	 engineered	 to	 express	 WT-CFTR	 under	 control	 of	 a	
doxycycline	 responsive	 transactivator	 to	 a	 level	 that	 is	 comparable	 with	 the	 endogenous	
expression	 in	 Calu-3	 (77).	 Apical	 expression	 and	 function	 of	 CFTR	 was	 confirmed	 by	
immunostaining	 and	 short-circuit	 current	 (Isc)	 measurement,	 respectively	 (77).	 CFBE	 cells	
were	 seeded	 onto	 permeable	 filter	 supports,	 allowed	 to	 differentiate	 for	 4	 days	 post-
confluence	 under	 liquid-liquid	 culture	 (LLC)	 conditions	 in	 presence	 (iCFTR+)	 or	 absence	
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(iCFTR-)	of	induced	CFTR	expression,	followed	by	a	shift	to	air-liquid	interface	(ALI)	to	mimic	
the	native	environment	of	 respiratory	epithelia.	 iCFTR+	and	 iCFTR-	ALI	 filters	do	not	differ	
with	respect	to	protein	content	or	total	metabolic	activity	(Scholte,	Veit	unpublished	data).	
To	examine	the	release	of	AREG	at	the	apical	and	basolateral	plasma	membrane,	polarized	
CFBE	cells	were	cultured	at	ALI	for	24	h	followed	by	medium	change	and	re-establishment	
of	LLC	conditions	for	3	h,	medium	collection	and	ELISA.	The	AREG	release	at	the	basolateral	
membrane	was	 four	 times	 higher	 in	 comparison	 to	 the	 apical	 release,	which,	 considering	
three	times	larger	area	of	the	basolateral	 in	comparison	to	the	apical	membrane,	suggests	
little	polarity	of	AREG	secretion	in	iCFTR	cells	(Fig.	1A).		
	
	
	
Figure	1	AREG	shedding	is	enhanced	in	CFTR	deficient	CFBE.	(A)	AREG	release	is	mainly	towards	the	
basolateral	 compartment.	 The	AREG	 release	 to	basolateral	 and	apical	 compartment	was	examined	
(ELISA)	in	24h	ALI	polarized	iCFBE+	and	iCFBE-	cells	followed	by	medium	change	and	re-establishment	
of	LLC	conditions	for	3	h.	The	AREG	release	at	the	basolateral	plasma	membrane	(PM)	was	3-4	times	
higher	 in	comparison	to	 the	apical	 release.	However,	considering	 the	 larger	area	of	 the	basolateral	
cellular	 membrane	 in	 comparison	 to	 the	 apical	 (approximately	 3	 times),	 it	 suggests	 modest	
basolateral	 polarity	 of	 AREG	 secretion	 in	 iCFTR	 cells.	 Statistical	 analysis:	 paired	 t-test.	 Values	
represent	means	of	n	independent	experiments	performed	in	triplicate	(three	filters	in	parallel	within	
one	experiment).	 (B)	Functional	CFTR	expression	decreases	AREG	release	 in	CFBE	cells.	Constitutive	
basolateral	 AREG	 release	 from	 under	 LLC	 conditions	 and	 from	 4-8h	 and	 8-24h	 ALI	 differentiated	
CFBE41o-	cells	with	(iCFTR+)	and	without	(iCFTR-)	induced	CFTR	expression.	The	low	basolateral	AREG	
release	under	LCC	was	increased	upon	transfer	to	ALI	conditions.	After	ALI	exposure,	during	the	time	
span	4-8h	induction	of	CFTR	expression	partially	attenuated	AREG	release,	which	was	maintained	in	
subsequent	8-24h	medium	collections.	 (C)	 Expression	of	 the	mutant	G551D-CFTR	 in	CFBE41o-	 cells	
(iG551D+)	did	not	significantly	reduce	AREG	release	in	comparison	to	CFBE41o-	cells	not	expressing	
G551D-CFTR	(iG551D-).		
	
AREG	levels	were	determined	by	ELISA	and	expressed	as	pg	AREG	per	filter	produced	per	hour.	Data	
were	collected	 in	parallel	 for	 iCFTR-	and	CFTR+	 in	 triplicate	 (three	different	 filters	per	experiment),	
averaged	and	presented	as	a	single	value	 in	a	 figure.	Horizontal	bars	 indicate	averages	of	averaged	
triplicates	of	n	separate	experiments	with	SEM	values.	Statistical	analysis:	unpaired	t-test.		
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The	 low	 constitutive	 AREG	 release	
under	 LLC	 conditions	 (~2	 pg/filter*hour)	
was	 increased	 by	 four	 to	 five	 fold	 upon	
transfer	to	ALI	conditions	(Fig.	1B).	This	was	
associated	 with	 a	 transient	 increase	 in	
AREG	 mRNA	 expression	 (Fig.	 2A).	 The	
increase	in	AREG	release	was	attenuated	by	
induction	 of	 CFTR	 expression,	 which	
reduced	 the	 AREG	 secretion	 rate	 by	 ~35%	
from	 ~9	 to	 6	 pg/filter*hour	 in	 the	
basolateral	 medium	 (Fig.	 1B).	 The	 CFTR	
suppressive	 effect	 was	 maintained	 in	
subsequent	 medium	 collections	 (8-24h)	
under	 ALI,	 however	 it	 was	 absent	 in	
epithelia	under	 LLC	 (Fig.	1B).	 Expression	of	
the	 mutant	 G551D-CFTR,	 which	 has	 a	
comparable	 biosynthetic	 processing	 and	
stability	to	the	WT	CFTR,	but	functionally	is	
severely	 impaired	 (77)	 (3),	 did	 not	
significantly	 reduce	AREG	 release	 (Fig.	 1C).	
Furthermore,	 this	 result	 excludes	 a	 direct	
influence	of	doxycycline	on	AREG	shedding	
activity	 in	 this	 system.	 Similarly,	 removing	
doxycycline	 from	 the	 medium	 for	 24h	
before	 the	 experiment	 did	 not	 affect	
shedding	activity	(n=1	in	triplicate,	data	not	
shown).	Also,	doxycycline	did	not	affect	the	
relative	expression	 levels	 of	AREG	 in	 these	
cells	 (Fig.	 2A).	 These	 data	 indicate	 that	
constitutive	 WT	 CFTR	 activity	 is	 necessary	
and	 sufficient	 to	 limit	 the	 excess	 secretion	
of	AREG	in	CF	epithelia	(Fig.	1B).	
	
The	 increased	 AREG	 release	 of	 CFBE	
epithelia	is	mediated	by	ADAM17	
The	 increased	 release	 of	 AREG	 in	 iCFTR-	
compared	to	iCFTR+	CFBE	cells	(Fig.	1B)	was	
not	reflected	by	a	difference	in	AREG	mRNA	
levels	 (Fig.	 2A),	 suggesting	 that	 the	 CFTR	
may	 influence	 the	 shedding,	 rather	 than	 the	 expression	 of	 AREG.	 AREG	 is	 expressed	 as	 a	
type-I	transmembrane	protein	(pro-AREG)	that	is	predominantly	directed	to	the	basolateral	
membrane	by	a	cytosolic	sorting	motif,	where	it	undergoes	constitutive	internalization	and	
recycling	(28).	The	ectodomain	shedding	of	pro-AREG	is	mediated	by	the	metalloproteinase		
A)	
B)	
C)	
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Figure	2	CFTR	expression	does	not	alter	the	mRNA	
levels	of	AREG,	ADAM17	or	EGFR.	The	mRNA	levels	
of	 AREG	 (A),	 ADAM17	 (B)	 and	 EGFR	 (C)	 were	
determined	 by	 qPCR	 in	 CFBE	 differentiated	 for	 5	
days	on	filter	supports	under	LLC	and	shifted	to	ALI	
for	 the	 indicated	 times.	 Data	 are	means	±	 SEM	of	
three	independent	experiments.	
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Figure	3	Increased	CFTR-dependent	basolateral	AREG	release	is	mediated	by	ADAM17	
(A)	Differentiated	CFBE	were	shifted	to	ALI	for	24	h	followed	by	addition	of	the	fluorogenic	ADAM17	
substrate	(10	µM,	1h)	to	the	basolateral	medium	in	presence	or	absence	of	TMI1	(2	µM,	n	=	3),	TMI-
2(1	µM,	n	=	5)	or	an	equivalent	amount	of	carrier	(DMSO,	n	=5).	Data	are	means	±	SEM	of	averaged	
independent	experiments	normalized	to	iCFTR-	(100%),	statistical	analysis	was	performed	by	one	way	
ANOVA.	(B)	8h	treatment	with	the	selective	ADAM17	inhibitor,	TMI-2	(1μM,	Wyeth)	decreased	AREG	
release	 to	 the	 same	 extend	 as	 treatment	 with	 an	 inhibitor	 targetting	 a	 broad	 spectrum	 of	
metalloproteases,	TMI-1	(2μM,	Wyeth),	providing	the	involvement	of	ADAM17	in	AREG	shedding	in	
24h	ALI	differentiated	iCFTR+	and	iCFTR-	CFBE41o-	cells.	
ELISA	 data	 were	 normalized	 to	 iCFTR-	 condition.	 Values	 represent	 means	 of	 n	 independent	
experiments	in	triplicates	(three	different	filters	per	experiment).	Statistical	analysis:	unpaired	t-test.	
Statistic	 of	 differences	 between	 iCFTR+	 and	 iCFTR-	 indicated	 at	 the	 top	 of	 the	 graph,	 differences	
between	control	condition	and	treatment	are	indicated	just	above	the	bars.		
	
	
	
ADAM17	(60)	and	occurs	mainly	intracellularly	in	differentiated	airway	epithelial	cells,	likely	
in	endosomal	compartments	(69).		
To	 measure	 the	 ADAM17	 activity	 in	 polarized	 CFBE	 monolayers	 under	 ALI	
conditions,	a	fluorogenic	ADAM17	substrate	was	added	to	the	basolateral	medium	for	2	h.	
In	 the	absence	of	CFTR	expression	 significantly	higher	amounts	of	 substrate	were	cleaved	
(Fig.	3A).	The	highly	specific	ADAM17	inhibitor	TMI-2	(1μM)	(86)	reduced	production	of	the	
fluorescent	product	to	a	similar	extent	as	a	broad	specificity	ADAM/MMP	inhibitor	(TMI-1)	
(2μM)	 confirming	 the	 involvement	 of	 ADAM17	 in	 this	 activity	 (Fig	 3A).	 Since	 CFTR	
expression	 or	 culture	 conditions	 did	 not	 alter	 the	 ADAM17	 mRNA	 levels	 (Fig.	 2B),	 these	
results	 suggest	 that	 under	 ALI	 conditions	 active	 CFTR	 decreases	 the	 ADAM17	 enzyme	
activity.	Consistent	with	this	observation	and	similar	to	the	fluorogenic	ADAM17	substrate	
release,	inhibition	of	the	ADAM17	activity	with	the	highly	specific	inhibitor	TMI-2	(1μM)	(86)	
also	 reduced	AREG	release	 to	a	similar	extent	as	a	broad	specificity	ADAM/MMP	 inhibitor	
(TMI-1)	 (2μM),	confirming	 the	 involvement	of	ADAM17	 in	 this	activity	 (Fig	3B)	 (85).	These	
data	suggest	that,	as	in	other	epithelial	cell	lines	(9)	and	primary	human	bronchial	epithelia	
(69),	 ADAM17	 is	 the	 main	 shedding	 protease	 involved	 in	 AREG	 release	 in	 CFBE	 cells.	
Moreover,	inhibition	of	ADAM17	reduced	the	CFTR-dependent	differences	in	proteolysis	of	
a	 fluorescent	 substrate	 (Fig	 3A)	 and	 in	 AREG	 release	 (Fig	 3B),	 suggesting	 that	 CFTR	
deficiency	increases	ADAM17	dependent	shedding	activity.	
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Figure	 4	 Basolateral	 AREG	 shedding	 is	 tightly	 regulated	 by	 protein	 phosphatases	 and	 kinases,	 in	
particular	EGFR/MAPK	
(A)	The	broad	range	tyrosine	kinase	inhibitor	genistein	(100	μM)	strongly	reduces	the	AREG	shedding	
in	 iCFBE41o-	 cells.	 (B)	 Herbimycin	 A	 (1	 μM),	 as	 a	 consequence	 of	 Hsp90	 inhibition	 destabilizes	
multiple	 kinases	 and	 results	 in	 decreased	 AREG	 release,	 particularly	 in	 iCFTR-	 CFBE41o-	 cells.	 (C)	
Conversely,	 the	 tyrosine	 phosphatase	 inhibitor	 sodium	 orthovanadate	 (25	 μM)	 induces	 AREG	
shedding,	 also	 in	 particular	 in	 iCFTR-	 CFBE41o-	 cells.	 (D)	 SRC	 kinase	 family	 inhibitor,	 PP2	 (10	 μM)	
decreased	 AREG	 shedding,	while	 the	 inactive	 analog	 PP3	 had	 no	 inhibitory	 effect	 (10	 μM)	 (E)	 The	
canonical	 inhibitor	 of	 EGFR	 AG1478	 (1μM)	 strongly	 inhibits	 AREG	 release,	 to	 the	 similar	 extent	 as	
selective	 ADAM17	 inhibitor	 TMI-2	 presented	 in	 Figure	 2	 (F)	 Inhibition	 of	 downstream	MAP	 kinase	
MEK1/2	 with	 U0126	 inhibitor	 (10	 μM)	 also	 reduces	 AREG	 shedding.	 Reduction	 of	 AREG	 shedding	
upon	 inhibition	 of	 EGFR/MAPK	 pathway	 proofs	 the	 existence	 of	 positive	 feedback	 loop	 in	
EGFR/ADAM17	axis.	
	
ELISA	 data	 were	 normalized	 to	 iCFTR-	 condition.	 Values	 represent	 means	 of	 n	 independent	
experiments	in	triplicates	(three	different	filters	per	experiment).	Statistical	analysis:	unpaired	t-test.	
Statistic	 of	 differences	 between	 iCFTR+	 and	 iCFTR-	 indicated	 at	 the	 top	 of	 the	 graph,	 differences	
between	control	condition	and	treatment	are	indicated	just	above	the	bars.		
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Figure	5	
CFTR	 deficiency	 increases	 apical	 localization	 and	 phosphorylation	 of	 EGFR	 in	 CFBE41o-	 cells	
cultured	at	ALI	
(A-D)	Western	blot	analysis.	In	four	separate	independent	experiments	iCFTR-	and	CFTR+	cells	were	
grown	in	quadruplicate	for	8h	at	ALI	and	analyzed	(see	Material	and	Method	section	for	details)	(A)	
EGFR	(green	fluorescence)	and	(B)	EGFR-P	(luminescence)	show	representative	results	of	blots	from	a	
single	 experiment.	Quantitative	 analysis	 of	 EGFR	 (C)	 and	 EGFR-P	 (D)	 of	 all	 data,	 normalized	 to	 the	
average	percentage	for	iCFTR-	cells	per	experiment	show	no	significant	effect	of	CFTR	expression	on	
total	 EGFR	 expression,	 but	 a	 significant	 reduction	 of	 EGFR	 phosphorylation.	 (E,F)	 Laser	 confocal	
fluorescence	 microscopy	 pictures	 of	 EGFR	 immunostaining	 in	 24h	 ALI	 exposed	 CFTR-	 and	 CFTR+	
iCFBE41o-	 cells	 showed	 that	 EGFR	 is	 predominantly,	 but	 not	 exclusively	 localized	 to	 lateral	
membrane.	 Particularly	 in	 iCFTR-	 CFBE41o-	 cells	 apical	 EGFR	 staining	 is	 localized	 to	 the	 apical	
membrane.	(G)	EGFR	apical	plasma	membrane	density	(PMD,	cell	surface	labeling	ELISA,	see	Material	
and	Methods)	 is	 higher	 in	 iCFTR-	 24h	ALI	 CFBE41o-	 cells	 than	 in	 iCFTR+,	 and	 this	 difference	 is	 not	
present	 in	LCC	cells	 (H)	EGFR	basolateral	PMD	in	CFBE41o-	cells	does	not	show	differences	 in	EGFR	
expression	between	iCFTR-	and	iCFTR+	CFBE41o-	cells	neither	under	ALI	nor	LCC	condition.	(I)	EGFR	
apical	and	(J)	basolateral	PMD	did	not	show	the	differences	in	apical	and	basolateral	EGFR	expression	
in	 iG551D-	and	 iG551D+	CFBE41o-	cells	 (n=number	of	 independent	experiments,	 in	triplicate	each).	
Statistical	analysis:	unpaired	t-test.		
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Figure	6	
EGF	stimulation	causes	EGFR	internalization	and	AREG	shedding	
(A)	EGFR	aggregates	3h	after	EGF	(10ng/ml)	stimulation	in	24h	ALI	exposed	CFBE41o-	cells	(untreated	
control:	Fig.	5A),	 (B)	This	 is	accompanied	by	strong	 induced	AREG	shedding	at	the	8h	and	24h	time	
points	(nearly	20	and	40-fold	respectively).		
	
ELISA	 data	 were	 normalized	 to	 the	 iCFTR-	 condition.	 Values	 represent	 means	 of	 n	 independent	
experiments	in	triplicates	(three	different	filters	per	experiment).	Statistical	analysis:	unpaired	t-test.	
Statistic	 of	 differences	 between	 iCFTR+	 and	 iCFTR-	 indicated	 at	 the	 top	 of	 the	 graph,	 differences	
between	control	condition	and	treatment	are	indicated	just	above	the	bars.		
	
	
	
Inhibition	of	EGFR	signaling	abrogates	the	CFTR-dependent	differences	in	AREG	release	
Since	it	is	not	obvious	how	the	loss	of	an	apical	anion	transporter	could	directly	lead	to	an	
increase	 in	ADAM17	activity,	which	 is	active	 in	 intracellular	compartments	 (69)	and	at	 the	
plasma	membrane	(8)	(63),	we	measured	the	involvement	of	signaling	pathways	upstream	
of	ADAM17.	Among	other	factors,	ADAM17	activity	is	regulated	by	receptor	tyrosine	kinases	
(RTKs)	(23).	The	broad-range	tyrosine	kinase	inhibitor	genistein	(100	μM)	strongly	reduced	
the	 AREG	 shedding	 and	 diminished	 the	 CFTR-dependent	 differences	 in	 cells	 under	 ALI	
conditions	 (Fig.	 4A).	 Similarly,	 treatment	with	 herbimycin	 A	 (1	 μM),	which	 inhibits	 Hsp90	
(80)	 leading	 to	 the	 destabilization	 of	 multiple	 kinases	 (70),	 resulted	 in	 decreased	 AREG	
release	 in	 non-CFTR	 expressing	 cells	 (Fig.	 4B).	 Consistent	 with	 the	 notion	 that	 tyrosine	
kinase	 signaling	 is	 involved	 in	 the	augmented	AREG	 shedding	 in	 the	absence	of	CFTR,	 the	
tyrosine	phosphatase	inhibitor	sodium	ortho-vanadate	(25	μM)	increased	AREG	release	(Fig.	
4C).	
	 Next,	we	inhibited	specific	candidate	tyrosine	kinases	that	are	involved	in	ADAM17	
activation.	The	SRC-kinase	in	part	regulates	ADAM17	activity	(63).	The	SRC	family	 inhibitor	
PP2	decreased	AREG	shedding	(10	μM,	Fig.	4D;	lower	concentrations	1	μM	and	3	μM;	were	
equally	effective,	data	not	shown),	while	the	inactive	analog	PP3	(10	μM)	had	no	effect.	The	
SRC-kinase	may	also	directly	phosphorylate	 and	activate	 the	EGFR,	bypassing	EGFR	 ligand	
binding,	which	results	in	downstream	MAP	kinase	activation	and	in	turn	ADAM17	activation	
(27)	 (43).	The	canonical	 inhibitor	of	EGFR	signaling	AG1478	(1μM)	strongly	 inhibited	AREG	
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release	 (Fig.	 4E).	 Similarly,	 inhibition	 of	 the	 downstream	 MAP	 kinase	 MEK1/2	 with	 the	
inhibitor	U0126	(10μM)	reduced	AREG	release	(Fig.	4F).	These	data	are	consistent	with	the	
existence	 of	 a	 positive	 feedback	 loop	 in	 the	 EGFR/ADAM17	 axis	 that	 involves	 the	MAPK	
pathway	(9)	(63)	(69).	Most	 importantly,	 inhibition	of	SRC,	EGFR	or	MEK1/2	abrogated	the	
CFTR-dependent	 differences	 in	 AREG	 shedding,	 indicating	 that	 non-functional	 CFTR	
activates	the	EGFR-ADAM17	axis.	
Figure	7	CFTR	mediates	oxidation	of	the	air	surface	liquid	(ASL),	but	not	cytosol	in	CFBE41o-	cells	
(A)	 Laser	 confocal	 fluorescence	microscopy	 pictures	 of	 iCFBE41o-	 cells	 lentivirally	 transduced	with	
glutaredoxin-1-redox	sensitive	GFP	(Grx-1-GFP)	(B)	The	ratiometric	fluorescence	measurements	(the	
ratio	 of	 405	nm	emission	 and	 488	nm	excitation)	 of	Grx-1-GFP	probe	 expressed	 in	 iCFBE41o-	 cells	
revealed	no	difference	in	cytosolic	glutathione	redox	potential	between	iCFTR+	and	iCFTR-	cells.	Cell	
permeable	 reducing	 agent	 DTT	 (0,5	 mM)	 was	 used	 as	 a	 control	 for	 ratiometric	 fluorescence	
measurements.	 (C)	 Laser	 confocal	 fluorescence	 microscopy	 pictures	 of	 iCFBE41o-	 cells	 lentivirally	
transduced	with	glutaredoxin-1-redox	sensitive	GFP	 fused	 to	C-terminal	GPI	anchor	and	N-terminal	
signal	 sequence	 (Grx-1-GFP-GPI)	 (D)	 The	 ratiometric	 fluorescence	 measurements	 of	 apically	
expressed	Grx-1-GFP-GPI	probe	in	iCFBE41o-	cells	measured	as	the	ratio	of	405	nm	emission	and	488	
nm	excitation	of	 the	probe	 revealed	oxidation	of	ASL	 in	CFTR	deficient	 cells.	 The	cell	 impermeable	
reducing	agent	MESNA	(50	μM)	was	used	as	a	control.		
Statistical	analysis:	unpaired	t-test;	n	indicates	the	number	of	independent	experiments	in	duplicate	
or	triplicate,	meaning	that	two	or	three	different	filters	were	used	per	experiment.		
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CFTR	 deficiency	 increases	 apical	 localization	 and	 phosphorylation	 of	 EGFR	 in	 CFBE	 cells	
cultured	at	ALI	
To	test	whether	the	EGFR	inhibitor-sensitive	and	CFTR	modulated	AREG	release	is	the	result	
of	 increased	 EGFR	 expression,	 the	 mRNA	 and	 protein	 levels	 of	 the	 receptor	 were	
determined	by	qPCR	(Fig.	2C)	and	immunoblot	(Fig.	5A-D),	respectively.	The	levels	of	EGFR	
mRNA	 at	 different	 times	 before	 and	 after	 shift	 to	 ALI	 conditions	 were	 not	 significantly	
different	 between	 CFTR	 and	 non-CFTR	 expressing	 cells	 (Fig.	 2C).	 Consistent	with	 this,	 the	
total	EGFR	antigen,	as	determined	by	western	blotting,	did	not	differ	significantly	between	
iCFTR-	and	iCFTR+	(Fig.	5A,	C).	
Indirect	 immunostaining	and	 laser	confocal	 fluorescence	microscopy	showed	EGFR	
was	 predominantly	 confined	 to	 the	 basolateral	 membrane	 in	 both	 iCFTR+	 and	 iCFTR-	
expressing	cells	(33),	but	a	small	proportion	of	the	EGFR	staining	was	localized	to	the	apical	
membrane	(Fig.	5E,F).	The	specificity	of	the	EGFR	immunofluorescence	signal	was	confirmed	
by	 the	 intracellular	 localization	of	EGFR	antigen	after	3	h	stimulation	with	EGF	 (Fig.	6A),	a	
known	 trigger	 for	 internalization	 and	 lysosomal	 degradation	 of	 the	 receptor	 (57).	 To	
establish	an	effect	of	CFTR	deficiency	on	EGFR	localization,	the	plasma	membrane	density	of	
EGFR	was	 determined	 at	 the	 apical	 and	 basolateral	 cell	 surface	 (Fig.	 5G,H).	 Here	 an	 anti-
EGFR	antibody	 recognizing	 the	extracellular	domain	of	EGFR,	 followed	by	an	HRP-coupled	
secondary	antibody	was	used	to	detect	 the	cell	 surface	 localized	receptor	by	 fluorescence	
spectroscopy	with	the	cell	 impermeable	Amplex	Red	as	HRP	substrate	(see	Methods).	The	
apical	 EGFR	 PM	density	was	 increased	 by	 ~30%	 in	 non-CFTR	 expressing	 cells	 cultured	 for	
24h	 under	 ALI	 conditions	 compared	 to	 CFTR-expressing	 cells	 (Fig.	 5G).	 In	 contrast,	 at	 the	
basolateral	 membrane	 in	 ALI	 cultured	 cells,	 and	 in	 cells	 grown	 under	 LLC	 conditions	 no	
CFTR-dependent	 differences	 in	 the	 EGFR	 PM	 expression	 were	 observed	 (Fig.	 5H).	
Furthermore,	expression	of	G551D-CFTR	in	cells	cultured	under	ALI	did	not	suppress	apical	
(Fig.	5I)	or	basolateral	EGFR	PM	density	(Fig.	5J).		
Taken	together,	these	results	indicate	that	functional	CFTR	deficiency	alters	the	net	polarity	
of	EGFR	under	ALI	conditions.	However,	the	majority	of	EGFR	is	still	localized	at	or	near	the	
basolateral	membrane	in	iCFTR-	cells	(Fig	5A).	
The	constitutive	phosphorylation	of	EGFR	at	Y1173,	a	measure	of	EGFR	activity,	was	
decreased	in	CFTR	expressing	cells	compared	to	CFTR	deficient	cells	cultured	for	8	h	under	
ALI	as	determined	by	phospho-immunoblotting	(Fig.	5	B,D,H),	whereas	the	total	amount	of	
EGFR	was	not	significantly	affected	by	CFTR	induction	(Figure	5C),	consistent	with	the	EGFR	
mRNA	results	(Figure	2A).	Activation	of	EGFR	by	exogenous	stimulation	with	10	ng/ml	EGF	
at	both	the	apical	and	basolateral	PM	resulted	 in	a	massive	CFTR-independent	 increase	 in	
AREG	 release,	 and	 gradually	 abolished	 the	 CFTR-dependent	 differences	 (Fig.	 6B).	 Taken	
together,	these	data	indicate	that	CFTR	expression	modulates	EGFR	trafficking	and	the	level	
of	 EGFR	 constitutive	 activity,	 but	 not	 the	 expression	 or	maximal	 signaling	 capacity	 of	 the	
EGFR	pathway.	
	
CFTR	mediated	shift	of	the	extracellular	redox	potential	attenuates	AREG	release.	
Since	the	expression	of	functional	CFTR	is	sufficient	to	limit	the	augmented	AREG	release	in	
CF	cells,	it	is	plausible	to	assume	that	CFTR-mediated	ion	transport	at	the	apical	membrane	
attenuates	the	constitutive	signaling	that	leads	to	AREG	shedding.	CFTR	transports	chloride,	
bicarbonate	and	reduced	glutathione	(GSH)	that	regulate	the	height,	pH	and	redox	potential	
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of	 the	 airway	 surface	 liquid	 (ASL),	 respectively	 (62).	 It	 was	 previously	 established	 that	
oxidation	activates	ADAM17	directly,	by	changing	its	conformation	(18)	(81)	and	indirectly,	
by	initiating	upstream	signaling	that	increases	ADAM17	activity	through	activating	SRC	(63)	
or	 EGFR	 (54).	 To	 determine	 if	 CFTR	 expression	 leads	 to	 changes	 in	 the	 cytosolic	 and	 ASL	
redox	state,	which	may	lead	to	induced	ADAM17	activity,	we	used	the	glutaredoxin1–redox-
sensitive	GFP	 (Grx1-roGFP)	 fusion	protein	 that	allows	 for	measurement	of	 the	glutathione	
redox	 potential	 by	 ratiometric	 fluorescence	 measurement	 (31).	 The	 unmodified	 (Grx1-
roGFP)	or	the	N-terminal	signal	sequence	and	C-terminal	GPI-anchor	signal	fused	(SS-Grx1-
roGFP-GPI)	redox	probes	were	delivered	by	lentiviral	transduction	into	the	CFBE-iCFTR	cells	
for	 expression	 in	 the	 cytosol	 or	 tethered	 to	 the	 outer	 leaflet	 of	 the	 plasma	 membrane,	
respectively	(Fig	7A).		
	
Figure	8	ROS	scavengers	decrease	AREG	release	from	CFBE41o-	cell	
(A)	Glutathione	(10	mM	GSH),	but	not	the	cell	permeable	GSH	ester	(1	mM),	strongly	inhibits	AREG	
release	in	iCFTR	CFBE41o-	cells	abrogating	differences	between	CFTR-	and	CFTR+	condition	(B)	A	ROS	
scavenger,	N-acetyl	cysteine	(5	mM	NAC)	and	NADPH	oxidase	inhibitor	diphenylene-iodonium	(5	μM	
DPI)	 significantly	decreases	AREG	release	 in	CFTR+	and	CFTR-	 iCFTR	CFBE	cells,	 showing	 the	 role	of	
ROS	in	regulation	of	ADAM17	activity.	
ELISA	 data	 were	 normalized	 to	 iCFTR-	 condition.	 Values	 represent	 means	 of	 n	 independent	
experiments	in	triplicates	(three	different	filters	per	experiment).	Statistical	analysis:	unpaired	t-test.	
Statistic	 of	 differences	 between	 iCFTR+	 and	 iCFTR-	 indicated	 at	 the	 top	 of	 the	 graph,	 differences	
between	control	condition	and	treatment	are	indicated	just	above	the	bars.	
	
	
In	 submerged	 non-polarized	 CFBE	 the	 cytosolically	 confined	 Grx1-roGFP	 redox	
probe	was	in	a	relatively	reduced	state,	as	measured	with	a	fluorescence	plate	reader	(data	
not	 shown).	 The	 redox	 probe	 was	 slightly	 further	 reduced	 by	 the	 addition	 of	 the	 cell-
permeant	 reducing	 agent	 dithiothreitol	 (DTT),	 but	 not	 the	 cell	 impermeable	 2-
mercaptoethanesulfonic	 acid	 sodium	 salt	 (MESNA).	 Grx1-roGFP	 was	 strongly	 oxidized	 by	
addition	of	hydrogen	peroxide	(H2O2)	(data	not	shown).	In	contrast,	the	GPI-anchored	Grx1-
roGFP	was	 in	oxidized	state	under	similar	conditions	and	was	only	slightly	oxidized	further	
by	H2O2,	but	strongly	reduced	by	both	the	cell-permeant	DTT	and	the	non-permeant	MESNA	
Figure 8
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addition,	 confirming	 the	extracellular	accessibility	and	 redox	sensitivity	of	 the	probe	 (data	
not	shown).		
	 On	 polarized	 filter	 grown	 CFBE	 at	 ALI,	 the	 apical	 Grx1-roGFP	 fluorescence	 was	
measured	by	ratiometric	 laser	confocal	 fluorescence	microscopy	using	an	upright	 confocal	
microscope	 after	 shifting	 the	 cells	 for	 24	 h	 to	 ALI	 (Fig	 7A).	 Under	 these	 conditions,	 CFTR	
expression	had	no	significant	effect	on	the	redox	state	of	the	cytosolic	probe	in	iCFBE	cells	
(Fig.	 7B),	 which	 already	 was	 almost	 at	 the	 maximally	 reduced	 state,	 as	 revealed	 by	 DTT	
addition	(Fig.	7B).	In	contrast,	induction	of	CFTR	expression	resulted	in	a	more	reduced	state	
of	 the	 ASL	 probe	 Grx1-roGFP-GPI	 (Fig.	 7C),	 approaching	 the	 minimal	 fluorescence	 ratio	
detected	in	the	presence	of	MESNA	(Fig.	7D).		 	
	 Supplementation	 of	 the	 basolateral	 and	 apical	 medium	 with	 GSH	 shortly	 before	
establishing	ALI	strongly	inhibited	the	AREG	release	in	non-CFTR	and	CFTR	expressing	cells,	
and	 abrogated	 the	 CFTR-dependent	 differences	 in	 AREG	 shedding	 (Fig	 8A).	 Addition	 of	
extracellular	GSH	 (3	mM	as	 in	Fig	8)	 inhibited	AREG	shedding	 to	 the	same	extent,	but	did	
not	significantly	reduce	EGFR	Y1173	phosphorylation,	suggesting	that	the	effect	was	not	due	
to	a	change	 in	 the	activation	of	EGFR	 (n=3	 independent	experiments	 in	 fourfold,	data	not	
shown).	 In	 contrast	 to	 GSH,	 the	 cell	 permeable	 GSH	 ester,	 which	 is	 cleaved	 by	 phospho-
diesterases	and	causes	an	 increase	 in	the	 intracellular	GSH	concentration	did	not	diminish	
AREG	 shedding	 significantly	 (Fig.	 8A).	N-acetyl	 cysteine,	 a	 cell	 permeant	precursor	of	GSH	
synthesis	 that	 by	 itself	 has	 an	 antioxidant	 effect	 (59),	 reduced	 AREG	 release	 (Fig.	 8B).	
Complementary	 to	 these	 results,	 reducing	 the	 cellular	 reactive	 oxygen	 species	 (ROS)	
production	using	diphenyleneiodonium	 (DPI),	 an	 inhibitor	of	 intracellular	NADPH	oxidases	
(NOX)	 and	dual	 oxidases	 (DUOX),	 also	 reduced	AREG	 release,	 although	 to	 a	 lesser	 extend	
(Fig.	8B).		
	
Taken	 together,	 our	data	 suggest	 that	 high	extracellular	GSH	does	not	 exert	 its	 inhibitory	
effect	 on	AREG	 shedding	 through	 inactivation	 of	 EGFR,	 but	 rather	 switches	ADAM7	 to	 its	
closed,	 inactive	 conformation	 (18).	 Reduced	 extracellular	 GSH	 in	 CFTR	 deficient	 epithelia	
would	have	the	opposite	effect.		
	
DISCUSSION	
ADAM17	shedding	of	AREG	is	enhanced	by	CFTR-deficiency.	
Here	 we	 report	 that	 dysfunctional	 CFTR	 in	 differentiated	 CFBE	 airway	 epithelial	 cells	
cultured	at	air-liquid	interface	induces	activity	of	ADAM17	(Fig	1B).	Importantly,	this	effect	
was	not	observed	in	a	normally	expressed	but	inactive	form	of	CFTR	(G551D)	(Fig	1C),	which	
shows	 that	 CFTR	 activity	 is	 required	 for	 ADAM17	 regulation.	 The	 increased	 ADAM17-
mediated	 AREG	 shedding	 caused	 by	 CFTR	 deficiency	 observed	 in	 our	 model	 likely	
contributes	 to	 mucus	 hypersecretion,	 inflammation	 and	 tissue	 remodeling	 in	 CF	 lung	
disease.	Further	studies	should	test	whether	ADAM17	activation	is	also	observed	in	the	CF	
airways	in	situ,	and	whether	attenuation	of	ADAM	activity	reduces	CF	pathology.	
	
Polarity	of	shedding.	
In	differentiated	ALI-CFBE41o-	cells,	we	found	that	total	AREG	shedding	towards	the	basal	
compartment	is	fourfold	higher	than	towards	the	apical	side	(Fig	1A).	This	is	consistent	with	
the	relative	membrane	surface	area	of	the	two	compartments,	suggesting	that	there	 is	no	
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strong	 preference	 for	 shedding	 polarity.	 Importantly,	 induction	 of	 CFTR	 does	 not	 have	 a	
significant	effect	on	the	polarity	of	secretion	(Fig	1A).	In	ALI	differentiated	primary	bronchial	
epithelial	 cells	 the	 basolateral	 to	 apical	 ratio	 is	 substantially	 higher	 (69),	 which	 may	 be	
explained	by	the	fact	that	these	cells	have	a	higher	columnar	morphology	compared	to	the	
low	 cubical	 CFBE	 cells.	 Since	 the	 volume	 of	 apical	 lining	 fluid	 is	 small,	 the	 actual	 apical	
concentration	of	 ligand,	which	determines	the	rate	of	receptor	binding,	 is	potentially	high.	
Therefore,	we	have	 to	 consider	 that	 also	ADAM	 ligands	 shed	apically	 from	epithelial	 cells	
contribute	 to	 luminal	 signaling	 in	 the	 lung,	where	myeloid	 cells	 likely	play	a	major	 role	 in	
determining	 the	downstream	effects	of	AREG	signals,	 in	particular	activated	macrophages	
during	acute	 injury	 response	 (82).	 Furthermore,	enhanced	expression	of	AREG	mRNA	was	
reported	 in	 alveolar	 neutrophils	 from	 CF	 patients,	 consistent	 with	 a	 heightened	 state	 of	
inflammation	(1).	
	
Regulation	of	ADAM17	mediated	shedding	activity	by	EGFR.	
To	 establish	 the	 mechanism	 by	 which	 CFTR	 deficiency	 changes	 the	 level	 of	 ADAM17	
dependent	 agonist	 shedding	 in	 iCFTR	 CFBE	 cells,	 we	 analyzed	 the	 involvement	 of	 several	
known	effectors.	First	we	showed	that	in	this	model	ADAM17-mediated	shedding	is	tightly	
regulated	 by	 protein	 phosphatases	 and	 tyrosine	 kinases,	 particularly	 by	 SRC,	 EGFR	 and	
MAPK	(Fig	4).	Under	basal	conditions	EGFR	emerged	as	a	potent	ADAM17	regulator.	When	
inhibited,	 it	 reduced	 ADAM17	 mediated	 shedding	 to	 the	 same	 extent	 as	 the	 selective	
ADAM17	inhibitor	TMI-2	(Fig	3B),	whereas	addition	of	the	EGFR	agonist	EGF	to	the	medium	
strongly	enhances	AREG	release	(Fig	6B).	This	is	consistent	with	results	with	other	epithelial	
models	 (9)	 (56)	 and	 our	 data	 in	 primary	 ALI-HBEC	 (69).	 In	 the	 latter,	 inhibition	 of	 EGFR	
reduced	ADAM17	dependent	AREG	and	IL-6R	shedding,	as	well	as	AREG,	IL6R	and	IL8	mRNA	
levels	to	the	same	extent	as	an	ADAM17	selective	inhibitor	(69).	Therefore,	there	is	a	close	
link	between	EGFR	and	ADAM17	activity	 in	airway	cells.	 It	 is	 likely	that	the	EGFR/ADAM17	
axis	 is	 established	 by	 a	 feedback	 loop	 in	which	 EGFR	 agonists	 such	 as	 AREG	 are	 shed	 by	
ADAM17,	activating	EGFR	and	downstream	MAPK	pathway,	which	in	turn	activates	ADAM17	
(9),	or	ADAM17	regulates	EGFR	expression	by	activation	of	Notch1	(5).	Hyperactivity	of	this	
EGFR/ADAM17	axis	in	CFTR	deficient	epithelia	may	affect	CF	lung	pathology	(24).		
	
EGFR	phosphorylation	is	enhanced	by	CFTR-deficiency.	
Exaggerated	epithelial	EGFR	expression	and	abnormal	signaling	are	observed	in	chronic	lung	
disease	such	as	COPD	and	asthma	(2)		(34)	(55),	which	emphasizes	its	potential	relevance	in	
CF.	Here	we	show	that	induction	of	functional	CFTR	expression	in	CFTR	deficient	airway	cells	
does	 not	 affect	 total	 EGFR	 protein	 (Fig.	 5)	 or	 mRNA	 expression	 (Fig	 2),	 however	 it	
significantly	reduces	the	level	of	EGFR	Y1173	phosphorylation,	a	measure	of	EGFR	activation	
(Fig.	 5D).	 Our	 data	 are	 consistent	 with	 increased	 phosphorylated	 EGFR	 (EGFR-P)	 levels	
reported	 in	 airway	 epithelium	 and	 inflammatory	 cells	 from	 CF	 patients	 in	 comparison	 to	
non-CF	 controls	 (47).	 Furthermore,	 our	 data	 show	 increased	 EGFR-dependent	 AREG	
shedding	 in	 iCFTR-	 cells	 (Fig	 4E	 and	 Fig.	 6B)	 suggesting	 that	 CFTR	 deficiency	 enhances	
cellular	 signaling	 through	 the	 EGFR/ADAM17	 axis.	 In	 accordance	with	 our	 results,	 several	
reports	 suggest	 that	 active	 CFTR	 suppresses	 other	 EGFR	 related	 inflammatory	 responses,	
like	IL8	secretion	and	mucin	production	(7)	(56)	(37)	(48).	
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CFTR-deficiency	affects	EGFR	trafficking.	
As	 summarized	 in	 the	 introduction,	 one	 of	 the	 factors	 regulating	 EGFR	 activity	 is	 its	
localization	 relative	 to	 its	 target	 molecules.	 Upon	 ligand	 binding	 EGFR	 dimerizes	 and	 is	
internalized	 to	 intracellular	 compartments	 where	 it	 is	 either	 inactivated	 or	 continues	
signaling	 (36)	 (73)	 (90)	 (72).	 We	 showed	 that	 in	 CFBE-ALI	 EGFR	 is	 primarily,	 but	 not	
exclusively	 localized	 at	 the	 basolateral	 membrane	 under	 basal	 ALI	 conditions	 (Fig	 5	 E,F).	
Surface	 ELISA	 showed	 an	 increase	 of	 EGFR	 trafficking	 to	 the	 apical	 membrane	 in	 CFTR	
deficient	ALI-CFBE	cells	(Fig	5G).	Addition	of	an	inhibitory	antibody	against	EGFR	(cetixumab)	
to	 polarized	 iCFTR	 did	 not	 reduce	 AREG	 shedding,	 whereas	 basal	 addition	 was	 effective	
(Scholte	et	al,	unpublished	data).	This	does	not	support	a	major	role	of	apical	EGFR	in	this	
process,	however,	abnormal	trafficking	of	EGFR	would	 likely	be	an	 important	 factor	 in	the	
regulation	of	the	EGFR/ADAM17	axis.	
EGF	 binding	 leads	 to	 EGFR	 internalization	 and	 lysosomal	 degradation,	 whereas	 AREG	
stimulation	causes	EGFR	internalization	and	recycling	to	the	membrane	(24)	(57).	Thus,	CFTR	
dependent	enhanced	shedding	of	AREG	(Fig.	1A)	may	lead	to	activation	of	EGFR	(Fig.	5B,D)	
and	 more	 frequent	 recycling	 to	 the	 membrane	 (Fig.	 5	 G),	 sustaining	 enhanced	 EGFR	
dependent	ADAM17	activity	through	the	feedback	loop.	
As	expected,	EGF	induced	EGFR	internalization	towards	a	perinuclear	compartment	in	iCFTR	
(Fig.	6A,B)	and	caused	a	massive	 increase	 in	ADAM17	shedding	activity	 (Fig	6B),	 gradually	
reducing	 the	 difference	 between	 iCFTR+	 and	 iCFTR-.	 However,	 further	 investigations	 are	
needed	to	establish	whether	abnormal	polarisation	and	trafficking	of	EGFR	plays	a	decisive	
role	 in	 CFTR	 dependent	 EGFR/ADAM17	 activity	 (39).	 	 Furthermore,	 we	 need	 to	 establish	
whether	 this	 is	 specific	 for	 EGFR	 or	 reflects	 a	 general	 imbalance	 of	 proteostasis	 and	
deficient	autophagy	in	reported	in	CF	epithelial	cells	(22)	(45).	Our	data	support	the	notion	
that	 CFTR	 deficiency	 changes	 the	 kinetics	 of	 EGFR/ADAM17/AREG	 trafficking	 and	 activity	
(24).	 Further	 studies	 in	 primary	 bronchial	 epithelial	 cells	with	well-defined	 tight	 junctions	
and	preferably	in	CF	lung	biopsies	need	to	be	performed	to	confirm	our	observations.		
	
Regulation	of	shedding	activity	by	SRC.	
The	ubiquitous	tyrosine	kinase	c-SRC	reportedly	causes	ROS	dependent	activation	of	EGFR	
and	ADAM17	in	immortalized	epithelial	cells	(41),(63)		suggesting	it	has	a	regulatory	role	in	
the	EGFR/ADAM17	signaling	cascade.	Indeed,	in	CFTR-deficient	CFBE	cells	inhibition	of	SRC	
(PP2)	 reduced	AREG	 release	 to	 the	 level	observed	 in	 cells	with	 induced	CFTR	activity	 (Fig.	
4D).		
A	role	of	other	SRC	family	members	in	the	enhanced	AREG	shedding	in	CFTR	deficient	CFBE	
cells	 cannot	 be	 ruled	 out,	 considering	 the	 limited	 specificity	 of	 PP2	 inhibition.	
Transactivation	 of	 EGFR	 by	 SRC	 has	 been	 reported	 (27)	 (43),	 but	 the	 mechanism	 and	
relationship	with	ligand	or	stress	induced	trafficking	remains	to	be	established.	Thus,	further	
studies	are	warranted	to	define	an	effect	of	CFTR	deficiency	on	SRC	trafficking	and	activity	
towards	its	substrates.	
	
Extracellular	 REDOX	 potential	 regulates	 EGFR/ADAM17-dependent	 AREG	 shedding	 from	
CFBE	cells.	
ADAM17	 activity	 is	 dependent	 on	 the	 interaction	 between	 a	 protein	 (thiol)	 disulfide	
isomerase	 (PDI)	 with	 the	 extracellular	 membrane	 proximal	 domain	 (MPD)	 of	 ADAM17,	
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which	 maintains	 ADAM17	 in	 an	 inactive,	 “closed”	 conformation.	 This	 thiol	 isomerase	 is	
active	 in	 the	 endoplasmic	 reticulum,	 presumably	 involved	 in	 protein	maturation,	 but	 has	
also	been	observed	 in	 the	extracellular	 space	 (18).	 It	 is	 inactivated	when	 the	extracellular	
environment	 is	 oxidized,	which	 results	 in	 an	 active	 “open”	 conformation	of	ADAM17	 (81)	
(18).	 In	 addition	 to	 this	 direct	 effect	 of	 oxidation	 on	 ADAM17	 activity,	 reactive	 oxygen	
species	 (ROS)	 may	 affect	 ADAM17	 indirectly	 through	 the	 activation	 of	 ROS	 sensitive	
molecules	 in	 the	ADAM17	signaling	pathway,	 like	SRC	 (63)	 (84)	and	EGFR	 (54).	 Therefore,	
we	speculated	that	a	change	in	redox	homeostasis	 is	 involved	in	enhanced	EGFR/ADAM17	
dependent	AREG	shedding	in	CFTR	deficient	cells.	
Indeed,	the	impermeant	natural	thiol	antioxidant	Glutathione	(GSH)	(29)	strongly	inhibited	
EGFR/ADAM17-mediated	shedding	of	AREG	in	CFBE	cells	(Fig.	8),	but	not	the	cell	permeant	
GSH	ester,	which	is	cleaved	by	intracellular	phosphodiesterases	increasing	the	intracellular	
GSH	 concentration	 (Fig.	 8).	N-acetyl	 cysteine	 (NAC),	 a	ROS	 scavenger	 and	 reducing	 agent,	
and	the	NOX	inhibitor	diphenyleneiodonium	(DPI)	reduced	AREG	release	to	a	lesser	extent.	
These	data	suggest	that	EGFR/ADAM17-mediated	AREG	release	is	primarily	sensitive	to	the	
extracellular	 redox	 potential	 through	 the	 extracellular	 PDI-MPD	 domain	 interaction	 (18),	
whereas	the	EGFR	and	SRC	redox	sensitive	cysteine	residues	that	are	localized	intracellularly	
(54)	play	a	 limited	 role.	 This	would	explain	why	high	extracellular	GSH	effectively	blocked	
AREG	shedding,	 likely	by	 inhibiting	ADAM	activity	at	 the	PDM	domain,	but	did	not	 reduce	
EGFR	phosphorylation	(Scholte	et	al,	data	not	shown).		
	
Abnormal	extracellular	redox	potential	in	iCFTR-	ALI	contributes	to	enhanced	EGFR/ADAM	
activity.	
The	redox	sensitivity	of	ADAM17	could	explain	its	enhanced	activity	in	CFTR	deficient	cells.	
CFTR	 is	 involved	 in	 the	maintenance	 of	 intra	 and	 extracellular	 redox	 potential	 in	 airways	
through	 its	 role	 in	 the	 transport	of	GSH	 (30)	 (89).	 In	CFTR-KO	mice	 reduced	 levels	of	GSH	
were	reported	in	the	luminal	fluid	in	comparison	to	wild	type	mice,	whereas	total	GSH	levels	
in	the	lung	tissue	did	not	differ	(78).	Furthermore,	in	wild	type	mice,	P	aeruginosa	infection	
increases	 GSH	 in	 the	 epithelial	 lining	 fluid,	 however,	 this	 infection	 induced-increase	 is	
absent	in	CFTR−/−	mice	(14).	Similarly,	GSH	levels	were	reduced	in	lung	lavage	fluids	of	CF	
patients	compared	to	healthy	subjects	(58).	This	is	attributed	to	defective	GSH	transport	in	
CFTR	 deficient	 epithelial	 cells	 (26),	 likely	 contributing	 to	 enhanced	 downstream	
inflammatory	 signaling	 in	CF	 lung	disease	 (32)	 (89).	 Importantly,	 treatment	of	CF	patients	
with	GSH	reduced	inflammatory	markers	in	BALF	(32).	The	decreased	GSH	in	the	epithelial	
lining	 fluid	may	 contribute	 to	 the	 poor	 response	 to	 infections	 and	 aberrant	 activation	 of	
inflammatory	molecules	sensitive	to	oxidation	(25).		
Consistent	with	the	role	of	CFTR	in	GSH	transport	we	established	enhanced	oxidation	of	ASL	
in	 iCFTR-	 cells	 compared	 to	 iCFTR+,	 monitored	 by	 Grx1-roGFP2	 anchored	 to	 the	 apical	
membrane	(Grx1-roGFP2-GPI)	(Fig.	7).	In	contrast,	the	ratiometric	measurement	of	cytosolic	
roGFP-Grx-1	 fluorescence	 did	 not	 reveal	 significant	 differences	 in	 the	 intracellular	 redox	
potential	between	 iCFTR-	cells	and	 iCFTR+	cells	 (31)	 (49)	 (Fig.	7D,E).	We	propose	 that	 this	
oxidized	extracellular	redox	potential,	which	is	likely	due	to	reduced	GSH	transport	in	iCFTR-	
cells,	 activates	 ADAM17	 shedding	 activity	 through	 the	 redox	 sensitive	 extracellular	MPD.	
How	 this	 GSH	 redox	 signal	 is	 transferred	 to	 the	 active	 ADAM17	 pool	 remains	 to	 be	
established	 in	 future	 studies.	 ADAM17	 and	 its	 substrates	 actively	 recycle	 through	 the	
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plasma	membrane,	exposing	the	MPD	and	protease	sensitive	domains	 to	 the	extracellular	
environment.	Though	ADAM17	reportedly	has	a	preferentially	basolateral	sorting	route,	we	
cannot	exclude	that	it	passes	the	apical	membrane,	in	particular	in	CFTR	deficient	cells	that	
have	improper	trafficking	of	membrane	proteins,	as	shown	by	our	(Fig	5)	and	published	data	
(45).	Furthermore,	we	cannot	exclude	that	the	apical	GSH	pool	affects	the	lateral	and	basal	
domains	of	the	epithelial	plasma	membrane,	 in	particular	 in	CFTR	deficient	cells	that	have	
instable	 tight	 junctions	 (42).	 Further	 studies	 with	 modified	 targeted	 redox	 probes	 in	
polarized	 are	 required	 to	 establish	 this.	 Finally,	we	 cannot	 exclude	 that	 extracellular	GSH	
affects	 the	 intravesicular	 compartments,	 in	 which	 ADAM17	 is	 active.	 We	 have	 shown	
previously	 (69)	 that	 CS	 induced	 interactions	 between	 ADAM17	 and	 its	 substrates	 occur	
intracellularly	 in	 polarized	 airway	 cells.	 GSH	 can	 enter	 the	 cell	 through	
endocytosis/pinocytosis,	 trans-cytosis,	 and	 in	 the	 shape	 of	 glutathione-protein	 conjugates	
(65),	which	could	allow	an	interaction	with	the	ADAM17	ectodomain	even	when	that	is	not	
apically	localized.		Further	studies	in	advanced	cell	culture	models	are	required	to	establish	
relative	ADAM17	and	GSH	localization	in	CF	airway	epithelia.	
	
Taken	together,	We	propose	that	supplementation	with	extracellular	GSH	severely	 inhibits	
ADAM17	 related	 AREG	 shedding	 through	 reduction	 and	 inactivation	 of	 its	 extracellular	
domain	(18).	Conversely,	an	oxidized	extracellular	redox	potential	(Fig	6),	due	to	insufficient	
GSH	secretion	 in	CFTR-	cells	 (4)	and	consistent	with	a	 lower	ASL	GSH	concentration	 in	 the	
ASL	 of	 CF	 patients	 and	 CF	 cell	 models	 in	 comparison	 to	 normal	 controls	 (26)	 (58)	 may	
activate	ADAM17,	resulting	in	enhanced	AREG	release	(Fig	1).	This	may	involve	the	feedback	
loop	action	of	the	EGFR/ADAM17	axis	and	enhanced	EGFR	activity	(Fig	5).	
	
Summary	and	conclusions	
Our	 data	 provide	 more	 insight	 in	 the	 role	 of	 CFTR	 deficiency	 in	 regulating	 the	
EGFR/ADAM17	 axis,	 which	 is	 likely	 involved	 in	 the	 triggering	 and	 resolution	 of	 CF	 lung	
inflammation.	 Activity	 of	 the	 EGFR/ADAM17	 shedding	 system	 is	 higher	 in	 differentiated	
CFTR	deficient	CFBE	 cells	 at	 air-liquid	 interface	 compared	 to	CFTR	expressing	 cells.	 This	 is	
related	 to	 stronger	 EGFR	 activation	 and	 abnormal	 trafficking	 in	 CFTR	deficient	 cells,	 likely	
involving	a	paracrine	feedback	loop	through	enhanced	ADAM17	dependent	AREG	shedding.	
The	 extracellular	 REDOX	 potential,	 which	 as	 we	 show	 strongly	 affects	 ADAM17	 shedding	
activity,	was	changed	to	a	more	oxidized	state	in	CFTR	deficient	cells,	likely	due	to	reduced	
GSH	 secretion.	We	 propose	 that	 abnormal	 extracellular	 redox	 potential	 in	 CFTR	 deficient	
epithelial	 cells	 enhances	 the	 basal	 activity	 of	 the	 EGFR/ADAM17	 axis.	 Further	 studies	 are	
required	to	establish	the	link	between	extracellular	redox	potential	and	EGFR/ADAM	activity	
in	primary	cells	and	airway	in	situ.	Based	on	our	results	we	propose	that	Intervention	in	this	
pathway	may	be	beneficial	to	CF	patients.	
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MATERIALS	AND	METHODS	
	
Compounds	and	antibodies	
TMI-2	 (PF-5480090)	 and	 TMI-1	 (85)	 were	 obtained	 from	 Wyeth	 inc.	 (Philadelphia,	
Pennsylvania,	 USA).	 AG1478	 (1	 µM),	 diphenyleneiodonium	 chloride	 (DPI),	 genistein,	
reduced	glutathione	(GSH),	herbimycin	A,	hydroxyl	peroxide	(H2O2),	N-acetylcystein	(NAC),	
orthovanadate,	 tert-butyl-hydroxyperoxide	 (t-BHP)	 were	 purchased	 from	 Sigma-Aldrich.	
EGF,	 PP2,	 PP3,	 UO126	 were	 purchased	 from	 R&D.	 Rat	 monoclonal	 anti-EGFR	 antibodies	
specific	 for	 extracellular	 domain	 used	 in	 dilution	 1:200	 for	 IF	 and	 1:1000	 for	 PM,	 were	
purchased	from	Abcam.		
	
CFBE	cell	culture.	
The	 generation	 of	 the	 human	 immortalized	 CFBE41o–	 cell	 line	 (abbreviated	 as	 CFBE)	
harboring	the	inducible	expression	of	WT-	or	G551D	CFTR	has	been	described	before	(77).	
The	CFBE	cells	were	propagated	on	plastic	dishes	coated	with	3	mg/ml	collagen	(Pure	Col,	
Advanced	 Biomatrix),	 1	 mg/ml	 human	 fibronection	 (BD	 Biosciences)	 with	 and	 100	 µg/ml	
bovine	serum	albumin	(Sigma-Aldrich)	in	LHC-basal	medium	(Biosource).	Cells	were	cultured	
in	 MEM	 (Gibco)	 supplemented	 with	 10%	 fetal	 bovine	 serum	 (FBS,	 Gibco),	 10	 mM	 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic	acid	(HEPES,	Gibco),	200mM	L-glutamine	(Gibco).	
Cells	 containing	 the	 transactivator	 alone	 (TetON)	were	maintained	 in	medium	 containing	
200	 μg/ml	 G418	 (Invitrogen),	 and	 cells	 harboring	 inducible	 CFTR	 expression	 were	
maintained	in	presence	of	200	μg/ml	G418	(Invitrogen)	and	3	μg/ml	Puromycin	(Invitrogen).	
When	cells	reached	80%	confluence,	they	were	transferred	on	the	1.12	cm2	Transwell	filters	
with	0.4μm	pore	size	(Corning)	at	a	density	of	1x105	cells	per	filter	and	cultured	with	0.5	ml	
and	1.5	ml	medium	in	the	apical	and	basolateral	chamber,	respectively.	24	h	after	seeding	
(day	1)	CFTR	expression	was	induced	with	500ng/ml	doxycycline.	At	day	4	the	medium	was	
changed	 to	OptiMEM	 (+/-	 doxycycline)	 supplemented	with	 2	mM	 L-glutamine	 (Gibco).	 At	
day	5	 compound	 treatments	were	performed	 in	OptiMEM	and	 samples	were	 collected	at	
different	 time	 points	 after	 ALI	 exposure:	 4h	 (0-4h),	 8h	 (4-8h),	 24h	 (8-24h).	 At	 each	
investigated	time	point	after	sample	collection,	whole	medium	was	changed.		
	
Generation	of	Redox	Sensor	Cells	
The	ratiometric	redox	sensor	Grx1-roGFP	(31)	was	shuttled	into	the	lentiviral	vectors	pLVX-
IRES-Hyg	 (clontech)	 for	 stable	 expression	 in	 different	 cellular	 compartments.	 The	 basic	
variant	 is	 expressed	 in	 the	 cytosol	 as	 described	 by	 Gutsher	 et	 al.	 Another	 variant	 was	
equipped	with	 a	N-terminal	 signal-sequence	and	a	C-terminal	 glycosylphosphatidylinositol	
(GPI)	anchor	consensus	sequence	(SS-Grx1-roGFP-GPI)	to	determine	the	redox	potential	of	
the	 ASL.	 CFBE	 cells	 with	 inducible	 expression	 of	 WT-CFTR	 were	 transduced	 with	 these	
lentiviral	particles	followed	by	selection	with	200	µg/ml	hygromycin	B.	
	
Measurement	of	redox	state	in	CFBE	redox	sensor	cells	
The	 initial	characterization	of	 the	redox	senor	cells	was	performed	 in	a	 fluorescence	plate	
reader.	For	this	purpose	CFBE	cells	expressing	the	redox	sensor	variants	were	seeded	 into	
black	96	wells	and	kept	for	≥4	days	post	confluent.	Fluorescent	 intensities	were	measured	
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at	 520	nm	 (±20	nm)	using	 TECAN	plate	 reader	 after	 excitation	with	 405	nm	and	488	nm,	
respectively.	Higher	405/488-ratio	value	represents	a	higher	oxidative	state	(49).		
To	 determine	 the	 redox	 state	 in	 differentiated	 CFBE	 under	 ALI	 CFBE	 redox	 sensor	 cells,	
grown	on	Snapwell	inserts	(Corning)	were	used	for	ratiometric	confocal	imaging.	Generally	a	
Z-stack	of	20-30	optical	xy-sections	was	acquired	(0.7-1-µm	apart)	with	LSM700	microscope	
(Carl	Zeiss,	Jena,	Germany)	equipped	with	a	water	immersion	objective	lens	(40x,	numerical	
aperture,	 0.8;	 achroplan;	 Zeiss).	 For	 immersion	 of	 the	 objective	 lens,	 cells	 were	 covered	
with	 non-toxic	 the	 hydrophobic,	 Fluorinert™	 FC-70	 fluid	 (boiling	 point,	 215°C;	 refractive	
index,	1.303;	Hampton	Research)	that	allows	normal	gas	exchange.	During	the	experiment	
cells	were	maintained	at	37°C,	with	5%	CO2	in	a	humidified	top-stage	incubator	mounted	on	
the	microscope.	The	biosensor	was	excited	sequentially	with	405	nm	and	488	nm	lasers	and	
emitted	intensities	were	collected	from	520	nm.	CFBE	cells	without	Grx1-roGFP2	were	used	
as	a	background	control.	Ratios	of	intensities	were	calculated	from	5	cells	on	a	single	apical	
(GPI)	 or	 intracellular	 z-slice	 that	was	 selected	manually	 from	 the	 Z-stack	 images	 for	 each	
cell.	 Three	microscopic	areas	were	 recorded	on	each	 filter.	The	 redox	probe	maximal	and	
minimal	oxidation	emission	ratios	were	determined	in	some	experiments	by	basal	addition	
of	H2O2	(100	µm)	and	500	µM	DTT	or	50	mM	MESNA,	respectively.	
	
AREG	ELISA	
Samples	 for	 AREG	 ELISA	 were	 collected	 form	 the	 basolateral	 and	 apical	 medium	 of	
differentiated	CFBE41o-	conditioned	for	the	 indicated	times.	AREG	levels	were	determined	
by	 ELISA	 (Duoset	 human	 AREG,	 DY262,	 R&D	 Systems)	 following	 the	 manufactures	
instructions.	 The	 final	 detection	 was	 performed	 with	 	 a	 SuperSignal	 ELISA	 Femto	
luminescence	 substrate	 (Pierce)	 on	 a	 VICTOR	 Light	 plate	 reader	 (PerkinElmer).	 Data	were	
corrected	 for	 the	 dilution	 factor	 and	 insert	 size.	 The	 amount	 of	 the	 shed	 AREG	 was	
expressed	 as	 pg/filter	 per	 hour.	Measurement	 of	 the	metabolic	 activity	 of	 the	 cells	 with	
alamar	blue	(Invitrogen)	showed	that	the	induced	CFTR	expression	had	no	effect	on	the	cell	
number	or	viability	of	the	CFBE	cells	(data	not	shown).	
	
EGFR	plasma	membrane	density	measurements	(PMD)	
The	 PM	 density	 of	 EGFR	 was	 determined	 by	 cell-surface	 ELISA	 (50).	 CFBE	 cells	 for	 PM	
density	 measurements	 were	 grown	 on	 1.12	 cm2	 Transwell	 filters	 with	 0.4μm	 pore	 size	
(Corning),	 as	 described	 above.	 At	 the	 indicated	 time	 points,	 the	 cells	 were	 incubated	 in	
reagent	diluent	(1%	BSA	in	PBS	containing	0.1	mM	CaCl2	and	1mM	MgCl2(PBSCM)	for	30	min	
at	 RT.	 EGFR	 localized	 at	 the	 apical	 or	 basolateral	membrane	was	 detected	 by	 incubation	
with	rat	monoclonal	anti-EGFR	antibody	specific	for	the	extracellular	domain	(1:500,	ab231,	
Abcam)	 followed	 by	 extensive	 washing	 and	 subsequent	 incubation	 with	 anti-rat-HRP	
antibody	 (1:1000,	 112-035-167,	 Jackson	 ImmunoResearch),	 both	 for	 60	min	 at	 RT.	 Excess	
antibody	 was	 removed	 by	 extensive	 washing	 with	 PBSCM,	 and	 specific	 binding	 was	
determined	 with	 Amplex	 Red	 (Invitrogen)	 HRP	 substrate.	 The	 fluorescence	 intensity	 was	
measured	at	544	nm	excitation	and	590	nm	emission	wavelengths	using	an	Infinite	M1000	
(Tecan)	 fluorescence	 plate	 reader,	 and	 values	 determined	 from	 cells	 without	 primary	
antibody	labeling	were	subtracted	as	background.	
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mRNA	isolation	and	qPCR	
The	mRNA	isolation	and	q-PCR	was	performed	as	described	previously	(77).	The	primers	are	
listed	in	Table	1.	
	
Table	1:	qPCR	primers	used	in	this	study	
Gene	symbol	 Direction	 Sequence	
AREG	 forward	 GTGGTGCTGTCGCTCTTGATA	
AREG	 reverse	 ACTCACAGGGGAAATCTCACT	
ADAM17	 forward	 TCTCCTATTCCTGACCAGCG	
ADAM17	 reverse	 GTCTGAGAGCAAAGAATCAAGC	
EGFR	 forward	 GGGCTCTGGAGGAAAAGAAA	
EGFR	 reverse	 AAATTCCCAAGGACCACCTC	
GAPDH	 forward	 CATGAGAAGTATGACAACAGCCT	
GAPDH	 reverse	 AGTCCTTCCACGATACCAAAGT	
	
Immunofluorescence	(IF)	
Cells	 for	 PM	measurements	 were	 grown	 under	 ALI	 on	 the	 1.12cm2	 Transwell	 filters	 with	
0.4μm	pore	size	 (Corning),	as	described	above.	At	 the	 investigated	 time	points,	cells	were	
fixed	 with	 4%	 paraformaldehyde	 (Sigma	 Aldrich)	 for	 10	 min	 at	 RT,	 followed	 by	
permeabilization	with	4%	paraformaldehyde	and	0,5%	Triton-X	(Sigma	Aldrich)	in	PBS	for	5	
min	 at	 RT.	 This	was	 followed	 by	 incubation	with	 100	mM	 glycine	 pH	 7.5	 for	 10	min	 and	
blocking	with	1%	BSA	 (in	PBSCM)	 for	45	min,	 incubation	 for	1h	with	 rat	monoclonal	 anti-
EGFR	 antibodies	 specific	 for	 the	 extracellular	 domain	 (1:200,	 ab231,	 Abcam),	 and	
subsequent	 incubation	with	 the	 secondary	 fluorescent	 antibody	 Alexa	 Fluor	 488	 (1:1000,	
A11006,	Invitrogen)	for	1h	at	RT	in	darkness.	Antibodies	were	diluted	in	0.5%	BSA	in	PBSCM.	
Nuclei	 were	 stained	 with	 300	 ng/ml	 DAPI	 for	 10	 min	 in	 darkness.	 Washing	 steps	 were	
performed	 with	 PBSCM.	 Cut	 out	 filters	 were	 mounted	 with	 mounting	 medium	 (100	mM	
Tris/HCl	pH	8.5,	10%	mowiol,	25%	glycine,	150	mM	1,4-Diazabicyclo[2.2.2]octane)	on	glass	
cover	 slides.	 20-30	 z-optical	 sections	were	acquired	using	a	 confocal	 LSM-780	microscope	
equipped	with	a	Plan-Apochromat	63X/1.40	oil	differential	 interference	contrast	objective	
(Carl	 Zeiss),	 reconstituted	 using	 the	 Zen	 2012	 software	 package	 and	 representative	 xz-
sections	are	shown.	
	
Western	blotting	
105	iCFTR	CFBE	cells	were	seeded	per	insert	(1.12cm²	PET	filters,	pore	size	0.4µm,Corning)	
with	 (iCFTR+)	 or	 without		 (iCFTR-)	 doxycycline	 induction.	 The	 cells	 were	 cultured	 as	
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described	 above	 in	 CFBE	 cell	 culture	 section.	 Four	 independent	 experiments	 were	
performed	 with	 four	 (3)	 or	 three	 (1)	 inserts	 per	 condition	 each.	At	 8h	 ALI,	 medium	 was	
collected	for	AREG	ELISA	(R&D	Systems	Europe,	Abingdon,	UK),	whereas	cell	samples	were	
transferred	to	100µl	RIPA	buffer	(50	mM	Tris	HCl,	150	mM	NaCl,	1%	Triton-X,	0,5%	Sodium	
deoxycholate,	 0,1%	 SDS)	 containing	 phosphatase	 (PhosStop,	 Sigma-Aldrich)	 and	 protease	
inhibitors	 (Complete	Mini,	 Roche).	 Protein	 concentration	was	 determined	with	 BCA	 assay	
(Pierce	 Rockford,	 IL).	 The	 lysates	 were	 centrifuged	 at	 15,000	rpm	 for	 15	min	 at	 4	°C.	 The	
clear	 supernatants	 were	 immediately	 transferred	 to	 SDS	 loading	 buffer	 (5µl	 4x	 sample	
buffer,	 1µl	 0.1M	 DTT,	 15µl	 protein	 sample)	 and	 stored	 at	 -20°C	 until	 use.	 7%	 gel	
electrophoresis	 was	 performed	with	 iCFTR+	 and	 iCFTR-	 samples	 loaded	 in	 parallel	 on	 the	
same	 gel	 and	 proteins	 were	 transferred	 to	 PVDF	 membranes	 (0.45	 micron	 filter,	 Merck	
Millipore).	The	membranes	were	blocked	with	3%	BSA	and	0,05%	Tween20	in	PBS,	and	then	
stained	for	EGFR	EP38Y	(1:5000,	Abcam),	and	a	fluorescent	second	antibody	(1:10.000,	926-
32213,	Li-Cor).	EGFR-P	was	detected	using	antibody	Tyr1173	(1:200,	Santa	Cruz)	and	a	HRP	
labeled	 second	 antibody	 (1:10.000,	 P0448,	 Dako).	 The	 proteins	 were	 detected	 using	
Amersham	 ECL	 prime	Western	 blotting	 detection	 reagent	 (GE	 Healthcare	 Europe	 GmbH)	
and	scanned	with		Alliance	(luminescence)	or	Odyssey	(fluorescence)	scanners.	In	separate	
experiments	equal	amounts	of	protein	from	iCFTR-	and	iCFTR+	cells	cultured	in	parallel	were	
loaded	on	the	same	blot.	The	density	of	each	band	was	quantitated	with	ImageJ	software.	
Acquired	data	 for	 EGFR-P	and	EGFR	were	normalized	 to	 the	average	 iCFTR-	data	 for	each	
individual	blot		and	presented	as	percentage	of	the	average	of	iCFTR-	values	in	Figure	5.	
		
ADAM17	substrate	assay	
The	ADAM17	enzyme	activity	 in	polarized	CFBE	grown	on	Transwell	 filters	and	exposed	to	
ALI	 for	 24	 h,	 was	 measured	 by	 supplementing	 the	 basolateral	 medium	 with	 10	 µM	
fluorogenic	 TACE	 substrate	 IV	 (Millipore).	 Following	 1	 h	 incubation	 the	 medium	 was	
collected	and	the	fluorescence	was	determined	at	320	nm	excitation	and	420	nm	emission	
wavelengths	using	an	Infinite	M1000	(Tecan)	fluorescence	plate	reader.	Values	determined	
from	filters	without	cells	were	subtracted	as	background	control.		
	
Statistical	analysis	
Statistical	analyses	were	performed	with	GraphPad	Prism	Software.	The	statistical	test	used	
for	 the	 specific	 experiment	 is	 indicated	 underneath	 each	 figure.	 Each	 experiment	 was	
performed	 in	 triplicate,	meaning	 that	 samples	 were	 collected	 from	 three	 different	 wells,	
grown	simultaneously,	averaged	and	considered	as	one	experiment	in	analysis	(indicated	by	
n).	Graphs	present	the	averages	of	n	experiments	with	SEM	values.	Differences	at	P-value	
>0.05	 were	 considered	 to	 be	 not	 statistically	 significant	 (ns>0.05),	 P-values	 <0.05	 were	
considered	 to	 be	 statistically	 significant	 and	 indicated	 as	 *P<0.05,	 **P<0.01,	 ***P<0.001,	
****P<0.0001.	
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Am J Physiol Lung Cell Mol Physiol 311: L1000–L1014, 2016. First
published September 23, 2016; doi:10.1152/ajplung.00298.2016.—Pro-
gressive lung disease with early onset is the main cause of mortality
and morbidity in cystic fibrosis patients. Here we report a reduction of
sphingosine-1-phosphate (S1P) in the lung of unchallenged
Cftrtm1EUR F508del CFTR mutant mice. This correlates with en-
hanced infiltration by inducible nitric oxide synthase (iNOS)-
expressing granulocytes, B cells, and T cells. Furthermore, the ratio of
macrophage-derived dendritic cells (MoDC) to conventional dendritic
cells (cDC) is higher in mutant mouse lung, consistent with unpro-
voked inflammation. Oral application of a S1P lyase inhibitor
(LX2931) increases S1P levels in mutant mouse tissues. This normal-
izes the lung MoDC/cDC ratio and reduces B and T cell counts. Lung
granulocytes are enhanced, but iNOS expression is reduced in this
population. Although lung LyC6! monocytes are enhanced by
LX2931, they apparently do not differentiate to MoDC and macro-
phages. After challenge with bacterial toxins (LPS-fMLP) we observe
enhanced levels of proinflammatory cytokines TNF-", KC, IFN#, and
IL-12 and the inducible mucin MUC5AC in mutant mouse lung,
evidence of deficient resolution of inflammation. LX2931 does not
prevent transient inflammation or goblet cell hyperplasia after chal-
lenge, but it reduces MUC5AC and proinflammatory cytokine levels
toward normal values. We conclude that lung pathology in homozy-
gous mice expressing murine F508del CFTR, which represents the
most frequent mutation in CF patients, is characterized by abnormal
behavior of infiltrating myeloid cells and delayed resolution of in-
duced inflammation. This phenotype can be partially corrected by a
S1P lyase inhibitor, providing a rationale for therapeutic targeting of
the S1P signaling pathway in CF patients.
cystic fibrosis; mouse model; dendritic cells; macrophages; granulo-
cytes
CYSTIC FIBROSIS (CF) is the most common recessive congenital
disease in Caucasians, affecting $75,000 patients worldwide.
It is caused by a deficiency of the CF transmembrane conduc-
tance regulator (CFTR) involved in transcellular ion and fluid
transport and characterized by severe progressive pancreatic,
intestinal, and lung pathology. Progressive distal airway dis-
ease, causing severe morbidity, is already observed in a ma-
jority of CF infants younger than 5 years (63, 68). This is
accompanied by airway remodeling, chronic inflammation and
bacterial infections, frequent exacerbations, and eventually
fatal loss of lung function. The molecular mechanisms in-
volved in the development of CF lung disease are not com-
pletely understood despite intensive research in the past two
decades. Experiments in cellular and animal models have
suggested that CFTR dysfunction affects a network of interre-
lated regulatory signaling molecules, including growth factor
shedding and cytokine secretion, which regulates cell fate
decisions, inflammation, and tissue remodeling in the affected
tissues. An effective therapy for a majority of CF patients is not
available, despite recent progress with CFTR-targeted pharma-
ceutics. Therefore additional or alternative intervention with
anti-inflammatory drugs should be considered (76).
Abnormal bioactive lipid metabolism in CF lung disease.
Previous studies in CF humans and CF mutant mice have
highlighted the involvement of various receptor-modulating
bioactive lipids in the development of CF lung pathology. In
particular the sphingosine pathway (77, 84) and phospholipase
A-dependent signaling pathways (18) are affected and are
likely involved in CF pathology through regulation of inflam-
mation, airway plugging, and tissue remodeling. Several phar-
maceutical interventions in these pathways were effective in
animal models, and clinical trials are underway, highlighting
the potential of anti-inflammatory treatment in addition to
CFTR targeted therapeutics (7, 18, 22, 24, 76, 86).
The role of S1P in CF lung disease. In the present study we
focus on sphingosine-1-phosphate (S1P), a receptor-activating
lipid that is involved in several cellular processes that are
crucial for the development of lung disease. S1P is produced
by intracellular kinases (S1PK1 and S1PK2) from sphin-
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gosines. S1P lyase (SPL) removes intracellular S1P from the
sphingolipid pool and is considered an important drug target
for cancer, inflammatory, and autoimmune disease (31, 32).
The food colorant 2-acetyl-4-tetrahydroxy butylimidazole
induces lymphopenia and effectively reduces SPL activity in
mice (65). The orally available chemical derivative SPL
inhibitor LX2931 (LX3305) reduced pathology in a mouse
model of rheumatoid arthritis (5), was well tolerated, and
showed clinical benefit in a phase II clinical trial (37).
S1P is transported to the extracellular compartment by ABC
transporters and the major superfamily member Spinster 2
(19), which allows autocrine and paracrine signaling to a
family of differentially expressed extracellular receptors
(S1P1–5), followed by activation of intracellular signaling path-
ways. S1P also acts on intracellular targets (1, 49, 60) and is
involved in NFkB activation (4, 49). In cross talk with other
signaling pathways, notably ceramides (77), S1P has important
effects on cell migration, growth, and differentiation and plays
a role in tissue repair. The importance of S1P metabolism in
inflammatory lung disease and fibrosis has been documented in
several publications in murine (50), rat (40), and canine models
of acute lung injury (71). In a recent report Xu et al. (85)
reported reduced S1P levels in bronchoalveolar lavage fluid
(BALF) of CFTR knockout (KO) mice, correlating with ab-
normal dendritic cell infiltration.
In the present study we have confirmed and substantially
extended these results using a unique mouse model
(Cftrtm1EUR) for the most common mutation in CF patients
(F508del CFTR), generated in our laboratory (21). These mice
display electrophysiological abnormalities and intestinal dis-
ease typical of CF (82). In the lung, enhanced lung mucin
secretion (82), abnormal lung inflammation and fibrotic re-
sponse to bleomycin (27, 45), excessive response to LPS and
Pseudomonas infection (48), and naphthalene injury (11) were
observed. Furthermore, lung epithelial cells in Cftrtm1EUR mice
show deficient autophagocytosis and accumulation of ag-
gresomes, reportedly mediated by excessive production of
reactive oxygen (42), which could affect the activity of key
enzymes in S1P metabolism or intracellular S1P receptor
systems.
Our data show that abnormal myeloid infiltration and de-
layed resolution of induced inflammation in Cftrtm1EUR mice
correlate with reduced lung tissue S1P levels, which can be
partially corrected by chronic treatment with the SPL inhibitor
LX2931.
METHODS
Animal studies. Breeding, maintenance, and genotyping of
Cftrtm1EUR F508del CFTR mice (F12 C57Bl/6 backcross) was per-
formed as described previously (21, 81, 82). Mice were kept in sterile
ventilated cages, with sterile normal chow and water ad libitum. Adult
males and females were used for intervention studies. All experiments
were performed with approval (DEC 138-11-09) of the Independent
Committee on Ethical Use of Experimental Animals, Rotterdam,
according to national and European Union guidelines. Oral LX2931
treatment was performed by adding 500 mg/l LX2931, obtained from
Lexicon Pharmaceuticals, to the drinking water for the period indi-
cated.
Salivary gland activity measurement (8) was performed as de-
scribed in Ref. 82. Briefly, in mice under ketamine/xylasine/diazepam
anesthesia, basal cholinergic secretion activity is inhibited by subcu-
taneous injection of atropine to the cheek (50 !l, 1 mM), and saliva
is collected at 3-min intervals in 2 " 20-mm filter paper, measured by
weighing the filter before and after collection. Adrenergic (CFTR-
dependent) secretion is induced by subcutaneous injection of 50 !l, 1
mM atropine 50 !l, 100 !M isoproterenol and followed for at least
four further 3-min intervals.
Gated microCT lung scanning was performed on a Quantum FX
CT scanner (Perkin Elmer), under isoflurane anesthesia. CT scans
were viewed and analyzed with Caliper Analyze software. Scoring of
CT scans was performed in a five-grade binning mode by measuring
the relative surface of the lung volume occupied by high-density
areas, indicating focal inflammation as illustrated in Fig. 8.
Histology and quantitative analysis. Animals were terminated with
a lethal dose of ketamine/xylazine/diazepam, blood was removed
from the circulation by ventricle perfusion with PBS. Lungs lobes and
other tissues were removed immediately and either fixed in 4%
paraformaldehyde/PBS and processed for standard paraffin histology
or snap frozen in liquid nitrogen for analysis. Hematoxylin-eosin,
periodic acid-Schiff (PAS)/Alcian blue (AB), and immunohistology
staining were performed using standard procedures. Quantification of
alveolar space sizes and septum thickness was performed using a
modification of the method described in Ramnath et al. (58). After
illumination correction, the final air space/septum masks are obtained
from the binarized channel images, and air spaces smaller than 300
pixels (31 !m2) are removed. For measuring the septum thickness, the
smallest distance between pairs of neighboring air spaces was used.
The mean value of the aggregated vector of the pairwise distances
defines a single septum thickness measure for the entire image. For
defining the neighborhood relation between the air spaces, skeleton-
ization of the identified septum region is performed. Consequently,
the entire image domain is subdivided into connected regions sepa-
rated by the obtained skeleton. Since each of the obtained regions
contains only one air space, both the air space and the region that
contains it are assigned the same unique label. Two air spaces are
considered as neighboring if the regions containing them are separated
by a single skeleton edge.
Cytokine analysis by sequential ELISA was performed essentially
as described by Van den Berg et al. (79). We analyzed cytokines in
total lung lysates made from the unperfused upper right lung lobe. The
total lung lysates were obtained by homogenizing the lung lobe, two
times in the TissueLyser II (Qiagen) for 90 s at 30 Hz, in ice-cold PBS
with protease inhibitor cocktail (Complete Mini, Roche), and stored at
#80°C for further analysis. Cytokines were analyzed in total lung
lysates by Sequential Enzyme-Linked Immuno Sorbent Assay
(ELISA) (R&D Systems Europe, Abingdon, UK), and 96-well micro-
titer plates (Nunc Immunoplate, Neptune, NJ) were coated with
anti-cytokine antibody (Duoset, R&D Systems, Minneapolis, MN)
diluted 1,000" in PBS (50 !l/well) overnight rotating at 300 rpm at
4°C. Plates were washed with PBS 0.05% Tween 20, incubated for 1
h with blocking solutions: Blocker Blotto in TBS (eotaxin, MCP-1),
Blocker Casein in PBS (KC, IL-6, IL-10, TNF-SR2, TNF-SR1,
IL-1ra, IL-6R, IL-P70, MIP-2, IFN$), and Super Blocking Buffer in
PBS (TNF-%, IL-1&) (150 !l/well, Pierce, Rockford, IL) at room
temperature. After washing, the lung lysate samples diluted in PBS
with 0.05% Tween 20 and standards (Duoset, R&D Systems) were
incubated for 2 h at room temperature on a plate shaker at 300 rpm.
Then the samples were removed and stored in a 96-deep-well poly-
propylene microtiter plate for further sequential use. After transfer,
the plates were washed and the polyclonal biotinylated detection
antibody in dilution buffer was added (Duoset, R&D Systems) (50
!l/well, 300 rpm). The plates were washed and incubated for 30 min
with streptavidin-conjugated horseradish peroxidase (Bio-Rad),
diluted 1:10,000 in PBS with 0.1% BSA and 0.05% Tween 20 (50
!l/well, 300 rpm), followed by 10 – 40 min incubation with the
TMB peroxidase substrate system (KPL, Gaithersburg, MD) (1:1,
100 !l/well). The reaction was stopped with 1.0 M sulfuric acid
(100 !l/well), and absorbance was measured using a plate reader
(Bio-kinetics, BioTek) at 450 nm. Data are expressed as picograms
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per milligram protein. Protein concentration in lung tissue samples
were determined by BCA kit (Pierce).
S1P and sphingosine measurements. Lipids extracted from the
unperfused middle lung lobe of Cftrtm1EUR mutant animals and littermate
controls aged 33–35 wk kept on normal chow were purified similarly as
described previously (9). Briefly, tissues are spiked with internal stan-
dards, homogenized in organic solvent [chloroform:methanol 2:1 (vol/
vol) and butylated hydroxyl anisole]. One volume of cold water is
added to the mixture and samples are mixed for 90 min at 4°C. The
organic phase is collected, to which diethyl ether is added to remove
protein contamination. The organic phase is dried and resuspended in
100 !l of chloroform, dried and resuspended in petroleum ether,
purified by thin-layer chromatography (TLC), and detected by iodine.
After scraping from the TLC plate, the amount of recovered lipids per
sample was normalized according to the protein content in the initial
samples measured via the bicinchoninic assay and then by normal-
ization to same amount of inorganic phosphate in each of the analyzed
samples. Final amounts were expressed in picomoles per nanomole of
total phospholipid phosphate present in each analyzed sample. Con-
tents of S1P and sphingosine in the samples were analyzed on a
Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass
spectrometer using electron impact ionization. The instrument was
tuned and calibrated for mass resolution and mass accuracy on a daily
basis. Accurate mass determination and MS/MS fragmentation
(LC/MS and LC/MS/MS): the LC/MS portion of the platform was
based on a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ-FT
mass spectrometer, which had a linear ion-trap front end and a Fourier
transform ion cyclotron resonance mass spectrometer back end. For
ions with counts greater than 2 million, an accurate mass measurement
could be performed. Accurate mass measurements could be made on
the parent ion as well as fragments. The typical mass error was less
than 5 ppm. Ions with less than 2 million counts require a greater
amount of effort to characterize. Fragmentation spectra (MS/MS)
were typically generated in a data-dependent manner. S1P measure-
ments in unperfused lung tissues from LX2931-treated mutant mice
were performed by LC-MS at Lexicon Pharmaceuticals laboratories,
using procedures described previously (5).
Flow cytometry. For flow cytometry we obtained anti-mouse
Ly6C-FITC (clone AL-21), SiglecF-PE (clone E50-2440),
Ly6G-PE (clone 1A8), CD103-PE (clone E50-2440), CD19-APC_
Cy7 (clone ID3), and CD64"AF647 (clone X54-5/7.1) from Becton
Dickinson (BD). Anti-mouse CD11b" Horizon450 (clone M1/70),
CD11c" PE_Cy7 (clone N418), CD3-APC_Cy7 (clone I45-2c11)
and MHCII-APC_Cy7 (clone I3/2.3), and inducible nitric oxide
synthase (NOS2/iNOS) PE-cyanine7 (clone CXNFT) were ob-
tained from eBioscience. Anti-mouse CD45-PE_TxRed (clone M5-
114.5) was obtained from BioLegend, and arginase-1-FITC (poly-
clonal sheep IgG) from R&D Systems. The life-dead marker
Aqua-AmCyan was obtained from Invitrogen. Lungs were digested
using RPMI containing Liberase TM (Roche) and 10 U DNAse
(Roche). Cell suspensions were lysed for 4 min at room tempera-
ture in 1 ml osmotic lysis buffer. All staining reactions were performed
at 4°C for 30 to 45 min. Cells were incubated with 2.4G2 Fc receptor
antibody to reduce nonspecific binding, together with monoclonal
antibodies. To facilitate intracellular staining of arginase-1 and
iNOS, cells were fixed and permeabilized using the Fixation/
Permeabilization Solution Kit of BD Biosciences. Cell data acqui-
sition took place on a LSRII flow cytometer (BD). Gating strategy
of CD45# cells was as follows: granulocytes (CD11b#Ly6G#
Ly6C"), macrophages (CD11c#CD11b"MHCII" SiglecF#);
Ly6Chigh monocytes (CD11c"MHCII"CD11b#LyC6high#); B
cells (CD19# MHCII# CD11c"); T cells (CD3# MHCII").
Dendritic cells (DC, CD11c#MHCII#); conventional DC (cDC:
CD11c# MHCII# CD11b# CD64"); monocyte-derived DC
(MoDC: CD11c# MHCII# CD11b#CD64#); CD103# DC
(CD11c# MHCII# CD11b").
RESULTS
Reduced sphingosine-1-P in Cftrtm1EUR mouse lung. We
analyzed lipid profiles by gas chromatography-mass spec-
trometry (GC-MS) in whole lung tissue from adult male
mutant C57Bl/6 Cftrtm1EUR F508del CFTR mice. Lipids
extracted from the unperfused middle lung lobe of mutant
animals (n $ 10) and littermate controls (n $ 8) aged 33–35
wk, kept on normal chow, were analyzed in parallel as
described in METHODS. We observed a reduction of total sphin-
gosine species and in particular a threefold reduction of S1P in
the lungs of unchallenged adult Cftrtm1EUR mutant mice com-
pared with wild-type (Fig. 1).
Abnormal infiltration of myeloid cells and DC imbalance in
F508del CFTR mouse lung. The reduction of lung S1P ho-
mozygous mutants in this strain correlates with enhanced
mucus production, low-level basal lung inflammation, and
enhanced response to bleomycin, lung injury, and Pseudomo-
nas aeruginosa infection (27, 42, 45, 48, 82), suggesting a
causal relationship between abnormal S1P tissue levels and CF
lung pathology. Therefore, we investigated the effect of the
SPL inhibitor LX2931 on basal and induced inflammation in
this model. First, we established the basal myeloid cell profile
in total lung by FACS analysis. The total number of CD45#
cells in F508del mutant mice is significantly higher than in
wild-type littermates (Fig. 2A). This can be attributed mainly to
a significant increase in total granulocytes (Fig. 2B) and to a
lesser extent alveolar macrophages (Fig. 2C) and Ly6Chigh
monocytes (Fig. 2D). The total number of B cells and T cells
is increased in mutant mice compared with wild-type, adding
substantially to the total number of CD45# cells (Fig. 2, E and
F). The total number of DCs is higher on average but not
significantly different from normal (Fig. 3A). Importantly,
however, we show here for the first time that the percentage of
CD11b# cDC is reduced in F508del CFTR mutant mouse lung
compared with normal (Fig. 3B), whereas we observe a sig-
nificant increase in the percentage CD64#MoDC, also known
Fig. 1. Sphingosine and sphingosine-1-phosphate (Sphingosine 1P) in F508del
CFTR mouse lung. Lipids were extracted from total unperfused middle lung
lobes from homozygous mutant mice (dd, n $ 10) and wild-type littermates
(WT, n $ 8) aged 33–35 wk, kept on normal chow, and analyzed by LC-MS
as described in METHODS. Data are shown as pmol/nmol total lipid phosphate.
Average % SD; **P & 0.01, unpaired t-test.
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as inflammatory DC (Fig. 3C). In contrast to Xu et al. (85) in
CFTR KO mice, we did not observe reduced CD103! DC in
our F508del CFTR mutant mice, either total numbers (not
shown) or as a percentage of DC (Fig. 3D).
We conclude that unchallenged adult mutant Cftrtm1EUR
mice under our conditions show enhanced myeloid cell infil-
tration and an increased MoDC/cDC ratio, compared with
wild-type littermates, consistent with sterile lung inflamma-
tion, which correlates with reduced S1P levels in the lung.
An S1P lyase inhibitor corrects abnormal MoDC/cDC ratio
in F508del CFTR mutant. To establish the role of S1P in this
hyperinflammatory phenotype of mutant mice, and the thera-
peutic potential of pharmaceutical intervention in this pathway,
we treated adult F508del CFTR mutant mice with the SPL
inhibitor LX2931 in drinking water for 2 wk. As expected (5),
this treatment caused a near-hundredfold increase in tissue S1P
levels in total lung tissue measured by LC-MS [0.3 vs. 55
ng/mg, homozygous mutant (dd) vs. dd treated with LX2931,
Fig. 2. Abnormal myeloid infiltration in F508del CFTR mutant mouse lung. Total lung from wild-type (WT; n " 12), mutant (dd; n " 15), and mutant mice
treated with SP-1 lyase inhibitor LX2931 in drinking water (dd LX; n " 6) were analyzed by FACS to quantitate myeloid subpopulations as described in
METHODS. Total cell counts per lung (average # SE) are shown for myeloid cells (CD45!; A), granulocytes (CD11b!Ly6G! Ly6C$; B), macrophages
(CD11c!CD11b$MHCII$ SiglecF!; C) LyC6high monocytes (CD11c$ MHCII$ CD11b! LyC6!; D), B cells (CD19! MHCII! CD11c$; E), and T cells
(CD3! MHCII$; F). **P % 0.01, *P % 0.05; 1-way ANOVA.
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n ! 10 in each group, P " 0.001]. Total white blood cell
counts were reduced by LX2931 treatment in mutant mice
(4.36 # 0.45 vs. 2.63 # 0.3 $ 109/l, dd vs. dd treated with
LX2931, n ! 10 in each group, P " 0.01), no morbidity or
mortality was observed in any of the LX2931-treated mutant
animals. These data are comparable to those previously re-
ported in wild-type mice with this compound (5). White and
red blood cells in untreated mutant mice were not significantly
different compared with normal littermates (3.9 # 0.5, n !
10). Red blood cells in LX2931-treated mutant mice were
comparable with normal and untreated mutant.
FACS analysis of myeloid cells from the lungs of LX2931-
treated mutant animals in parallel with untreated animals re-
vealed a complex response. First, we observe no effect on total
CD45% (Fig. 2A) or total DC cell counts (Fig. 3A) in the lung.
However, we see an increase in cDC and a concomitant
reduction of MoDC. Thus LX2931 corrects the abnormal
MoDC/cDC composition in mutant mice to wild-type levels
(Fig. 3, B and C). Furthermore, LX treatment reduced the
percentage of CD103% DC (Fig. 3D), which are considered
important regulators of the airway immune response (16, 34).
Remarkably, cells gated as granulocytes and Ly6C% mono-
cytes are significantly increased by LX2931 (Fig. 2, B and D).
Consistent with this increase, the myeloid attractant MCP-1
was moderately enhanced in lung tissue of mutant mice by
LX2931 treatment, but not MIP-2, eotaxin, IFN&, and IL12p70
(Fig. 4).
The LX2931-mediated influx of granulocytes and Ly6C%
monocytes may represent myeloid-derived suppressor cells
(MDSC), defined as CD11b% Gr1/Ly6G% myeloid cells.
These cells are considered anti-inflammatory by suppressing
NK cell activity and T cell proliferation (59, 66). In a recent
study, Liu et al. (39) have shown that MDSC recruitment to the
concanavalin A-induced inflamed liver in mice is enhanced by
the S1P receptor modulator FTY720, reducing hepatic injury.
Therefore, we stained in FACS analysis CD45% cells from
total lungs of F508del CFTR mutant mice, untreated and
treated with LX2931 (n ! 6 in each group) for the MDSC
markers arginase (ARG1) and iNOS/NOS2. However, we did
not observe staining for ARG1 in any of the myeloid subpopu-
lations, including Ly6C% monocytes, ruling out significant
recruitment of MDSC in response to LX2931 (data not shown).
Interestingly, we observed a distinct iNOS% granulocyte
population in unchallenged mutant mice (Fig. 5), which was
not detected in normal mice (n ! 3, not shown). This confirms
basal lung inflammation in mutant mice. This iNOS% granu-
locyte population in mutant mice was significantly reduced by
LX2931 treatment (Fig. 5), suggesting a reduction of lung
inflammation.
Fig. 3. Abnormal dendritic cell population in F508del CFTR mutant mouse lung. Lung homogenates from wild-type (WT; n ! 12), mutant (dd; n ! 15), and
mutant mice treated with SP-1 lyase inhibitor LX2931 in drinking water (dd LX; n ! 6) as described in Fig. 2 were analyzed for markers of dendritic cells (DC).
A: total DC per lung (CD11c%MHCII%). B: percentage monocyte-derived DC of total DC (MoDC, CD11c% MHCII% CD11b% CD64%). C: percentage
conventional DC (cDC, CD11c% MHCII% CD11b% CD64'). D: percentage CD103% DC (CD103% CD11C% MHCII% CD11b'). Average # SE, **P "
0.01; *P " 0.05, 1-way ANOVA.
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Furthermore, LX2931 treatment caused a strong reduction of
the enhanced B cells and T cells counts in mutant lung, even
below values observed in normal mice (Fig. 2, E and F). The
relevance of these results for CF pathology will be discussed
below.
S1P lyase inhibitor does not recover F508del CFTR epithe-
lial fluid transport activity. It has been postulated that inflam-
mation and associated cellular stress reduces the efficiency of
F508del CFTR trafficking or conversely that inefficient folding
of mutant CFTR causes oxidative stress and defective mem-
brane trafficking of murine and human F508del CFTR (14, 43).
S1P has also been linked to inflammation, autophagy, and
oxidative stress (26, 55). Therefore, we considered that mod-
ulation of S1P signaling could have an effect on F508del CFTR
activity. We have investigated this in a separate experiment
using several independent assays.
Consistent with previous data, adult (80–115 days) un-
treated male and female mutant mice were on average 10%
underweight (Table 1) compared with age- and sex-matched
wild-type littermates, primarily due to enterocyte CFTR defi-
ciency (82). Two weeks of LX2931 treatment does not signif-
icantly affect the increase in body weight compared with
untreated mutant mice. This confirms that LX2931 treatment
does not negatively affect the health of the mice, and also that
no major rescue of intestinal CFTR activity occurs under our
conditions. Isoproterenol-induced salivary gland fluid secretion
activity is severely affected in F508del CFTR mutant mice
(82). LX2931-treated mutant mice on average did not show a
Fig. 4. Total lung cytokines in unchallenged F508del mutant and LX2931-treated mice. Total lung extracts of untreated adult mutant mice (dd) or treated with
LX2931 (dd LX), compared with wild-type littermates (WT), were analyzed in parallel by sequential ELISA as described in METHODS. Data are expressed as
pg/mg protein. Average ! SE, **P " 0.01; *P " 0.05, 1-way ANOVA.
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significant increase in isoproterenol-induced fluid secretion
(Fig. 6) Furthermore, we report here for the first time frequent
plugging of ducts in the parotic salivary gland with mucous
material in F508del CFTR homozygous mice, which is virtu-
ally absent in wild-type mice. This is not observed in the
submandibular and sublingual glands. Treatment with LX2931
for 3 wk does not significantly affect parotic duct plugging in
mutant mice (Fig. 7).
We conclude that increasing S1P tissue levels by LX2931
treatment does not significantly affect F508del CFTR channel
activity and associated fluid transport in secretory epithelia in
this model. Changes affecting the behavior of myeloid cells
cannot be excluded, however (10, 35), and are the subject of
current studies.
S1P lyase inhibitor does not interfere with bacterial toxin-
induced myeloid infiltration in F508del CFTR mice. To estab-
lish whether LX2931 has an effect on bacterial toxin-induced
inflammation in mutant mice, we treated mutant and wild-type
mice intranasally with bacterial liposaccharides (LPS) in com-
bination with the modified peptide fMLP, that is required for
full polymorphonuclear leukocytes activation and neutrophil
elastase secretion (13).
Mutant mice, both untreated and LX2931 treated, respond to
LPS/fMLP with a substantial weight loss (10–20%) 48 h after
challenge, whereas wild-type mice suffered only a minor
change (Table 1). Two of 13 untreated mutant animals did not
survive the first week after treatment; no mortality was ob-
served in the LX2931-treated group. One week after challenge,
recovery of body weight is not complete in untreated and
LX2931-treated mutant animals, in contrast to normal (Ta-
ble 1). We conclude that F508del CFTR mutant mice are
more susceptible to LPS/fMLP induced weight loss than
wild-type, in agreement with previous findings using LPS
only and Pseudomonas aeruginosa challenge (48). Further-
more, LX2931 treatment does not prevent this aspect of
acute LPS-induced pathology.
Transient lung inflammation was monitored by microCT
scanning before, 48 h after and 1 wk after challenge (Fig. 8). In
all LPS/fMLP-treated animals we observed high-density areas
covering 0–40% of the left and right lung lobes, indicating
large areas of intense focal inflammation. In unchallenged
mutant and wild-type animals this was not observed (not
shown). Using a five-grade scoring scheme, microCT scores
were high in all groups at 48 h (Fig. 8). One week after
challenge, no remaining foci were observed in the wild-type
group, whereas in a minority of the of the untreated and
LX2931-treated mutant animals low but detectable focal mi-
croCT scores were still present. Thus by this method we find
Fig. 5. SP-1 lyase inhibitor (LX2931) reduces iNOS expression in granulocytes from F508del CFTR mouse lung. In a separate experiment, lungs from
unchallenged adult F508del CFTR mutant mice (n ! 6) were analyzed by FACS, as in Figs. 2 and 3. A: percentage of granulocytes gated as iNOS" were
threefold higher in untreated mutant mice compared with mutant mice treated with LX2931 (**P # 0.01, unpaired t-test). B: representative scatter graphs of
untreated mutant (dd) and LX2931-treated mutant (dd LX) show the distinct iNOS" granulocyte subpopulation, which is absent in normal littermates (n ! 3)
and isotype control (not shown).
Table 1. Effect of LPS/fMLP and LX2931 on mouse body weight
N Age, days (SD) Initial weight, g (SD) % Weight change 2 wk % Weight change LPS 48 h % Weight change LPS 7 days
dd female 7 81.4 (23.5) 18.3* (2.3) 4.2 (6.6) $8.0* (8.9) $0.6 (3.2)
dd male 6 112.5 (46.3) 22.3* (1.2) 9.4 (11.0) $13.2* (8.2) $8.2* (2.1)
dd female LX 5 90.2 (25.8) 17.8* (3.7) 15.9 (7.6) $19.1* (2.7) $12.9* (8.2)
dd male LX 7 90.2 (25.8) 22.8* (1.9) 9.8 (4.4) $11.2* (5.3) $12.9* (8.2)
WT female 12 95.0 (19.5) 20.9 (0.9) 4.3 (4.7) 0.5 (6.4) 0.1 (8.7)
WT male 8 115.6 (47.4) 25.8 (2.0) 5.0 (4.8) $0.6 (6.3) 0.7 (4.5)
Initial body weight of age- and sex-matched F508del mutant (dd) and normal littermates (WT) were monitored in parallel. Data are presented are presented
as average (% SD). A subset of the dd mice were treated with LX2931 in the drinking water, as described in METHODS. After 2 wk the percentage change in body
weight was recorded (% weight change 2 wk). Subsequently all mice were treated intranasally with LPS/fMLP, and the change in body weight was determined
after 48 h and 1 wk. Untreated male and female mutant mice are &10% underweight compared with age- and sex-matched littermates, consistent with previous
data, primarily due to intestinal disease. Two-week LX2831 treatment does not significantly affect average body weight of dd mice. LPS/fMLP challenge causes
a reduction of body weight in mutant but not in normal animals after 48 h, but no mortality (*P # 0.01 compared with sex-matched WT, ANOVA-Tukey). One
week after challenge, we observe an incomplete recovery of body weight in mutant mice. Treatment with LX2931 does not significantly affect this response.
This suggests that LX2831 does not substantially correct mutant CFTR activity, nor does it have adverse effects during basal of challenge conditions.
L1006 S1P LYASE INHIBITOR CORRECTS LUNG INFLAMMATION IN CF MICE
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00298.2016 • www.ajplung.org
 by 10.220.32.246 on Novem
ber 15, 2016
http://ajplung.physiology.org/
Downloaded from
 
	 120	
	 	
no evidence for a reduction of focal myeloid infiltration by
LX2931 in mutant animals either in acute phase or during
resolution.
Whereas focal infiltration was transient, an increase in thick-
ness and apparent density of the septa of the alveolar region is
observed in the microCT scans of all experimental groups 1 wk
after challenge (not shown). This is confirmed by quantitative
histology of all mice 2 wk after challenge. Inflammatory scores
for septal infiltration, focal inflammation, and luminal mono-
cytes were high compared with unchallenged in all experimen-
tal groups. In quantitative analysis of paraffin sections, septum
thickness is also increased by LPS/fMLP challenge in mutant
and wild-type mice compared with untreated (Fig. 9). Remark-
ably, this parameter is significantly higher in LX2931-treated
mutant mice compared with untreated mutant, suggesting an
increase in myeloid infiltration compared with untreated mu-
tant 2 wk after LPS challenge, consistent with the microCT
data (Fig. 8).
LPS/fMLP induced Muc5AC expression is reduced by
LX2931. Unchallenged untreated or LX2931-treated mutant
and wild-type mice do not show goblet cells in the bronchi by
PAS/AB staining of paraffin sections. In contrast, distinct
bronchial goblet cell hyperplasia is observed 2 wk after LPS/
fMLP challenge in all experimental groups to a comparable
extent (Fig. 10, A and B). LX2931 treatment did not signifi-
cantly reduce bronchial goblet cell numbers. Importantly, we
observed a higher expression of the inflammation-responsive
mucin mMUC5AC in mutant mice compared with wild-type in
total lung extracts from LPS/fMLP-challenged mice (Fig.
10C). In LX2931-treated mutant mice a significant reduction
toward wild-type values was observed. This suggests that
LX2931 does not interfere with inflammation-induced goblet
cell hyperplasia in this model but does reduce the expression of
inducible gel-forming mucins, which is of considerable impor-
tance for CF pathology.
High LPS/fMLP induced cytokine levels in mutant mice
restored by LX2391. We measured a panel of cytokines known
to be involved in the resolution of inflammation by sequential
ELISA in total lung homogenates of mutant and wild-type
mice, 2 wk after challenge (Fig. 11). In F508del CFTR mutant
mice we report here for the first time a twofold IFN! and
fourfold interleukin 12 (IL-12p70) level compared with wild-
type 2 wk after LPS/fMLP challenge (Fig. 11, A and B). Also,
Fig. 6. Salivary gland activity in LX2931-treated F508del mutant mice is not
affected. LX2931-treated mutant mice (dd LX) did not show a significant
increase in cAMP-induced salivary gland activity (mg·min"1·kg"1) compared
with untreated mutant (dd), which is severely affected compared with wild-
type littermates (WT) in F508del CFTR mice (1-way ANOVA, Tukey’s test)
(82). Isoproterenol-induced salivary gland fluid secretion was measured in
parallel in adult mutant mice that were untreated (dd, n # 6) or treated with
LX2931 (dd LX n # 7), compared with wild-type littermates (WT, n # 4).
Data are expressed as mg·min"1·kg"1 body wt (average $ SE).
Fig. 7. LX2931 does not rescue parotic duct plugging in
F508del CFTR. Paraffin sections of parotic glands were
stained for mucus by PAS stain, from adult mutant mice
that were untreated (dd, n # 7) or treated with LX2931
as described (dd, LX; n # 9), compared with wild-type
littermates (WT, n # 5). In normal mice major ducts
(arrows) were free of mucous material (A), whereas in
F508del CFTR mice variable but frequent plugging
with PAS positive material was observed (arrows) (B).
This plugging was not observed in the submandibular
and sublingual glands of mutant mice (not shown). C:
multiple (3–6) nonsequential low sections of each
mouse were analyzed and the percentage of plugged vs.
open ducts was calculated. The graph shows the average
per experimental group $ SE. Plugging is significantly
higher in mutant mice compared with WT (Kruskal-
Wallis/Dunn’s test). Treatment with LX2931 has no
significant effect on parotic duct plugging.
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TNF!, IL-10, and KC showed increased levels in mutant mice
after challenge (Fig. 11, C–E).
Importantly, the high IFN", IL12P70, KC, and IL-10 levels
2 wk after challenge are corrected toward normal values by
LX2391 treatment (Fig. 11). TNF! shows a similar trend, but
this does not reach statistical significance in this experiment. A
notable exception to this pattern is the increase of the monocyte
attractant MCP-1 (CCL2) induced by LX2931 (Fig. 11F),
which is increased by LX2931 treatment. This is consistent
with the enhanced myeloid infiltration after LPS/fMLP chal-
lenge (Figs. 8 and 9).
We conclude that resolution of LPS/fMLP-induced inflam-
mation is delayed in F508del mutant mice compared with
normal. Furthermore, LX2391 treatment corrects the enhanced
expression of several, but not all proinflammatory cytokines
under these conditions.
DISCUSSION
Abnormal dendritic cell ratio and myeloid infiltration in CF
mouse lung. Unchallenged Cftrtm1EUR F508del CFTR mice
kept under pathogen-free conditions display low-level lung
inflammation (36, 43, 82). In this model we show here an
enhanced level of myeloid cell (CD45#) infiltration, mainly
granulocytes and B and T cells (Fig. 2), and low levels of cDC,
whereas MoDC are increased (Fig. 3, B and C). MoDC arise
from Ly6cHi monocytes at inflammatory sites (56) and play a
proinflammatory role via the production of chemokines with
chemotactic activity for effector T cells, monocytes and gran-
ulocytes (53). Therefore, the presence of high MoDC numbers
in the lung may perpetuate inflammation in these mutant mice.
In addition, we observed a distinct iNOS-expressing granu-
locyte population that was not present in wild-type mice
(Fig. 5). iNOS expression is associated with inflammation and
tissue damage. This suggests that the iNOS# granulocyte
population in mutant mice is an aspect of basal inflammation
caused by CFTR deficiency. A third subset, CD103# DC,
involved in antiviral responses (17), is not significantly differ-
ent from normal in F508del CFTR mice (Fig. 3, A and D). Xu
et al. (85) reported an increase in the percentage of CD11c#
CD11b# DC in CFTR KO mice, which does not discriminate
between CD64$ cDC and CD64# MoDC as in our approach.
In contrast to our results (Fig. 3D), they reported a reduced
percentage of CD103# DC (CD11C# MHCII# CD11b$).
The apparent discrepancy could be related to strain or hus-
bandry differences. However, a direct comparison of these data
sets is difficult, since Xu et al. do not report absolute counts
and the use of a marker to exclude dead cells from analysis.
In CF infants with early-stage lung disease, CT scans show
bronchial thickening and distal air-trapping even in the absence
of apparent bacterial infection (41, 68), suggesting unprovoked
inflammation in CF lung. In newborn CF piglets, however, a
CF-like lung pathology develops within months without en-
hanced neutrophil infiltration prior to infection, arguing against
significant sterile inflammation in newborn CF pig lung (2, 6,
69). However, no detailed quantitative analysis of tissue DC
and other myeloid populations by FACS was reported in early
stages of disease in either CF pig or human. Therefore, abnor-
malities similar to what we report here in adult mutant mice
could be involved in the development of chronic CF lung
disease in human.
Fig. 8. Focal inflammation induced by bac-
terial toxins analyzed by microCT. Gated
lung microcomputed tomography (microCT)
scans on a Quantum FX CT scanner (Perkin
Elmer) under isoflurane anesthesia was per-
formed on all animals treated with LPS/
fMLP as described in METHODS. CT scans
were viewed and analyzed using Caliper
Analyze software. Scoring of CT scans was
performed in a 5-grade binning mode by
measuring the relative surface of the lung
volume occupied by high-density areas (ar-
rows), as in the representative figures ob-
tained with a F508del CFTR mutant mouse
before (A), 48 h after (B), and 1 wk after (C)
intranasal LPS/fMLP challenge of each ani-
mal. D: quantitative scoring of focal inflam-
mation. Wild-type (WT, n % 17), homozy-
gous F508del CFTR mutant (dd, n % 14),
and homozygous mutant orally treated with
LX2931 (dd LX, n % 11) for 3 wk prior to
challenge and 2 wk after challenge (average
score & SE). Before-challenge scores were
zero in all animals (not shown). At 14 days
lungs were collected for quantitative histol-
ogy and ELISA (Figs. 9–11).
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Sustained response to LPS/fMLP challenge in F508del mu-
tant mice. Enhanced levels of proinflammatory cytokines,
including TNF-! and KC 2 wk after LPS/fMLP exposure,
show defective resolution of inflammation in F508del CFTR
mutant mice (Fig. 11). This is consistent with earlier reports of
enhanced and sustained lung pathology after naphthalene-
injury (11), bleomycin (27), LPS, and Pseudomonas aerugi-
nosa challenge (48) in this model.
Our present data show enhanced levels of both IFN" and the
active form of IL-12 (IL-12p70) in the lung of LPS/fMLP
challenged mutant mice, 2 wk after exposure. IFN" overex-
pression causes enhanced macrophage and neutrophil infiltra-
tion in mice (30). Th1-dependent IFN" production is stimu-
lated by IL-12, which in turn is secreted by triggered mature
DC (30). Thus it seems likely that the high numbers of lung
MoDCs in F508del CFTR mutant mice contribute to the
delayed resolution of induced inflammation through activation
of the IL12/IFN" axis. Consistent with our finding, IFN" is
increased in BALF of young CF patients compared with
non-CF (74).
IL-10 levels were high in mutant mice 2 wk after LPS/fMLP
challenge compared with wild-type, which is also testimony to
an abnormal resolution of inflammation. IL-10 is often consid-
ered an anti-inflammatory signal and therefore benign. How-
ever, this concept has been challenged in the context of chronic
lung inflammation. Chronic overexpression of IL-10 causes a
strong fibrotic response, likely through upregulation of MCP-1
(CCL2), enhanced myeloid infiltration, and a bias toward M2
macrophage differentiation (70). Proinflammatory macroph-
age polarization and accumulation were also observed in
Cftrtm1EUR (FVB) mice (45). Furthermore, a stronger fibrotic
response to bleomycin-induced inflammation was reported in
this strain, with enhanced myeloid infiltration and MCP-1
signaling (27). Both in the Cftrtm1EUR and the IL-10 overex-
pression models isolated myofibrocytes displayed a profibrotic
phenotype compared with control, suggesting that chronic lung
inflammation in CF lung changes the epigenetic program of
subepithelial connective tissue, involving the IL-10/MCP-1
axis.
Inflammation in Cftrtm1EUR mice correlates with low lung
S1P levels. The effect of CFTR deficiency on myeloid infil-
tration and DC imbalance (Figs. 2 and 3) and resolution of
inflammation (Fig. 10 and 11) is not readily explained at the
molecular level. The myeloid attractants MCP-1, MIP-2, and
eotaxin were not significantly increased in unchallenged mu-
tant mice under our basal conditions (Fig. 4). However, CFTR
deficiency affects other processes that control myeloid cell
behavior in the lung, in particular the production of bioactive
Fig. 9. Quantitative analysis of myeloid infiltration
after LPS/fMLP challenge. Representative hematox-
ylin-eosin stain of normal mouse lungs before (A)
and 2 wk after (B) LPS/fMLP challenge show sus-
tained septum thickening, associated with appear-
ance of ARG1-positive interstitial and luminal my-
eloid cells in all experimental groups (not shown).
C: quantitative analysis of septum thickness, as
described in METHODS, of LPS/fMLP treated and
untreated mice as in Fig. 5. A significant increase in
septum thickness was observed 2 wk after LPS/
fMLP challenge in normal (WT), mutant (dd), and
most strongly in mutant mice treated with LX2931
(dd LX) (n # 9 mice per experimental group, 3–4
nonadjacent sections per mouse were analyzed).
**P $ 0.01, ***P $ 0.001, 1-way ANOVA.
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lipids, as exemplified in our study. CFTR deficiency in epithe-
lial cells reportedly causes destabilization of membrane protein
scaffolds involving lysolipid receptors (25), ion transport sys-
tems (12, 20, 67) and tight junctions (64), activation of cellular
phospholipase A (18), ceramidases (22), and enhanced oxida-
tive stress associated with abnormal autophagy (43). Further-
more, CF lung DCs, macrophages, and neutrophils show phe-
notypic abnormalities (29, 54, 61, 78, 86). Any of these
processes may affect inflammatory signaling in CF lungs. Here
we report low sphingosines and S1P in total lung tissue of
unchallenged Cftrtm1EUR F508del CFTR mice that are kept on
normal chow (Fig. 1). This confirms and extends the data of Xu
et al. (85), who reported low S1P in BALF of a C57/Bl6 CFTR
KO (Cftrtm1UNC) strain. Low sphingosine levels have been
reported in another CF mouse model related to enhanced
susceptibility to bacterial infections (51, 72), which we also
observe in our model (48).
Abnormalities of sphingolipid metabolism in CF mutant
mice and patients have been extensively studied, focusing on
the role of acid sphingomyelinase (SMase) in ceramide syn-
thesis (23, 73, 83). In the Cftrtm1EUR model, acid and alkaline
sphingomyelinase (SMase), and neutral ceramidase activities
are normally expressed in mutant mouse lung (47). Enzymes
directly involved in S1P metabolism, in particular sphingosine
kinase SPHK (33) and SPL (31), do not emerge from differ-
ential lung transcriptome analysis in our mouse model (Scholte
BJ, unpublished observations). However, further studies are
required to establish the relationship between CFTR deficiency
and the activity and tissue distribution of key enzymes and
transporters that determine the intracellular and extracellular
S1P gradients that orchestrate S1P receptor activity.
Treatment with a SLP inhibitor corrects inflammation in
unchallenged Cftrtm1eur mice. Oral treatment of adult F508del
homozygous mice with the SPL inhibitor LX2931 strongly
enhanced S1P lung tissue levels, as expected (5). No serious
adverse effects were noticed during the 3 wk of the experiment.
The relative abundance of the proinflammatory MoDC and
reduced levels of cDC in mutant mouse lung are corrected by
LX2931 treatment (Fig. 3). This suggests that the abnormal
S1P level is a causative factor in CF lung inflammation in this
model. We also observe a significant reduction of CD103! DC
in LX2931-treated mutant mice compared with untreated. To-
gether, these data suggest that LX2931 shifts the mutant mouse
lung DC population toward a lower state of inflammation.
LX2931 increases lung granulocyte and LyC6! monocyte
infiltration in unchallenged mutant mice (Fig. 2), consistent
with an increased level of MCP-1 in LX2931-treated mutant
mice (Fig. 4). These LX2931 induced LyC6! monocytes do
not have a suppressor cell (MDSC) phenotype, lacking the
typical ARG1! iNOS! FACS stain. Importantly, however,
they do not differentiate to proinflammatory MoDCs and mac-
rophages, as they would under inflammatory conditions, since
their total numbers are not affected (Fig. 2). Furthermore, the
infiltrating granulocytes show reduced iNOS expression in
LX2931-treated mutant mice (Fig. 5). Together, this suggests
that LX2931 allows monocyte and granulocyte infiltration to
the lung but induces a block in differentiation toward proin-
flammatory phenotypes.
Since our primary purpose was to establish the role of S1P
in CF lung inflammation we did not test the effect of LX2931
on wild-type cells from our colony. In an SPL KO mouse
model, alveolar myeloid infiltration is reported, comparable to
our observations in mutant mice treated with LX2931 (3, 80)
(Fig. 2, B and D). However, this was not observed in wild-type
mice treated with LX2931 (T. Oravecz, unpublished data) or
the parent compound THI (5), or in a strain expressing reduced
levels (17%) of SPL activity (80). As our data indicate, CF
mouse lungs may offer a different signaling environment
compared with wild-type mice, resulting in enhanced infiltra-
tion of myeloid cells during LX2931 treatment, that do not
differentiate to proinflammatory phenotypes.
Total B cell and T cell counts, which are increased in mutant
mouse lungs, are strongly reduced by LX2931 treatment below
wild-type levels (Fig. 2, E and F). The role of T and B cells in
CF lung pathology is not well understood. Infiltrating B cells
form lymphoid aggregates in CF lungs during end stage disease
Fig. 10. Enhanced MUC5AC production in F508del
CFTR mutant mouse lung after LPS/fMLP chal-
lenge is reduced by SP-1 lyase inhibitor (LX2931).
Representative micrographs (hematoxylin-eosin/
PAS staining) of unchallenged F508del CFTR mu-
tant mouse (A) 2 wk after LPS/fMLP challenge (B)
(bar: 100 "m). Mutant (n # 20) and normal mouse
lung (n# 20) show very few goblet cells in bronchi.
Goblet cell hyperplasia is observed 2 wk after LPS/
fMLP challenge in bronchi of all normal (n # 17)
and mutant (n # 14) animals, including animals
treated with LX2931 (n # 9). C: total lung extracts
of LPS/fMLP-treated mutant mice (dd) and wild-
type littermates (WT) were analyzed in parallel by
ELISA for murine MUC5AC 2 wk after challenge.
Mutant mice produced more mMUC5AC antigen
than normal, which was reduced to normal levels by
LX2931 treatment (dd LPS LX) as in Fig. 5 (n #
10). **P $ 0.01; *P $ 0.05, 1-way ANOVA.
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(28). B cell differentiation factor (BAFF) is high in BALF from
young CF patients compared with healthy controls, suggesting
involvement in early CF lung disease (46). B cell depletion is
considered a potential treatment in chronic inflammatory dis-
orders (38) and may be beneficial to CF patients as well. T cell
subpopulation (Th17/Th2) imbalance was reported in CF lung
(74). However, subtype-specific quantitative data on T cell
infiltration in early human CF or CF pig lung have not been
reported to our knowledge. Clearly, further studies are required
to establish the role of T and B cell subtypes in CF pathology
and the potential use of pharmaceutical intervention.
LX2931 reduces LPS/fMLP induced inflammatory response
in mutant mice. LX2931 treatment does not prevent the LPS/
fMLP induced acute myeloid infiltration (Fig. 8) or subsequent
hyperplasia of goblet cells in mutant mice but reduces the
enhanced production of mMUC5AC to normal levels (Fig. 10).
This is highly relevant to CF since CFTR deficiency in humans
causes abnormal mucus viscosity and clearance, which con-
tributes to the progression of CF lung disease (52, 57, 63, 68).
Whether LX2931 can prevent or reduce distal airway plugging
in CF infants by reducing inflammation and associated mucin
secretion remains to be established.
MCP1 levels are enhanced in LX2931-treated mutant ani-
mals after challenge (Fig. 11F), which is likely related to the
increased myeloid infiltration under these conditions (Fig. 9).
However, since LX2931 prevents proinflammatory differenti-
ation of infiltrating cells this does not lead to more severe
pathology (Table 1, Fig. 10). In contrast, the proinflammatory
Fig. 11. Abnormal cytokine levels in F508del CFTR mouse lung after LPS/fMLP challenge partially corrected by SP-1 lyase inhibitor (LX2931). Total lung
extracts of wild-type (WT), F508del CFTR (dd), and mutant treated with LX2931 (dd LX) were analyzed by sequential ELISA 2 wk after LPS/fMLP challenge
for IFN! (A), IL12p70 (B), TNF-" (C), IL-10 (D), KC (E), and MCP-1 (F). Results from individual mice are shown as pg/mg total protein. ***P # 0.001; **P #
0.01; *P # 0.05, 1-way ANOVA.
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IL8 orthologue KC, IL-10, as well as IFN! and IL-12 are
significantly reduced by LX2931 treatment after LPS/fMLP
challenge (Fig. 11, A and B). This suggests that LX2931
treatment attenuates the IL12/IFN inflammation cascade, pos-
sibly through an effect on the resident DC population (Fig. 3).
The molecular mechanism of action of LX2931. Our data do
not support a correction of mutant CFTR activity by LX2931,
since it does not correct the low body weight (Table 1),
CFTR-dependent salivary gland fluid transport activity (Fig.
6), or parotic duct plugging in CF mutant animals (Fig. 7).
Chronic treatment with the SPL inhibitor THI, a parent com-
pound to LX2931, strongly increased S1P tissue levels in
medullary structural cells and also severely reduced S1P1
receptor expression on infiltrating thymocytes, probably by
ligand-induced receptor inactivation (44). By analogy, it is
highly likely that chronic LX2931 treatment inactivates S1P1
receptors by substantially increasing S1P levels in susceptible
tissues. This may subsequently affect trafficking and differen-
tiation of lymphoid cells.
Summary and perspective. Our results reveal for the first
time by FACS analysis and sequential ELISA that unchal-
lenged F508del CFTR mutant mouse lung displays abnormal
myeloid infiltration and a delayed resolution of LPS/fMLP
induced inflammation. This allows us to extend previous stud-
ies with experimental therapeutics in this model, targeting
F508del mutant CFTR (15, 62, 75, 81) or using anti-inflam-
matory drugs (18, 43, 45). Our data and recent reports in the
literature cited above imply that CF lung pathology should be
considered a disease of myeloid cells as well as epithelial cells
and can be at least partially corrected using drugs targeting
affected signaling pathways (76).
Treatment with the SPL inhibitor LX2931 successfully re-
verses the low lung tissue S1P levels of F508del CFTR mutant
mice and partially corrects the excessive basal and induced
inflammation responses in these mice. This would support the
hypothesis that pharmaceutic intervention in this pathway
could be advantageous to the patients. Since the compound was
shown to be safe in animals (Ref. 5; this study) and in humans
(37), an intervention in CF patients could be considered.
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GENERAL	DISCUSSION	AND	FUTURE	PERSPECTIVES	
	
General	introduction	
Airway	epithelium,	apart	 from	providing	a	 structural	barrier	 against	microbes	and	 inhaled	
particles	 (mucociliary	 clearance),	 also	 plays	 an	 active	 role	 in	 a	 first	 line	 of	 inflammatory	
responses	[1],	and	thus	emerged	as	a	therapeutic	target	in	chronic	lung	disease	[2].	Airway	
epithelial	 cells	 respond	 dynamically	 to	 bacterial	 and	 viral	 infections	 [3]	 [4]	 [5]	 or	 inhaled	
noxious	 particles	 by	 transducing	 inflammatory	 signals	 [6]	 [7].	 They	 produce	 cytokines,	
growth	 factors	and	other	 inflammatory	mediators	 to	recruit	a	 range	of	 inflammatory	cells	
including	 neutrophils	 and	 macrophages	 [1]	 [8].	 Importantly,	 airway	 epithelial	 cells	 also	
cross-talk	 with	 the	 underlying	 fibroblasts/myoblasts	 [9]	 [10].	 This	 trans-signaling,	 when	
exaggerated	 by	 stress	 factors	 and	 bacterial	 infections	 during	 the	 course	 of	 disease	
development,	 leads	 to	 structural	 changes	 of	 the	 tissue	 structure	 termed	 lung	 tissue	
remodeling,	a	feature	of	both	CF	and	COPD	pathology	[11]	[12]	[13].	
	
A	disintegrin	and	metalloprotease	17	(ADAM17),	a	sheddase,	formerly	known	as	TACE,	that	
releases	 a	 broad	 spectrum	 of	 soluble	 biologically	 active	 substrates	 from	 airway	 epithelial	
cells	 is	 recognized	as	an	 important	 transducer	of	airway	epithelial	cis-	and	trans-	signaling	
[14].	The	growth	factor	AREG	[15]	and	cytokine	receptor	IL6R	[16],	both	shed	by	ADAM17,	
activate	EGFR	and	gp130	respectively,	and	have	been	linked	to	lung	pathology	[17]	[18]	[19],	
but	 were	 never	 directly	 investigated	 in	 the	 context	 of	 COPD	 and	 CF	 lung	 malfunction.	
Therefore,	 the	 main	 aim	 of	 this	 thesis	 was	 to	 elucidate	 whether	 ADAM17	 responds	
differently	 to	external	stimuli	 like	cigarette	smoke	 (CS)	 in	COPD	airway	epithelial	cells	and	
whether	CFTR	deficiency	activates	ADAM17	as	a	cell	autonomous	defect.	During	the	course	
of	our	studies	it	emerged	that	EGFR	is	an	equally	potent	regulator	of	IL6R	and	AREG	release	
and	mRNA	expression	 as	ADAM17,	 indicating	 the	 role	of	 the	 EGFR-ADAM17	axis	 in	COPD	
and	 CF	 pathology	 (Chapter	 2	 and	 3).	 It	 is	 known	 that	 both	 EGFR	 and	 ADAM17	 play	 an	
essential	 role	 in	 lung	 tissue	 inflammation	and	 regeneration	 [20]	 [21].	However,	 so	 far	 the	
role	 of	 ADAM17	 and	 EGFR	 has	 only	 been	 broadly	 studied	 in	 carcinogenesis	 and	 little	 is	
known	 about	 the	 organization	 and	 function	 of	 this	 signaling	 network	 in	 differentiated	 CF	
and	COPD	airway	epithelial	cells.		
	
In	view	of	the	comparable	pathological	events	in	CF	and	COPD	[22]	[23]	[24]	(Chapter	1)	and	
the	recently	observed	downregulation	of	CFTR	by	CS	exposure	[25]	[26],	we	proposed	that	
the	molecular	mechanism	underlying	the	development	of	these	diseases	is	similar	and	may	
involve	abnormal	activation	of	the	EGFR-ADAM17	axis.	Our	studies	and	the	literature	cited	
show	 that	 ADAM17-mediated	 release	 of	 bioactive	 substrates	 is	 a	 tightly	 regulated,	
multistep,	 spatiotemporal	 process	 that	 likely	 requires	 activation	 by	 upstream	 kinase	
signaling	 (Chapter	 2	 and	 3)	 [27],	 trafficking	 of	 ADAM17	 towards	 the	 substrate	 in	 the	
intracellular	 compartment	 (Chapter	 2)	 [28],	 thiol-isomerase	 and	 redox	 regulated	 disulfide	
bridge	 rearrangements	 (Chapter	 3)	 [29],	 and	dissociation	of	 the	 inhibitory	protein	 TIMP-3	
[30].	 EGFR/ADAM17	 signaling	 cross-talks	 with	 many	 regulatory	 pathways	 like	 TLR5,	 G-
coupled	 receptors,	 p38	MAPK,	 ERK1/2	 (Chapter	 2	 and	 3)	 [31]	 [32]	 [33]	 [34]	 [35].	 In	 this	
thesis	we	addressed	some	of	the	issues	of	ADAM17	activation	and	the	role	of	EGFR	in	this	
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signaling	cascade	 in	order	 to	define	the	druggable	 targets	 in	 the	ADAM17/EGFR	axis	 in	CF	
and	COPD	pathology	(Chapter	1,	Figure	7).	
	
A	model	of	lung	pathology	
Although	mouse	models	can	contribute	considerably	to	our	understanding	of	CF	(Chapter	4,	
Appendix)	 and	 COPD	 lung	 pathology	 [36],	we	 have	 focused	 on	 differentiated	 at	 air-liquid	
interface	human	airway	epithelial	cells	in	culture.	Firstly,	because	it	has	been	reported	that	
ADAM17	activity	towards	its	substrates	is	species	specific,	as	exemplified	by	IL-6R	[37]	[38]	
[10].	Additionally,	 in	 humans	 and	pigs,	 the	 loss	 of	 CFTR	 impairs	 respiratory	host	 defenses	
due	 to	 acidification	 of	 ASL	 causing	 airway	 infection,	 but	 in	 mice	 this	 acidification	 is	 not	
observed	[39].	CF	mice	do	not	develop	CF	type	obstructive	distal	lung	disease	[40],	however,	
they	do	show	evidence	of	chronic	lung	disease	characterized	by	inflammation	and	MUC5AC	
hypersecretion	with	abnormal	myeloid	 infiltration	and	exaggerated	 responses	 to	bacterial	
challenge	 (Chapter	 4,	 Appendix).	 To	 provide	 clinically	 relevant	 data	 focusing	 on	 the	
contribution	 of	 airway	 epithelial	 cells	 to	 the	 signaling	 cascade,	 we	 investigated	 our	
hypothesis	in	human	bronchial	epithelial	cells	cultured	at	the	air-liquid	interface.		
We	 examined	 the	 effect	 of	 cigarette	 smoke	 (CS)	 on	 the	 ADAM17/EGFR	 axis	 in	 well-
differentiated	bronchial	 epithelial	 cells	 from	COPD	patients	under	air-liquid	 interface	 (ALI)	
(ALI-COPD	 HBEC)	 (Chapter	 2).	 This	 gave	 us	 the	 opportunity	 to	 compare	 airway	 epithelial	
cells	 from	COPD	with	non-COPD	 subjects.	Apart	 from	 that	we	exposed	 the	 cells	 to	whole	
cigarette	smoke,	 instead	of	cigarette	smoke	extract	(CSE)	or	noxious	particles,	that	cannot	
be	 considered	 as	 the	 substitute	 of	 whole	 cigarette	 smoke	 [41]	 (Chapter	 2).	 Although	we	
were	able	to	obtain	significant	differences,	we	noticed	that	primary	human	bronchial	cells	
from	different	donors	respond	with	high	variability	to	external	stimuli	(Chapter	2).	This	can	
be	considered	as	a	disadvantage	of	the	primary	culture	model	in	the	event	of	studying	the	
effect	of	CFTR	deficiency	on	downstream	pathways.	Apart	from	that,	cell	material	from	the	
CF	 patient	 population	 allows	 us	 only	 limited	 access	 to	 end-stage	 disease	 after	 lung	
transplant.	An	alternative	would	be	epithelial	cell	culture	from	nasal	brushes,	however,	this	
does	not	allow	expansion	of	large	amounts	of	cells	for	culture,	and	this	system	differs	from	
the	distal	airways	and	 is	also	characterized	by	a	 large	donor	and	subculture	variation	[42].	
Thus,	 in	 further	 studies	 to	 define	 the	 effect	 of	 CFTR	 deficiency	 on	 ADAM17/EGFR	 axis	
activity,	 we	 used	 a	 well-characterized	 airway	 epithelial	 cell	 line	 CFBE41o-	 differentiated	
under	 air-liquid	 interface	 with	 inducible	 CFTR	 expression	 (ALI-CFBE41o-).	 This	 model	
allowed	us	not	only	to	overcome	donor	and	culture	variation	(Chapter	3),	but	also	the	use	of	
CFTR	inhibitors	or	siRNA	to	obtain	CFTR	deficient	cells	 is	not	preferred	due	to	reported	off	
target	 effects	 [43]	 [44].	 In	 future	 studies	 in	 our	 laboratory	 induced	pluripotent	 stem	 cells	
(iPS)	 from	 CF	 patients	 and	 parallel	 lines	 corrected	 by	 gene	 editing	 will	 be	 used.	 This	 will	
allow	us	to	study	CFTR	deficiency	in	a	single	genetic	background	in	differentiated	epithelial	
lineages.	
ADAM17	is	the	main	sheddase	of	IL6R	and	AREG	in	human	bronchial	epithelial	cells	
Previous	 studies	 have	 shown	 that	 external	 stress	 factors	 (like	 cigarette	 smoke	 extract	 [7]	
[45]	 [46]	 [47]	 [48]	 [49],	 bacterial	 or	 viral	 infections	 [3]	 [4],	 cytokine	 or	 growth	 factor	
treatment	 [50]	 [51])	 abnormally	 activate	ADAM17	 and	 EGFR	 in	 different	 airway	 epithelial	
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cell	models,	mainly	in	submerged	cell	lines.	As	an	extension	of	previous	finding,	the	studies	
described	 in	 this	 thesis	 show	 the	mechanism	of	ADAM17	 activation	 in	 CF	 and	COPD	 lung	
disease	in	an	advanced	model	of	lung	airway	epithelial	cells.	By	using	the	selective	ADAM17	
inhibitor	 TMI-2	 (Wyeth),	 we	 showed	 that	 ADAM17	 is	 the	main	 sheddase	 responsible	 for	
AREG	and	 IL6R	 release	 from	differentiated	primary	 airway	epithelial	 cells	 (Chapter	 2)	 and	
AREG	from	ALI-CFBE	cell	line	(soluble	IL6R	has	not	been	detected	in	supernatants	from	ALI-
CFBE41o-	in	our	assay)	(Chapter	3).		
	
ADAM17	 establishes	 a	 signaling	 axis	with	 EGFR,	 regulating	 protein	 and	mRNA	 levels	 of	
ADAM17	substrates.		
To	 further	 investigate	 the	 signaling	 cascade	 leading	 to	 release	of	ADAM17	 substrates,	we	
tested	 several	 kinases	 that	 have	 been	 potential	 regulators	 of	 ADAM17	 signaling	 cascade,	
like	SRC	[52]	or	ERK1/2/MAPK	[35]	[33],	but	EGFR	emerged	as	the	most	potent	regulator	of	
AREG	and	IL6R	release,	with	a	strength	equal	to	ADAM17	(Chapter	2).	These	data	provided	
the	 proof	 of	 existence	 of	 a	 EGFR-ADAM17	 positive	 feedback	 loop	 [53]	 [52]	 [54],	 also	 in	
differentiated	airway	epithelial	cells	(Chapter	1,	Figure	4).	Importantly,	for	the	first	time	we	
present	evidence	that	both	EGFR	and	ADAM17	regulate	not	only	protein	 release,	but	also	
mRNA	expression	of	IL6R	and	AREG.	The	involvement	of	EGFR	in	mRNA	regulation	of	other	
signaling	molecules	 such	 as	 IL-8	 has	 been	 already	 shown	 [7]	 [49].	Here	we	observed	 that	
also	 a	 selective	 ADAM17	 inhibitor	 blocks	 IL8	 mRNA	 production	 in	 ALI-HBEC	 through	 the	
feedback	 loop	action	of	 the	system	(Chapter	2).	Thus,	our	 results	highlight	 that	 the	EGFR-
ADAM17	axis	is	a	potent	regulator	of	both	ADAM17	substrate	shedding	and	EGFR	targets	at	
the	 protein	 and	 mRNA	 level	 in	 airway	 epithelial	 cells,	 likely	 playing	 a	 crucial	 role	 in	
inflammation	and	tissue	repair.	
	
Airway	epithelial	cells	from	COPD	patients	respond	more	strongly	to	cigarette	smoke	than	
normal	
In	 COPD	ALI-HBEC	we	 showed	 that	 under	 basal	 conditions	 release	 of	 ADAM17	 substrates	
does	 not	 depend	 on	 COPD	 disease	 status,	 but	 upon	 CS	 exposure	 both	 AREG	 and	 IL-6R	
release	 is	 stronger	 in	 COPD	 cells.	 The	 difference	 between	 COPD	 and	 non-COPD	 in	 CS-
induced	ADAM17	activity	 is	not	caused	by	changes	 in	the	relative	mRNA	levels	of	AREG	or	
IL-6R	in	COPD	ALI-HBEC.	Thus,	we	concluded	that	COPD	lung	disease	makes	airway	epithelial	
cells	more	sensitive	to	external	stress	factors.	Since	our	studies	show	induction	of	ADAM17	
activity	upon	CS	exposure,	 and	previous	 studies	of	Amatngalim	et	 al	 showed	 that	CS	 also	
induces	phosphorylation	of	EGFR	[7],	it	is	likely	that	the	difference	between	COPD	and	non-
COPD	 is	 due	 to	 post-transcriptional	 regulation	 of	 ADAM17	 and	 EGFR	 activity	 (Chapter	 2).	
This	 may	 include	 the	 level	 of	 ADAM17	 and	 EGFR	 phosphorylation	 (Chapter	 2	 and	 3)	 or	
structural	 changes	 (disulfide	 bridges)	 (Chapter	 3).	 Epigenetic	 changes,	 involving	 DNA	
methylation	and	histone	modifications,	causing	various	levels	of	metaplasia,	may	also	play	a	
role.	DNA	methylation	 is	affected	 in	COPD	lung	tissue	and	mice	exposed	to	CS	[55],	and	 is	
likely	 also	 a	 factor	 in	 CF	 lung	 disease	 development,	 though	 this	 has	 not	 been	 studied	 in	
detail.	 It	 has	 been	 proposed	 that	 both	 CF	 and	 COPD	 patients	 have	 altered	 microRNA	
(miRNA)	expression	[56]	[57]	[58]	[59],	which	may	affect	ADAM17	[60]	[61]	[62]	and	EGFR	
[63]	 [64]	 activity.	Of	 interest	 to	 our	 purpose	 is	 the	 fact	 that	 both	miRNA	 and	 epigenetics	
offer	new	possibilities	of	therapeutic	intervention.		
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CFTR	dysfunction	 hyperactivates	 the	ADAM17/EGFR	 axis	 and	 is	 a	 possible	 link	 between	
pathological	events	observed	in	COPD	and	CF	
To	further	establish	the	importance	of	the	EGFR-ADAM17	axis	in	lung	pathology,	we	showed	
that	 CFTR	 deficient	 airway	 epithelial	 cells	 have	 induced	 ADAM17	 activity	 and	 EGFR	
phosphorylation	(Y1173),	compared	to	CFTR	expressing	cells	(Chapter	3).	These	data	suggest	
that	CFTR	deficient	 cells	 have	 an	 intrinsic	 defect	 in	 the	ADAM17/EGFR	 signaling	pathway.	
Kim	 et	 al	 reported	 that	 CFTR	 inhibitor	 treatment	 increases	 EGFR	 and	 ADAM17	 related	
inflammatory	 responses	 in	 submerged	 immortalized	 cells	 [65].	 However,	 we	 used	
differentiated	 cells	 under	 ALI	 conditions	 with	 inducible	 CFTR	 expression,	 overcoming	 the	
off-target	 effects	 of	 CFTR	 inhibitors	 [43]	 [44]	 and	 donor	 variation	 observed	 in	 ALI-HBEC	
(Chapter	2).	Importantly,	enhanced	ADAM17	shedding	activity	and	EGFR	phosphorylation	in	
CFTR	 deficient	 cells	 is	 not	 caused	 by	 a	 difference	 in	 induced	mRNA	 levels	 of	 ADAM17	or	
EGFR,	 suggesting	 that	 dysfunctional	 CFTR	 affects	 ADAM17/EGFR	 signaling	 post-
transcriptionally.	Moreover,	the	difference	was	only	observed	during	ALI	culture,	and	not	in	
submerged	 conditions,	 suggesting	 that	 CFTR	 deficient	 cells	 in	 comparison	 to	 cells	 with	
induced	 CFTR	 activity	 adapt	 abnormally	 to	 the	 ALI	 environment,	 affecting	 the	
ADAM17/EGFR	 axis	 activity.	 This	 also	 highlights	 that	 3D	 ALI	 culture,	 but	 not	 submerged	
cultures,	resembles	the	in	vivo	conditions	more	precisely.		
	
Interestingly,	 CS	 recently	 has	 been	 shown	 to	 reduce	 CFTR	 function,	 observed	 as	 CFTR	
internalization	[25],	reduced	CFTR	activity	measured	by	nasal	potential	differences	(NPD)	in	
patients	 and	 ASL	 dehydration	 in	 airway	 epithelial	 cells	 [26],	 mimicking	 this	 aspect	 of	 CF	
pathology	[23]	[24]	[66].	Recent	studies	show	that	treatment	with	cigarette	smoke	extract	
(CSE)	 transiently	 also	 reduced	 CFTR	 gating	 activity,	 due	 to	 formation	 of	 acrolein	 adducts,	
and	that	short	term	(1	h)	application	of	VX-770	partially	restores	CFTR	function	[67].	Thus,	
the	 CS	 induced	 ADAM17/EGFR	 axis	 activity	 (Chapter	 2)	 and	 the	 CFTR-dependent	 AREG	
release	 in	 CFBE	 cells	 (Chapter	 3)	 suggest	 that	 CFTR	 dysfunction	 is	 a	 common	 cause	 of	
enhanced	activity	of	the	EGFR/ADAM17	axis	observed	in	CF	and	COPD	lung	disease.		
We	 measured	 CFTR	 related	 short-circuit	 current	 (Isc)	 24h	 after	 CS	 exposure,	 when	 we	
observed	 induced	 shedding	 activity,	 but	 at	 this	 time	 point	 we	 did	 not	 observe	 abnormal	
CFTR	function	(data	not	shown).	However,	CFTR	internalizes	quickly	after	CS	exposure	and	
complete	recovery	takes	approximately	24h	[25]	[68].	Therefore,	further	experiments	with	
shorter	 time	 points	 are	 required	 to	 establish	 the	 relationship	 between	 CFTR	 activity	 and	
shedding	in	our	CS	exposure	system.	
Solone	et	al	showed	that	the	CFTR	potentiator	Ivacaftor	(VX-770)	activated	CFTR-dependent	
chloride	 transport	 in	 non-CF	 patients,	 increased	 ASL	 height	 and	 mucociliary	 transport,	
suggesting	this	may	be	of	therapeutic	 importance	for	COPD	patients	[26].	However,	 in	our	
culture	 model	 we	 showed	 that	 long-term	 treatment	 (24h)	 of	 ALI-HBEC	 with	 VX-770	
enhances	CS	triggered	IL6R	and	AREG	secretion	significantly,	in	comparison	to	CS	exposure	
alone	(M	Stolarczyk,	3	independent	experiments	in	triplicate	P<0.05;	data	not	shown).	In	the	
light	 of	 conflicting	 data	 showing	 that	 chronic	 treatment	with	 VX-770	 either	 reduces	wild-
type	CFTR	function	[69],		improve	CFTR	function	[26]	or	has	no	effect	on	CFTR	activity	[70],	it	
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is	difficult	to	establish	whether	the	increase	in	shedding	is	related	to	CFTR	inactivation	or	to	
an	off	target	effect	of	VX-770	on	the	ADAM/EGFR	axis.	It	is	clear,	however,	our	present	data	
do	not	support	the	option	to	treat	COPD	or	smoking	patients	with	VX-770	chronically,	as	a	
therapy.	 In	 the	 future	 new	 generation	 potentiators,	 which	 are	 currently	 developed	 by	
several	teams,	could	be	further	investigated	in	our	system.		
One	 should	 consider	 here	 the	 long-term	 and	 short-term	 effects	 of	 CS	 exposure.	 COPD	
patients	 still	have	COPD	pathology	 long	after	 they	 stop	smoking	and	 their	CFTR	 levels	are	
restored.	This	is	probably	related	to	long-term	epigenetic	changes	and	metaplasia	in	COPD	
caused	by	frequent	CS	exposure,	as	also	suggested	by	our	experiments	(chapter	2),	and	not	
with	 the	 acute	 effects	 of	 CS.	 Long-term	 suppression	 of	 CFTR	 activity	 in	 CF	 patients	 and	
associated	pathology	would	likely	have	similar	effects.	This	may	mean	that	fully	developed	
CF	 lung	disease	cannot	be	treated	with	CFTR	targeted	agents	only,	but	requires	additional	
treatment	to	counter	these	effects.	
EGFR/ADAM17	axis	is	regulated	by	CFTR	related	oxidative	stress	
The	 extracellular	 membrane	 proximal	 domain	 of	 ADAM17	 [29]	 [71]	 and	 the	 intracellular	
domain	 of	 EGFR	 [72]	 are	 both	 activated	 in	 an	 oxidized	 environment,	 in	 particular	 by	
rearrangements	 of	 intramolecular	 disulfide	 bridges	 by	 thiol-isomerases	 (PDI)	 that	 are	 not	
only	 involved	 in	 ER	 protein	maturation,	 but	 also	 act	 on	 the	 extracellular	membrane	 [29]	
[71].	 ADAM17	 can	 also	 be	 activated	 by	 upstream	 signaling	 kinases	 sensitive	 to	 ROS,	 for	
instance	 SRC	 [73].	 In	 line	 with	 these	 observations,	 we	 showed	 in	 Chapter	 3	 that	 AREG	
shedding	mediated	 by	 ADAM17	 is	 sensitive	 to	 ROS	 scavengers	 (NAC,	 DPI)	 and	 it	 is	 most	
strongly	inhibited	by	addition	of	an	impermeant	natural	thiol	antioxidant	glutathione	(GSH)	
[74].	 These	 data	 suggested	 that	 the	 ADAM17/EGFR	 axis	 is	 sensitive	 to	 the	 extracellular	
redox	 potential.	 By	 expression	 of	 roGFP-Grx-1	 fused	 to	 GPI	 [75]	 [76],	 which	 enables	
ratiometric	 measurements	 of	 the	 apical	 extracellular	 redox	 potential,	 we	 detected	
enhanced	oxidation	in	the	apical	lining	fluid	of	CFTR	deficient	CFBE41o-	cells.	In	contrast,	we	
reported	unchanged	cytoplasmic	redox	potential	in	CFTR	deficient	CFBE41o-	cells	expressing	
roGFP-Grx1.	 Thus,	 we	 propose	 that	 induced	 ADAM17	 dependent	 AREG	 shedding	 in	 CFTR	
deficient	cells	(Chapter	3)	 is	caused	by	an	abnormal	ratio	of	GSH/GSSG	in	the	extracellular	
environment.	However,	at	this	stage	it	 is	still	not	clear	whether	this	hyperoxidation	occurs	
only	in	ASL	or	also	in	other	compartments,	such	as	the	lateral	and	intra-vesicular	space.		
CFTR	 was	 previously	 reported	 to	 regulate	 the	 extracellular	 redox	 potential	 through	 GSH	
transport	in	the	airways	[77]	[78],	so	it	 is	 likely	that	the	abnormal	transport	of	GSH	causes	
ASL	oxidation.	In	line	with	our	speculations,	in	lung	lavage	fluids	of	CF	patients	the	levels	of	
GSH	were	 reduced	 in	 comparison	 to	 healthy	 controls	 [79].	 Furthermore,	we	observe	 that	
several	lipid	markers	of	oxidative	stress	in	lung	lavages	(BALF)	from	juvenile	CF	patients,	in	
particular	 isoprostanes	 which	 are	 peroxidation	 products	 of	 unsaturated	 fatty	 acids,	
correlate	with	the	severity	of	CF	 lung	disease	(Scholte,	Stick	et	al,	 in	preparation).	Current	
longitudinal	studies	by	our	group	of	bronchial	lavage	fluids	from	CF	infants	will	focus	on	the	
relationship	 between	 oxidative	 stress	 signaling	 and	 the	 development	 of	 CF	 lung	 disease.	
Also	 in	 our	 F508del	 CFTR	 mouse	 model	 enhanced	 inflammation	 (Chapter	 4,	 Appendix)	
correlates	 with	 lipid	 markers	 of	 oxidative	 stress	 (Scholte,	 Radzioch,	 in	 preparation).	
Importantly,	GSH	administration	in	CF	patients	reduced	inflammatory	markers	in	BALF	[80].	
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The	 impaired	GSH	transport	 in	CF	may	enhance	downstream	signaling	[77]	 [80]	and	affect	
activity	of	ADAM17,	which	 is	 sensitive	 to	 redox	potential	 through	 its	extracellular	domain	
[29].	Since	the	extracellular	domain	of	ADAM17	is	not	primarily	exposed	to	the	extracellular	
apical	 membrane,	 it	 is	 also	 plausible	 that	 the	 GSH/GSSG	 ratio,	 which	 is	 an	 indicator	 of	
oxidative	 stress,	may	be	altered	 in	 the	ER	 compartment	 [81],	where	 it	may	affect	protein	
disulfide	bridge	formation	[82]	in	the	ADAM17	molecule.	However,	redox	potentials	at	the	
cell	 surface	 and	 in	 the	 ER	were	 not	 different	 in	 CF	 nasal	 epithelial	 cells	 in	 comparison	 to	
CFTR	 corrected	 cells,	 as	 measured	 with	 roGFP1	 [83].	 But	 as	 indicated	 previously,	 nasal	
epithelial	cells	and	bronchial	epithelial	cells	may	differ	in	their	properties.		
Interestingly,	 it	 has	 been	 proposed	 that	GSH/GSSG	 balance	may	 affect	 the	 optimal	 redox	
potential	for	PDI	to	catalyze	disulfide	bond	formation	not	only	at	the	external	surface	of	the	
plasma	membrane,	but	also	in	the	ER	[82]	[83]	[84].	PDI	has	been	shown	to	be	affected	by	
GSH/GSSG	 balance,	 so	 it	 is	 likely	 that	 CFTR	 related	 ER	 oxidative	 stress	 [85]	may	 interfere	
with	 ER	 GSH/GSSG	 balance	 and	 thus	 directly	 activate	 PDI/ADAM17	 signaling	 cascade	
inducing	 EGFR/ADAM17	 axis	 activity	 in	 CF	 bronchial	 epithelial	 cells.	 Importantly,	 PDI	may	
also	 be	 a	 therapeutic	 target,	 as	 shown	 in	 the	 context	 of	 carcinogenesis	 [86],	 so	 further	
studies	 of	 membrane	 trafficking	 are	 of	 interest	 to	 establish	 the	 exact	 localization	 and	
mechanism	 how	 PDI	 and	 abnormal	 GSH	 levels	 affect	 ADAM17	 activity	 in	 CFTR	 deficient	
bronchial	epithelial	cells.		
Does	ADAM17	 shed	 its	 substrates	 at	 the	 cell	membrane	or	 in	 the	 intracellular	 vesicular	
compartment?	
Most	 of	 the	 reports	 assume	 that	 ADAM17	 cleaves	 it	 substrates	 at	 the	 extracellular	
membrane,	but	 this	has	not	been	confirmed	yet.	 Lorenzen	et	al	 showed	 that	an	ADAM17	
construct	containing	the	unmodified	intracellular	part	was	expressed	at	the	cell	surface	to	a	
lesser	 extent	 than	 the	GPI	 anchored	 variant	 [87].	 In	 accordance	with	 this,	 ADAMs	and	 its	
substrates	 have	 been	 localized	 in	 various	 subcellular	 compartments	 like	 lysosomes	 [88],	
endosomes	 [89]	 [90]	 and	 exosomes	 [91],	 thus	 it	 is	 difficult	 to	 identify	 an	 exact	 site	 of	
ADAM17	mediated	 shedding	 [28].	We	 show	 for	 the	 first	 time	 by	 proximity	 ligation	 assay	
(PLA)	 that	 upon	CS	 exposure	ADAM17	 and	ADAM17-P	 appears	 in	 close	 proximity	with	 its	
substrates	 AREG	 and	 IL-6R	 in	 the	 intracellular	 compartment	 in	 ALI-HBEC,	 whereas	 under	
basal	 condition	ADAM17	or	ADAM17-P-substrate	 complexes	were	 infrequent	 (Chapter	 2).	
However,	our	data	do	not	establish	whether	ADAM17	sheds	its	substrate	in	the	intracellular	
vesicles	 followed	 by	 secretion,	 or	 whether	 the	 ADAM17/substrate	 complexes	 in	 these	
vesicles	need	to	be	transported	to	the	membrane	first	 in	order	to	deliver	ADAM17	and	its	
substrate	 for	 cleavage.	 In	 both	 cases	 a	 vesicle	 trafficking	 and	 membrane	 fusion	 event	 is	
involved,	which	may	be	subject	to	regulation.	
In	 line	 with	 our	 observation,	 Soond	 et	 al	 showed	 that	 expression	 of	 constitutively	 active	
MEK-1	and	ERK	in	HeLa	cells	relocates	ADAM17	fused	to	GFP	(ADAM17-GFP)	from	the	ER	to	
intracellular	 vesicles	 that	 are	 distinct	 from	 the	 ER	 [35].	 Also	 the	 phosphorylated	 form	 of	
ADAM17	at	position	T735	fused	to	GFP	(ADAM17-T735-GFP)	co-localized	with	the	ER-Golgi	
transport	marker	Sec-	23/COPII	and	trans-Golgi	network	protein	TGN-46	[35].	Furthermore,	
Lorenzen	 et	 al	 based	 on	 the	 co-immunoprecipitation	 of	 both	 immature	 and	 mature	
ADAM17	with	its	substrate	suggested	that	ADAM17	and	its	substrate	meet	in	the	ER/Golgi	
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pathway,	and	that	the	pro-domain	does	not	interfere	with	the	enzyme-substrate	interaction	
[87].	 All	 these	 data	 may	 explain	 the	 CS	 triggered	 ADAM17-substrate	 interaction	 in	 the	
intracellular	 vesicular	 compartment	 observed	 by	 us	 (Chapter	 2).	 However,	 they	 do	 not	
suffice	to	clarify	the	molecular	regulation	of	ADAM17-mediated	shedding.		
	
According	 to	 some	 reports	 PKC	activation	by	PMA	 induces	ADAM17	dependent	 shedding,	
without	increasing	ADAM17	at	the	extracellular	membrane	[71]	[92],	whereas	other	studies	
did	 show	 that	 PMA	 stimulation	 increases	 expression	 of	 ADAM17	 at	 the	 cell	 surface	 and	
decreases	 the	 presence	 of	 L-selectin	 at	 the	 cell	 surface,	 indicating	 that	 the	 cleavage	 of	
ADAM17	substrates	occurs	at	the	cell	membrane	[93].	Further	studies	by	Xu	et	al.	suggested	
that	ADAM17	is	localized	at	the	cell	surface	as	a	dimer	and	associates	with	tissue	inhibitor	of	
metalloproteinase-3	(TIMP-3)	[34].	Upon	activation	with	PMA	or	anisomycin,	the	amount	of	
ADAM17	 at	 the	 cell	 surface	 increases,	 followed	 by	 dissociation	 of	 ADAM17	 from	 TIMP-3,	
and	 ADAM17	 dimers	 convert	 to	 monomers.	 According	 to	 the	 authors,	 these	 monomers	
correspond	to	the	active	form	of	ADAM17	and	are	predominantly	found	in	cytoplasm	[30],	
suggesting	that	the	monomers	are	internalized	and	shedding	may	occur	intracellularly.	Also	
recent	reports	suggest	that	ADAM-mediated	cleavage	occurs	from	an	intracellular	vesicular	
pool	 in	several	cell	types	[88]	[94].	 In	 line	with	these	studies,	Doedens	et	al	proposed	that	
endocytosis	from	the	cell	surface	is	a	pre-requisite	for	ADAM17	catalytic	activity	[95].	As	an	
extension	of	these	studies,	[90],	two	proteins	that	regulate	ADAM17-dependent	shedding	of	
EGFR	 ligands,	 annexins	 [96]	 and	 a	 phospho-furin	 acidic	 cluster	 sorting	 protein	 2	 (PACS-2)	
[90]	 have	 also	 been	 shown	 by	 proximity	 ligation	 assay	 (PLA)	 to	 be	 in	 close	 proximity	 to	
ADAM17	 in	 the	 intracellular	 vesicular	 compartment,	 again	 suggesting	 that	 the	 shedding	
process	may	occur	from	intracellular	compartment.	However,	all	these	data	do	not	provide	
the	complete	picture	of	ADAM17	activation	and	localization.	Thus,	in	light	of	other	and	our	
findings	it	is	important	to	address	where	PDI	leads	to	conversion	of	ADAM17	conformation,	
does	 it	affect	the	 interaction	of	ADAM17	with	TIMP3	and	what	 is	the	role	of	GSH	in	these	
events.	 These	 questions	 should	 be	 addressed	 in	 general	 terms	 as	 well	 as	 in	 CFTR	
experimental	systems.	
	
Taken	together,	our	data	showed	that	upon	activation,	ADAM17	or	its	phosphorylated	form	
interact	with	the	substrate	in	an	intracellular	vesicular	compartment	(Chapter	2).	However,	
further	 studies	 focusing	 on	 dynamic	 trafficking	 events	 and	 protein-protein	 interactions	
during	 the	 activation	 of	 the	 ADAM17	 system	 are	 required	 to	 reveal	 whether	 induced	
ADAM17	 proteolytic	 activity	 occurs	 in	 the	 intracellular	 vesicles	 or	 requires	 membrane	
trafficking.	These	questions	need	to	be	addressed	to	allow	the	design	of	a	next	generation	
of	 drugs	 targeting	 ADAM17	 activity,	 that	 avoids	 the	 disadvantages	 of	 current	 systemic	
ADAM	inhibitors	[97].	
	
Is	 dynamic	 trafficking	 of	 EGFR	 and	 ADAM17	 an	 additional	 regulatory	 mechanism	 of	
EGFR/ADAM17	axis	activation?	
• ADAM17-substrate	 complexes	 appear	 in	 the	 intracellular	 compartment,	 whereas	
EGFR	internalizes	after	CS	exposure	
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We	 showed	 that	 not	 only	 the	 localization	 of	 ADAM17	 and	 it	 substrates	 changes	 upon	
activation	by	CS,	but	also	EGFR	undergoes	 internalization	 from	the	basolateral	membrane	
into	an	intracellular	compartment	in	CS	treated	ALI-HBEC	(Chapter	2,	Figure	S2),	associated	
with	enhanced	EGFR	phosphorylation	 [7].	However,	we	have	not	established	yet	whether	
EGFR-P	co-localizes	with	ADAM17-P-substrate	complexes	in	the	intracellular	compartment,	
where	they	potentially	may	activate	each	other.	The	co-localization	of	EGFR	and	ADAM17-
substrate	 complexes	 and	 their	 role	 in	 shedding	 in	 human	 airway	 epithelial	 cells	 upon	
activation	 is	 an	 important	 research	 question	 that	 should	 be	 further	 investigated.	
Additionally,	the	multifunctional	sorting	protein	PACS-2	involved	in	retrograde	trafficking	of	
membrane	 proteins	 from	 endosomes	 and	 Golgi	 not	 only	 regulates	 ADAM17	 trafficking	
toward	 an	 active	 pool	 and	 thus	 shedding	 of	 EGFR	 substrates,	 but	 also	 affects	 EGFR	
phosphorylation	 [90],	 giving	 another	 indication	 for	 the	 importance	 of	 co-trafficking	 as	 a	
potential	regulatory	mechanism	of	the	ADAM17/EGFR	axis.		
	
Up	till	now,	EGFR	signaling	has	been	believed	to	occur	at	the	plasma	membrane,	however,	
upon	 activation	 by	 ligand	 binding,	 EGFR	 is	 rapidly	 internalized	 into	 endosomes	 [98].	 Also	
EGFR	 ligands	 undergo	 intracellular	 trafficking	 [9].	 Different	 stress	 factors	 lead	 to	
accumulation	 of	 EGFR	 in	 non-degradative	 endosomes	 [99]	 [100]	 [101]	 [102],	 and	 this	
endocytic	 trafficking	has	been	 correlated	with	active	 signal	 transduction	 [103]	 [104]	 [105]	
[91]	[106]	[107]	[108].	We	observed	that	CS	exposure	causes	EGFR	internalization	(Chapter	
2),	 which	 may	 prolong	 EGFR	 signaling	 from	 an	 intracellular	 vesicular	 pool.	 Interestingly,	
inhibition	of	EGFR	with	tyrosine	kinase	inhibitors	(AG1478	and	BIBW2948BS)	prevents	EGF-
induced	 EGFR	 internalization	 [109].	 These	 data	 have	 been	 confirmed	 in	 ex-vivo	 EGF-
stimulated	airway	biopsies	form	patients	who	inhaled	EGFR	inhibitor	(BIBW2948	BS)	prior	to	
the	 experiment,	 which	 caused	 diminished	 EGFR	 internalization	 [109].	 Thus,	 our	 and	
published	data	highlight	the	importance	of	investigating	further	the	role	of	EGFR	trafficking	
upon	 exposure	 to	 external	 stimuli,	 like	 CS	 or	 in	 CFTR	 deficiency.	 Apart	 from	 that,	 the	
secretion	 of	 EGFR	 and	 its	 ligands	 into	 exosomes	 has	 been	 reported	 [9]	 [110].	 Exosomes	
containing	EGFR	or	its	ligands	can	be	taken	up	by	epithelial,	endothelial,	and	fibroblast	cells	
[91]	[110],	thus	it	would	be	interesting	to	investigating	their	role	in	the	trans-signaling.		
	
• EGFR	appears	in	the	apical	compartment	in	CFTR	deficient	cells		
The	 protein	 trafficking	 pathways	 together	 with	 tight	 junctions	 establish	 the	 apical-
basolateral	polarity	in	epithelial	cells.	EGFR	and	its	ligands	are	preferentially	delivered	to	the	
basolateral	 cell	 surface	 and	 they	 all	 have	 a	 conserved	 basolateral	 sorting	motif	 [9]	 [111].	
Overexpressed	 EGFR	 in	 polarized	 epithelial	 kidney	 cells	 additionally	 appears	 at	 the	 apical	
cell	 membrane	 and	 as	 a	 consequence	 of	 this	 mistrafficking,	 EGFR	 is	 less	 sensitive	 to	
downregulation	 and	 undergoes	 less	 efficient	 endocytosis,	 which	may	 result	 in	 prolonged	
EGFR	activity	[112].	We	observed	that	upon	induction	of	CFTR	in	CFBE41o-ALI	cells	EGFR	is	
expressed	mainly	at	the	basolateral	membrane,	but	in	CFTR	deficient	cells	it	appears	more	
frequently	 at	 the	 apical	 side	 (Chapter	 3).	 Thus,	 we	 speculate	 that	 this	 apically	 expressed	
receptor	may	 be	 less	 sensitive	 to	 downregulation	 [112]	 and	more	 susceptible	 to	 external	
stimuli.	
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There	 are	 several	 possible	 scenarios	 that	may	 explain	 abnormal	 EGFR	 trafficking	 in	 CFTR	
deficiency.	 Firstly,	 EGFR	 trafficking	 is	 highly	 pH	 sensitive.	 In	 acidic	 endosomes	 TGF-α	
dissociates	from	EGFR	which	results	in	recycling	of	unbound	EGFR	to	the	plasma	membrane	
[113]	 and	 its	 exposure	 to	 other	 ligands	 [113]	 [111],	 whereas	 in	 an	 acidic	 environment	
binding	of	betacellulin	to	EGFR	is	highly	resistant	[113].	This	suggests	that	ligand	binding	and	
EGFR	behavior	depends	on	acidification	of	its	cellular	environment.	In	CF	human	and	CF	pig	
the	airway	surface	 liquid	 	 (ASL)	 is	acidified	 [114]	 [39].	The	pH	 in	 the	 lateral	compartment,	
where	 most	 EGFR	 appears	 to	 be	 localized,	 has	 not	 been	 investigated	 yet.	 Also,	 it	 is	 still	
contested	whether	endosomal	and	lysosomal	pH	differs	in	primary	human	airway	epithelial	
cells	from	CF	versus	non-CF	patients	[115]	[116]	[117].	Therefore,	further	investigations	are	
required	 to	 establish	 whether	 vesicular	 or	 apical	 pH	 affects	 EGFR	 trafficking	 in	 CFTR	
deficiency.	
	
Another	possible	 link	between	CFTR	deficiency	and	abnormal	EGFR	activity	 is	 its	effect	on	
common	 factors	 regulating	 EGFR	 and	 CFTR	 trafficking.	 For	 instance,	 Wiskott-Aldrich	
Syndrome	 protein	 N-WASP	 when	 inhibited	 accelerates	 CFTR	 internalization	 in	 HT29	
intestinal	 adenocarcinoma	 cells	 [118],	 whereas	 in	 murine	 and	 HeLa	 cells	 it	 impairs	 EGF-
mediated	endocytosis	of	EGFR	 [119]	 [120].	Some	studies	also	suggest	a	 role	of	SRC	 family	
kinases	 in	 EGFR	 trafficking	 [102]	 [121],	 which	 also	 phosphorylate	 CFTR	 [122]	 [123]	 [124]	
[125].	 Targeting	 these	molecules	 in	 CFTR	deficient	 tissues	may	normalize	 EGFR	 trafficking	
and	thus	downregulate	EGFR	signaling.	Our	observation	that	EGFR	is	mislocalized	in	CF	cells	
(Chapter	 3)	 may	 be	 related	 to	 the	 finding	 that	 CFTR	 depletion	 by	 siRNA	 delays	 EGFR	
degradation	 in	 16HBE14o-	 cells.	 This	 delayed	 EGFR	 degradation	 can	 be	 abrogated	 by	
application	 of	 the	 ROS	 scavenger	 cystamine	 or	 BECN-1	 expression	 that	 encodes	 an	
autophagy	 activator	 protein,	 Beclin-1.	 [126].	 These	data	 are	part	 of	 a	 series	 of	 studies	 by	
Maiuri	 et	 al,	 which	 implicate	 CFTR	 deficiency	 in	 ROS	 related	 abnormalities	 in	 aggresome	
formation,	 defective	 autophagy	 and	 inflammatory	 signaling	 [127]	 [128]	 [129]	 [130]	 [131].	
Thus,	abnormal	trafficking	of	EGFR	and	other	elements	of	the	EGFR/ADAM17	axis	observed	
in	CFTR	deficiency	is	potentially	linked	to	ROS	induced	defective	autophagy	[128].		
	
Crosstalk	between	different	pro-inflammatory	pathways	in	CF	lung	inflammation.	
The	data	presented	in	Chapter	4	and	the	Appendix,	show	that	not	only	the	EGFR/ADAM17	
axis,	but	multiple	pro-inflammatory	and	tissue	remodeling	signaling	pathways	are	involved	
in	CF	lung	disease,	in	accordance	with	abundant	evidence	presented	by	other	authors.	The	
molecular	link	between	CFTR	deficiency,	the	EGFR/ADAM17	axis	and	these	parallel	signaling	
pathways	is	not	immediately	obvious	and	requires	further	studies.				
	
Multiple	bioactive	lipids	are	affected	in	CF,	in	particular	the	sphingosine	pathway,	probably	
signaling	 through	 the	 complex	 S1P	 receptor	 system	 (Chapter	 4).	 Extracellular	 S1P	 induces	
ADAM17	 activation	 via	 p38MAPK	 in	 an	 immortalized	 cell	 model	 [132].	 Enhanced	
inflammatory	 responses	 mediated	 by	 interleukin-1-beta	 (IL-1β)	 in	 F508del	 CFTR	 mutant	
mouse	 lung	 provides	 another	 node	 in	 the	 signaling	 web	 relating	 CFTR	 deficiency	 with	
inflammation	(Appendix).	The	 IL-1β	signaling	pathways	cross-talks	with	the	EGFR/ADAM17	
signaling	cascade,	 in	airway	epithelial	cell	 lines	 IL-1R	activates	ADAM17/EGFR/IL8	signaling	
[65].	Interestingly,	in	human	chondrocytes	extracellular	S1P	signaling	down	regulates	IL-1β-
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induced	 phosphorylation	 of	 p38MAPK	 [133]	 suggesting	 cross-talk	 between	 S1P,	 IL-1β	 and	
the	ADAM17/EGFR	pathway.		However,	how	these	signaling	pathways	interact	in	CF	lungs	in	
situ	remains	to	be	established.		
	
Current	studies	in	our	laboratory	also	show	a	change	in	ceramide	species	ratio	in	bronchial	
lavage	 fluid	 (BALF)	 from	 preschool	 CF	 children,	 in	 F508del	 mutant	 mouse	 lung,	 and	 in	
primary	 bronchial	 cells	 from	 CFTR	 deficient	 piglets	 in	 ALI	 culture	 (Scholte	 et	 al	 in	
preparation).	 A	 CFTR	 dependent	 change	 in	 the	 ceramide	 membrane	 pool	 likely	 plays	 an	
important	role	in	membrane	protein	trafficking	and	receptor	signaling,	in	particular	of	EGFR	
during	oxidative	stress	[134].		
	
Moreover,	 we	 observe	 enhanced	 lysolecithin	 (LPC)	 and	 lysophosphatidic	 acid	 (LPA)	
concentrations	in	CF	infant	BALF,	positively	correlating	with	CF	lung	disease	(Scholte	et	al,	in	
preparation).	 This	 is	 probably	 related	 to	 enhanced	 activity	 of	 phospholipase	 A	 activity	
observed	previously	 in	CFTR	deficient	epithelia	[150].	Preliminary	studies	in	our	 laboratory	
also	 show	 that	 LPA	 receptor	 agonists	 strongly	 activate	 the	 EGFR/ADAM17	 activity	 and	
secretion	 of	 pro-inflammatory	 cytokines	 in	 human	 bronchial	 cells,	 evidence	 of	 strong	
crosstalk	 between	 these	 pathways,	 likely	 contributing	 to	 chronic	 inflammation	 in	 the	 CF	
lung.		
	
Taken	together,	 these	data	provide	a	strong	rationale	 for	cross-talk	between	CFTR	related	
oxidative	 stress,	 lysolipid	 and	 sphingosine	 metabolism,	 IL-1β	 and	 the	 ADAM17/EGFR	
pathway	 in	 CFTR	 deficiency.	 At	 this	 time	 we	 cannot	 establish	 whether	 there	 is	 a	 simple	
linear	cascade	of	events,	or	a	more	diffuse	imbalance	of	multiple	related	signaling	pathways	
caused	 by	 the	 CFTR	 primary	 defect	 leading	 to	 pro-inflammatory	 and	 tissue	 remodeling	
signaling.	 Therefore,	 this	 should	 be	 further	 investigated	 in	 ALI-HBEC	or	 even	 better	 in	 3D	
organotypic	 culture	 (lung	 on	 a	 chip),to	 mimic	 the	 conditions	 in	 vivo,	 in	 order	 to	 better	
understand	the	activation	of	EGFR/ADAM	signaling	pathway	in	CF	and	COPD	lung	disease.		
	
Clinical	relevance	
Our	 studies	 show	 that	 lung	 disease	 in	 CF	 and	 COPD	 is	 characterized	 by	 exaggerated	
ADAM17/EGFR	signaling,	which	is	a	proven	druggable	target.	In	a	clinically	relevant	model,	
air-liquid	interface	culture	of	primary	epithelial	cells,	we	show	that	cells	from	COPD	patients	
respond	more	pronouncedly	to	external	triggers	like	CS	exposure,	and	that	these	responses	
involve	the	ADAM17/EGFR	axis	 (Chapter	2).	 In	CFBE41o-	cells	differentiated	under	ALI,	we	
showed	 that	 the	 ADAM17/EGFR	 axis	 is	 activated	 as	 a	 cell	 autonomous	 defect	 caused	 by	
CFTR	 deficiency	 (Chapter	 3).	 CFBE	 cells	 give	 a	 representation	 of	 the	 in	 vivo	 situation,	
however,	 the	data	should	be	verified	 in	differentiated	CF	primary	human	airway	epithelial	
cells	and	more	advanced	systems.		
	
Considering	the	involvement	of	ADAM17	and	EGFR	in	many	pathological	events	observed	in	
CF	 and	COPD	 [21]	 [20],	 like	 inflammatory	 responses	 [135]	 [136],	 regeneration	 [137]	 [138]	
and	 mucus	 hypersecretion	 [139]	 [140],	 intervention	 in	 this	 signaling	 pathway	 could	 be	
beneficial	 to	 alleviate	 these	 symptoms.	 Importantly,	 both	 ADAM17	 and	 EGFR	 not	 only	
mediate	 inflammatory	 processes,	 but	 also	 are	 linked	 with	 protective	 responses	 to	 injury	
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(wound	healing),	so	complete	blocking	of	EGFR	or	ADAM17	may	have	serious	effects	on	the	
anti-inflammatory	and	pro-regenerative	responses.	Finding	the	balance	between	removing	
excessive	 inflammation	 while	 keeping	 the	 protective	 responses	 to	 infection	 and	 injury	
would	 be	 the	main	 goal	 in	 CF	 and	 COPD	 therapy.	 Several	 inhibitors	 or	 antibodies	 against	
EGFR	[109]	[141]	and	ADAM17	[142]	are	currently	 in	clinical	trials	showing	positive	results	
mainly	 in	 cancer	 treatment.	 Initial	 experiments	 in	 our	 laboratory	 testing	 systemic	
application	 of	 the	 ADAM	 inhibitors	 TMI1	 and	 TMI2	 (Wyeth)	 in	 our	 mouse	 model	 of	 CF	
showed	 only	 a	 partial	 reduction	 of	 pro-inflammatory	 cytokine	 signaling	 after	 a	 challenge	
with	 either	 naphthalene,	 causing	 airway	 injury,	 or	 intranasal	 LPS/fMLP	 causing	 acute	
neutrophilemia	 (Scholte	et	al,	unpublished).	Further	studies	should	 try	 to	 find	 the	optimal	
dose	 range	 of	 available	 compounds,	 but	 also	 define	 alternative	 druggable	 targets	 in	 the	
ADAM17/EGFR	 pathway.	 Furthermore	 localized	 delivery	 methods,	 avoiding	 the	
disadvantages	 of	 systemic	 inhibitors	 that	 were	 initially	 developed	 for	 cancer	 treatment	
should	 be	 considered.	 Novel	 developments	 include	 the	 use	 of	 single	 chain	 humanized	
antibodies,	and	technology	that	allows	targeted	delivery	of	nano-carriers	to	inflamed	tissue.	
	
Our	 studies	 also	 highlight	 the	 involvement	 of	 oxidative	 stress	 (ROS/GSH)	 as	 one	 of	 the	
important	regulators	of	EGFR/ADAM	axis	activity,	which	offers	opportunities	for	treatment	
of	both	CF	and	COPD.	Thus	so	far	such	attempts	have	met	with	limited	success,	due	to	the	
limitations	 of	 the	 available	 experimental	 treatments.	 Further	 development	 of	 such	
interventions	would	be	warranted.	
	
Conclusions	and	future	direction	
The	results	provided	in	this	thesis	help	to	explain	the	activation	of	the	ADAM17/EGFR	axis	in	
CF	 and	 COPD	 lung	 disease.	 However,	 to	 define	 the	 druggable	 targets	 in	 this	 signaling	
cascade	 future	 studies	 should	 identify	 the	 molecular	 events	 leading	 to	 activation	 of	
ADAM17/EGFR	axis	in	more	detail.		
	
Here	we	showed	for	the	first	time	that	EGFR	is	a	potent	regulator	of	ADAM17	activity	and	
that	they	both	regulate	IL-6R	and	AREG	protein	release	and	mRNA	synthesis	(Chapter	2).	As	
an	extension	of	our	results	(Chapter	2),	studies	by	Amatngalim	et	al	show	the	importance	of	
EGFR/ERK1/2/MAPK	pathway	in	CS	induced	regulation	of	IL-8	mRNA	levels	[7].	This	supports	
the	 hypothesis	 that	 EGFR	 establishes	 a	 positive	 feedback	 loop	 with	 ADAM17	
(EGFR/ADAM17	 axis).	 Furthermore,	 our	 studies	 point	 towards	 SRC	 as	 the	 druggable	
candidate	 in	 the	ADAM17/EXFR	axis.	 It	not	only	affects	ADAM17	activity	 (Chapter	3)	 [52],	
but	also	CFTR	can	be	phosphorylated	by	tyrosine	kinases	from	the	SRC	family	(Fyn,	Lyn,	Fgr,	
Src)	 in	 vitro	 [122]	 [123]	 [124]	 [125].	 However,	 we	 have	 not	 observed	 an	 induced	 SRC	
phosphorylation	 level	 in	CFTR	deficient	compared	to	CFTR	expressing	CFBE41o-	cells	 (data	
not	 shown).	Current	 studies	 are	aimed	at	 SRC	 regulation	 in	primary	differentiated	 cells	 in	
response	to	oxidative	stress.		
	
Since	 ROS	 activates	 ADAM17,	 EGFR	 and	 SRC	 directly	 or	 indirectly	 [29]	 [52]	 [72],	 and	 is	
thought	to	be	induced	in	CFTR	deficiency	[128],	we	questioned	whether	it	is	a	link	between	
CFTR	 deficiency	 and	 ADAM17	 activity.	 Our	 data	 show	 that	 airway	 epithelial	 cells	 are	
oxidized	 extracellularly,	 but	 not	 in	 the	 cytosol.	 Thus,	 we	 propose	 that	 extracellular	
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GSH/GSSG	 imbalance	 induces	 CFTR-mediated	 EGFR/ADAM17	 signaling,	 contributing	 to	
inflammation	 and	 tissue	 remodeling.	However,	 in	 the	 light	 of	 findings	 cited	 above,	 also	 a	
GSH/GSSG	 imbalance	 in	 the	 ER	 lumen	 may	 affect	 ADAM17	 activity,	 by	 PDI-mediated	
conformational	 changes	 of	 ADAM17	 [29]	 [84].	 In	 line	 with	 these	 speculations,	 upon	 CS	
exposure	 ADAM17	 appears	 in	 close	 proximity	 with	 its	 substrates	 in	 the	 intracellular	
compartment	 in	 ALI-HBEC	 (Chapter	 2).	 Thus	 CFTR	 dependent	GSH/GSSH	 imbalance	 in	 ER,	
may	 directly	 affect	 PDI-mediated	 ADAM17	 activation,	 bypassing	 the	 ADAM17/EGFR	 axis.	
Our	 data	 show	 that	 extracellular	 GSH	 completely	 inhibits	 ADAM17	 dependent	 AREG	
shedding,	but	not	EGFR	phosphorylation	in	CFBE	cells	(Chapter	3).	However,	further	studies	
should	 reveal	 if	 CFTR	 deficiency	 and	 extracellular	 GSH	 affect	 PDI	 dependent	 ADAM17	
mediated	shedding	in	the	ER	lumen	or	in	a	related	subcellular	compartment.,		
	
Based	 on	 our	 data	 and	 recent	 reports,	 we	 also	 speculate	 that	 trafficking	 of	 EGFR	 and	
ADAM17	may	be	one	of	the	regulatory	mechanisms	activating	EGFR/ADAM17	axis	in	CF	and	
COPD	 pathology.	 Upon	 CS	 exposure	 ADAM17-substrate	 PLA	 signal	 appears	 in	 the	
intracellular	 compartment	 in	 ALI-HBEC	 (Chapter	 2),	 where	 also	 EGFR	 internalizes.	 In	 line	
with	our	 findings,	 the	presence	of	EGFR	 in	endosomes	and	exosomes	has	been	described,	
similar	 to	 ADAM17	 and	 its	 substrates,	 however,	 the	 mechanism	 of	 the	 EGFR/ADAM17	
signaling	via	a	vesicular	compartment	 is	still	poorly	understood.	Also	apical	mislocalization	
of	EGFR	 induced	by	CFTR	deficiency	 in	CFBE41o-	cells	 (Chapter	3)	 raises	the	question	how	
CFTR	 deficiency	 affects	 the	 EGFR	 and	 ADAM17	 localization	 and	 thus	 whether	 it	 has	
consequence	 for	activation	of	 the	EGFR/ADAM17	axis	 in	CF	pathology.	Thus,	 validation	of	
the	 CFTR-dependent	 EGFR	 trafficking	 to	 the	 apical	 membrane	 in	 primary	 CF	 bronchial	
epithelial	 cells	would	be	 important.	 So	 far	 several	potentially	 common	 regulators	of	EGFR	
and	CFTR	endocytic	 trafficking	have	been	 identified,	 like	an	autophagy	activator	Becline-1	
[128]	[143]	[144],	[145],	Transglutaminase	2	(TG2)	[127]	[128]	[146]	[147]	[148],	p62	[128]	
[126]	and	Rab5	[126]	[149],	providing	potential	druggable	targets	for	mistrafficked	EGFR	in	
CFTR	deficiency,	which	should	be	tested	in	primary	CF	airway	epithelial	cells.		
	
Taken	together,	we	highlight	the	need	to	further	investigate	the	spatiotemporal	regulation	
of	 the	 EGFR/ADAM17	 axis,	 localize	 the	 place	 of	 shedding	 of	 the	 ADAM17	 substrates,	 the	
role	of	 redox	potential	 (measured	as	GSH/GSSG	ratio)	and	 the	druggable	 intermediates	 in	
the	 ADAM17/EGFR	 pathway	 (membrane/intracellular)	 in	 CFTR	 deficiency	 and	 upon	
exposure	 to	 stress	 factors	 like	 CS.	 This	 is	 also	 crucial	 in	 order	 to	 define	 the	 methods	 of	
potential	drug	delivery	to	the	airways	(permeable/impermeable	agents).		
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Abstract
Cystic fibrosis is associated with increased inflammatory responses to pathogen
challenge. Here we revisited the role of IL-1b in lung pathology using the
experimental F508del-CFTR murine model on C57BL/6 genetic background
(Cftrtm1eur or d/d), on double deficient for d/d and type 1 interleukin-1 receptor (d/d X
IL-1R12/2), and antibody neutralization. At steady state, young adult d/d mice did
not show any signs of spontaneous lung inflammation. However, IL-1R1 deficiency
conferred partial protection to repeated P. aeruginosa endotoxins/LPS lung
instillation in d/d mice, as 50% of d/d mice succumbed to inflammation, whereas all
d/d x IL-1R12/2 double mutants survived with lower initial weight loss and less
pulmonary collagen and mucus production, suggesting that the absence of IL-1R1
signaling is protective in d/d mice in LPS-induced lung damage. Using P.
aeruginosa acute lung infection we found heightened neutrophil recruitment in d/d
mice with higher epithelial damage, increased bacterial load in BALF, and
augmented IL-1b and TNF-a in parenchyma as compared to WT mice. Thus,
F508del-CFTR mice show enhanced IL-1b signaling in response to P. aeruginosa.
IL-1b antibody neutralization had no effect on lung homeostasis in either d/d or WT
mice, however P. aeruginosa induced lung inflammation and bacterial load were
diminished by IL-1b antibody neutralization. In conclusion, enhanced susceptibility
to P. aeruginosa in d/d mice correlates with an excessive inflammation and with
increased IL-1b production and reduced bacterial clearance. Further, we show that
neutralization of IL-1b in d/d mice through the double mutation d/d x IL-1R12/2 and
in WT via antibody neutralization attenuates inflammation. This supports the notion
that intervention in the IL-1R1/IL-1b pathway may be detrimental in CF patients.
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	 	Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disease that affects 1
newborn out of 3,500 in the USA (WHO), and 1 per 2,000–3,000 in Europe, with
an average 40-year life expectancy. This pathology is caused by mutations within
the gene encoding the CFTR (Cystic Fibrosis Transmembrane Conductance
Regulator) chloride channel [1]. In humans, the most common mutation
(F508del) found in patients is a deletion of phenylalanine 508 (F508del) in the
CFTR chloride channel [2], the modified protein is not efficiently folded and is
rapidly degraded [3]. CF affects secretory epithelia from different organs, leading
to gastro-intestinal tract pathology, with a reduced pancreatic digestive enzyme
production [4] and chronic intestinal malabsorption [5]. CF mortality and
morbidity are mainly due to respiratory disease, characterized by the production
of abnormally viscous mucus, plugging of distal airways, and increased
susceptibility to chronic infections with opportunistic bacteria, excessive lung
inflammation, bronchiectasis and fibrosis leading to progressive loss of lung
function [6]. The exact molecular link between CFTR mutations and
hypersensitivity to infections remains unclear and controversial. In CF patients, S.
aureus predominates in the lung of children and teenagers, while P. aeruginosa
prevails in adults [7]. Exopolysaccharide-enriched biofilms produced by P.
aeruginosa increase the mucus viscosity, resistance to antibiotics and host immune
effectors. Chronic bacterial infections are common in CF patients and facilitates
lung inflammation, mucous obstruction and tissue remodeling, resulting in fatal
loss of function [1]. CF lungs display excessive inflammatory response, especially
with increased neutrophil recruitment [8], the mechanism of this phenomenon is
not adequately explained. However, intervention in this process likely will benefit
CF patients.
The role of the pro-inflammatory signaling cytokine Interleukin 1b (IL-1b) in
CF lung disease has been reported before. P. aeruginosa induces IL-1b or IL-18
production through NLRC4 inflammasome activation [9, 10]. P. aeruginosa
flagellin and highly acylated LPS is recognized by TLR5 [11] and TLR4 [12]
respectively. Human polymorphisms observed in the IL1B gene were associated
with CF disease [13]. CFTR deficient mice were found to be more susceptible to
acute [14, 15] and chronic [16] P. aeruginosa infection and display an exacerbated
inflammatory response to LPS and P. aeruginosa activated alveolar macrophages
from F508del mutant mice have enhanced expression of IL-1b [17, 18]. Huaux et
al recently showed a deregulated inflammatory and fibrotic response in F508del
mutant mice to bleomycin, which is IL-1R1 signaling dependent [19, 20].
Here we revisited the role of IL-1b in the resolution of P. aeruginosa infection,
in a murine model based on mice carrying the most common CF mutation
F508del CFTR [21–23]. In this study, we show that excessive activation of IL-1b
correlates with increased bacterial load, inflammation and lung damage in F508del
CFTR mice. Further, we show that IL-1b antibody neutralization attenuates the
inflammatory response to P. aeruginosa infection.
IL-1b in P. aeruginosa Pneumonia
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Materials and Methods
Mice
Mice were on C57BL/6(J) background, wild type (WT), or homozygotes for
F508del CFTR mutation in the murine Cftr gene (Cftrtm1eur or d/d) [21–23], and
deficient for type 1 interleukin 1 receptor (d/d X IL-1R12/2) [24]. Mice, obtained
from Erasmus MC Rotterdam [21] were bred at TAAM – UPS 44, Orle´ans
(Institut Transgenose) and manipulated in an SPF zone. This study was carried
out in strict accordance with the recommendations of CNRS, and in the Guide
"Animaleries de laboratoire’’. The protocol was approved by the Committee on
the Ethics of CNRS of Orle´ans (Permit Number: CLE CCO 2012-042). All animals
are under daily inspection by the animal facility staff and the experimenters. All
efforts were made to minimize suffering.
IL-1b antibody administration
Mice were treated intraperitoneally, once a week for 8 weeks, with anti-IL-1b
antibody (Dr. Hermann Gram, Novartis Pharma, Basel) [25], 10 mg/kg. Control
mice received 150 mL PBS. Mice were euthanatized 1 week after the last treatment,
by carbon dioxide inhalation (80–90% in a dedicated inhalation chamber).
Repeated LPS induced lung inflammation (4 weeks)
Mice were treated intranasally with 80 mg of P. aeruginosa endotoxins/LPS [Sigma
Chemical Co., St. Louis, MO] in 40 mL PBS, under isoflurane anesthesia, once a
week for 4 weeks. Control mice were untreated. Mice were euthanatized 24 h after
the last challenge, by carbon dioxide inhalation (80–90% in a dedicated inhalation
chamber). All animals are under daily inspection by the experimenters. Humane
endpoints were used during this survival study: in case that mice unexpectedly
present obvious health problems (over 20% weight loss, signs of suffering,
difficulties in their movements and uptake of water and food, apathy) were
sacrificed, by carbon dioxide inhalation (80–90% in a dedicated inhalation
chamber).
Pseudomonas aeruginosa infection
Mice were infected with freshly prepared inoculum of P. aeruginosa strain 2310.55
of serotype IATS O11. An overnight culture in 10 mL BHI medium was prepared,
starting from the frozen stock at 37 C˚ and shaken at 150 rpm. Of this culture,
2.5 mL was taken to start a fresh 10 mL BHI culture. The culture was stopped
when an OD of about 0.4 was reached (corresponding to a bacterial titer of about
26108 bacteria/ml). Mice were anaesthetized with a low dose of intravenous
ketamine/xylazine (1.25 mg/ml/0.5 mg/mL) and 40 ml of the bacterial solution or
the corresponding vehicle solution (isotonic saline) was applied intranasally using
an ultrafine pipette tip. Mice were monitored until they woke up and evaluated
6 h and 24 h after infection.
IL-1b in P. aeruginosa Pneumonia
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IL-1b antibody administration to infected mice
Mice were treated intraperitoneally, with anti-IL-1b antibody (Novartis Pharma,
Basel) [25], 200 mg/mice, 15 h and 1 h before P. aeruginosa infection. Control
mice received 150 mL PBS. Mice were euthanatized 20 h after infection, by carbon
dioxide inhalation (80–90% in a dedicated inhalation chamber).
Bacterial load in lung
Lung total weights were recorded after sacrifice and expressed as a percentage of
the body weight. Lung homogenates were prepared in 1.5 ml of isotonic saline
solution using a Dispomix tissue homogenizer (Medic Tools). Tenfold serial
dilutions of homogenate were plated on BHI agar (BHI 37g/l, Agar 15g/l) plates
(Biovalley). Plates were incubated at 37 C˚ and 5% CO2 and the numbers of CFU
were enumerated after 24 h.
Bronchoalveolar lavage (BAL)
After CO2 inhalation deep euthanasia, bronchoalveolar lavage fluid (BALF) was
collected by cannulating the trachea and washing the lung with 1 mL saline at
room temperature. The lavage fluid was centrifuged at 2,000 rpm for 10 min at
4 C˚ and the supernatant was stored at 280 C˚ for analysis. The cell pellet was
resuspended in PBS, counted in a haemocytometer chamber and cytospin
preparations were made using a Shandon cytocentrifuge (1000 rpm for 10 min).
The cells were stained with Diff-Quick (Dade Behring, Marburg, Germany) and
counted for neutrophils, macrophages, lymphocytes and eosinophils.
Total RNA extraction and RT-q-PCR from lung
Total mRNA was isolated from homogenized lung using TRI-Reagent (Sigma),
purified by RNeasy Mini Kit (Qiagen, Valencia, CA), and quantified by
NanoDrop (Nd-1000). Reverse transcription was performed in with
SuperScriptIII Kit according manufacturer’s instructions (Invitrogen). cDNA was
subjected to quantitative real-time PCR using primers for Il1b, Il6 or Ccl2
(Qiagen) and GoTaq qPCR-Master Mix (Promega). GAPDH and 18S expression
was used for normalization. Raw data were analyzed using the Relative Expression
Software Tool (REST, http://www.rest.de.com/).
Cytokine and chemokine measurement
TNF-a, IL-6, IL-1b and keratinocyte-derived chemokine (KC or CXCL-1)
concentrations in BALF and lung homogenates were measured by ELISA (Duoset
Kit; R&D Systems) according to the manufacturer’s instructions.
IL-1b in P. aeruginosa Pneumonia
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MPO activity in lung
Lungs were homogenized in Dispomix [MedicTools. Zug, CH] with 1.5 mL NaCl
0.9%, and centrifuged. The supernatant was discarded. The pellet was
homogenized in 1 mL PBS - HTAB 0.5% - EDTA 1 mM. After centrifugation,
20 mL supernatant were added with: 1 mL HBSS, 200 mL of PBS - HTAB 0.5% -
EDTA 1 mM buffer, 100 mL o-Dianisidine (1.25 mg/mL) and 100 mL H2O2
0.048%. The reaction was stopped with 100 mL NaN3 1%. MPO (myeloperox-
idase) activity was determined as absorbance at 460 nm against medium.
Protein assay
Total protein concentration was analyzed in BALF, using Bradford assay with
BIORAD DC Protein assay kit (Biorad), according to the manufacturer’s
instructions.
Histology
Lungs were fixed in 4% buffered formalin, dehydrated in ethanol and embedded
in paraffin. Sections (3 mm) were stained with haematoxylin and eosin (H&E),
CAB (collagen staining) or PAS (mucus staining) and all lung sections were
evaluated by two independent observers for pathological changes, collagen
deposition, mucus production and cellular recruitment.
Statistical analysis
Statistical evaluation of differences between the experimental groups was
determined by using Mann-Whitney non-parametric test, or Log Rank test for
survival. All tests were performed with GraphPad Prism [GraphPad Software Inc.,
San Diego, CA, USA; www.graphpad.com]. A P-value ,0.05 was considered
significant and symbolized with *; ** for p,0.01 and *** for p,0.001. A P-
value.0.05 was considered not significant and symbolized with ns.
Results
1. IL-1b signaling enhances lung inflammation in F508del CFTR
mutants in response to LPS
Since LPS, P. aeruginosa [14–16] and bleomycin induced injury and inflammation
[26] are increased in F508del CFTR (d/d mice), and since the IL-1R1 pathway is
involved [20, 27] and required for the development of bleomycin-induced fibrosis
[20], we studied the role of the IL-1b pathway in the response to inflammation
and lung damage in F508del CFTR mice. In order to induce chronic lung damage,
repeated P. aeruginosa LPS challenges were performed in d/d and in double
mutant d/d x IL-1R12/2 mice, and compared to untreated WT littermate
controls. Lung analysis was performed at day 29, 24 h after the last LPS challenge.
Survival upon repeated LPS challenge was reduced to 50% in the d/d mice, while
IL-1b in P. aeruginosa Pneumonia
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100% of double KO d/d x IL-1R12/2mice survived (Fig. 1.A). The results suggest
that in F508del CFTR mutant, the active IL-1b pathway is deleterious in response
to repeated inflammatory injury. Reduced survival of d/d mice was apparently
associated with higher loss of body weight at day 7, as compared to d/d x IL-1R12/2
mice (Fig. 1.B). Nevertheless, all surviving mice recovered their initial weight
after 4 weeks, indicating tolerance to repeated LPS challenges. LPS-induced
inflammation was confirmed by increased total cell number in BALF (macrophages
and lymphocytes) 24 h after the last challenge but no significant difference was
observed between d/d and d/d X IL-1R12/2 mice at this time point (Fig. 1.C).
Similarly, P. aeruginosa LPS also induced a recruitment of neutrophils in BALF of
both d/d and d/d X IL-1R12/2mice (Fig. 1.C). No increase compared to untreated
WT mice of the CCL2 chemokine and IL-6 could be detected in lung homogenate
after repeated LPS challenges (Fig. 1.D and E). These results also suggest tolerance
since LPS is known to induce these cytokines after single challenge [28]. Single acute
LPS challenge is also known to induce IL-1b [29]. Indeed, the pulmonary IL-1b
production was still augmented after repeated LPS challenges in d/d mice, but to a
lesser extend in d/d x IL-1R12/2 mice (Fig. 1.F). Semi-quantitative analysis of the
lung histology indicated a distinct increase of cell infiltration, mucus production
and collagen deposition in d/d mice upon repeated LPS challenges as compared to
untreated control mice. Numerous inflammation parameters were reduced in d/d x
IL-1R12/2 mice compared to d/d, but did not reach statistical significance likely
due to the low number of surviving d/d mice (Fig. 1.A and F-J). In conclusion, the
present data support the notion that in response to LPS challenge, IL-1b participates
in inflammation and fibrosis in F508del CFTR mutants, and that genetic ablation of
IL-1R1 signaling has a protective effect.
2. Increased inflammatory response after P. aeruginosa injection
in cystic fibrosis lung
To further support this hypothesis in another model of CF pathology we used P.
aeruginosa infection, a common lung infection occurring in CF patients. We
established the model in our facility previously and showed that antibody
neutralization of LPS inhibited acute and fatal P. aeruginosa induced pneumonia
[30]. First, a P. aeruginosa (PA011) infection was performed in WT and d/d mice,
WT mice administered saline were used as control. Twenty hours after P.
aeruginosa infection, all mice developed severe pathology, as indicated by weight
loss (Fig. 2.A). Lung inflammation, analyzed by the myeloperoxidase (MPO)
activity, total cell and neutrophil counts in BALF was significantly increased in all
Fig. 1. IL-1b participates in pathologic inflammation in F508del CFTR mutants, in response to P. aeruginosa LPS. d/d and double KO d/d x IL-1R12/2
mice were treated intranasally with 80 mg of P. aeruginosa endotoxins/LPS in 40 mL PBS, once a week for 5 weeks. Untreated WT mice (UT) were used as
control. Survival is presented in (A) and body weight variation 24 h after the last LPS challenge in (B). Absolute numbers of cells, (macrophages,
lymphocytes and neutrophils) were measured in BALF 24 h after the last LPS challenge (C). CCL2 (D), IL-6 (E) and IL-1b (F) were measured in lung
homogenate. Cell infiltration was observed on H&E staining (G), mucus production on PAS staining (H) and collagen deposition on CAB staining (I).
Histopathological scores are shown in (J). n56–7 initially, n53 for d/d+LPS mice 24 h after last challenge instillation. Values are in mean +/2 SEM; * for
p,0.05 and ns for non-significant.
doi:10.1371/journal.pone.0114884.g001
IL-1b in P. aeruginosa Pneumonia
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	 	groups compared with uninfected mice (Fig. 2.B and C). The bacterial load in the
lung at 20 h did not differ between the groups (Fig. 2.D). However, bacterial load
(CFU) detected in BALF of d/d mice was two logs higher in d/d mice than in WT
mice (Fig. 2.D). Increased CFU in BALF of d/d mice was associated with
heightened neutrophil recruitment as compared with WT mice (Fig. 2.C). This
correlated with increased epithelial injury in d/d mice, compared to WT mice
(Fig. 2.E) indicating that pulmonary epithelial damage and protein release were
enhanced in d/d mice compared to WT mice (Fig. 2.G and H). KC chemokine
(CXCL1), known to attract neutrophils is increased in all groups after P.
aeruginosa infection, as compared with uninfected mice (Fig. 2.F). In d/d mice,
IL-1b and TNF-a levels were substantially higher in the lung than in WT mice.
Histological analysis showed augmented cell infiltration in d/d mice as compared
with WT mice after P. aeruginosa infection (Fig. 2.I and J).
3. IL-1b antibody neutralization attenuates P. aeruginosa-induced
inflammation
First, to study IL-1b function at steady state in the lung, we investigated the effect
of a long-lasting anti-IL-1b antibody treatment in wild type mice or in mice with
F508del CFTR mutation (d/d). Following 8-week antibody treatment, the young
adult mice (14-week-old females and males) were investigated. The treatment was
well tolerated; no mortality or morbidity was observed in any of the experimental
groups. Histological analysis did not reveal any significant differences of cell
recruitment, mucus production and collagen deposition in the lung (Fig. 3.A-C)
between WT and d/d mice treated with control PBS or anti-IL-1 antibody. Lung
mRNA expression of Il1b, Il6 and Ccl2 was assessed by qPCR and no significant
difference was found among the control and the anti-IL-1b antibody administered
groups (Fig. 3.D and E). Therefore, this investigation suggests that under basal
conditions, in the absence of stimulation, no significant difference is detected
between d/d and WT control mice. The F508del CFTR murine model (on C57BL/
6 background), displayed no significant spontaneous lung inflammation under
these conditions. Furthermore, long-term IL-1b antibody treatment had neither a
significant effect on pulmonary morphology, nor on basal expression of Il1b, Il6
and Ccl2, suggesting that IL-1b plays no significant role in steady state conditions.
Subsequently, the role of IL-1b upon P. aeruginosa infection was studied using
neutralizing antibodies in C57BL/6 mice. Mice were infected by intranasal
instillation with 106 CFU of P. aeruginosa (strain PA011) in order to induce an
acute inflammation analyzed at 20 h. To test the role of IL-1b, mice received two
Fig. 2. P. aeruginosa infection induces an increased inflammation in d/d mice. WT and d/d mice received 26105 CFU of P. aeruginosa PA011
intranasally, and WT mice treated with NaCl 0.9% were used as control. Body weight variation 20 h after infection is shown in (A). Myeloperoxidase activity
was quantified (B) and absolute numbers of cells; (macrophages and neutrophils) were measured in BALF (C). Bacterial load (total CFU) was determined in
BALF and in lung homogenate (D). Total protein concentration was evaluated in BALF (E) and KC (F), IL-1b (G) and TNF-a (H) were measured in lung
homogenate. Cell infiltration was observed on H&E stained slide (I) and scored (J). (n55–6) Values are in mean +/2 SEM; * for p,0.05; ** for p,0.01 and
*** for p,0.001. ns for non-significant.
doi:10.1371/journal.pone.0114884.g002
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Fig. 3. Anti-IL-1b antibody treatment has no significant effect on lung ultrastructure, nor on IL-1b, IL-6
and CCL2 mRNA production in lungs. Wild type (WT) and F508del CFTR mutation homozygote (d/d) mice
(14-week-old females and males) were treated intra-peritoneally, once a week for 8 weeks, an anti-IL-1b
antibody (10 mg/kg), or PBS. Mice were euthanatized 1 week after the last treatment and lung structure was
observed on H&E stained slides observed at620 magnification (A). Cellular infiltration (B) was quantified on
these H&E slides and mucus production (C) was analyzed on CAB stained lung slides. Lung injury score was
recorded in anti-IL-1b antibody treated mice compared with PBS treated mice. (D and E) mRNA production of
IL-1b, IL-6 and CCL2 was measured, and normalized with 2 housekeeping gene expression (Hprt1 and
Gapdh). The effect of anti-IL-1b antibody treatment compared to PBS control in WTand d/d animals is shown
in (D), and the effect of F508del CFTR mutation compared to WT is shown in (E). (n56–7)
doi:10.1371/journal.pone.0114884.g003
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Fig. 4. IL-1b participates in P. aeruginosa-induced inflammation at 20 h in WT mice. WT mice received 106 CFU of P. aeruginosa PA011 intranasally,
and WT mice treated with NaCl 0.9% were used as control. A group of WT mice was also treated intraperitoneally with anti-IL-1b antibody, 200 mg/mice,
15 h and 1 h before infection. Body weight variation 20 h after infection is shown in (A). Bacterial load was determined in BALF and in lung homogenate (B),
myeloperoxidase activity was quantified (C) and absolute numbers of cells, (macrophages and neutrophils) were measured in BALF (D). Protein
concentration was evaluated in BALF (E) and IL-1b (F), KC (G), TNF-a (H) and IL-6 (I), were measured in BALF and in lung homogenate. Cell infiltration was
observed on H&E stained slide (J) and scored (K). (n55–6) Values are in mean +/2 SEM; * for p,0.05; ** for p,0.01 and *** for p,0.001. ns for non-
significant.
doi:10.1371/journal.pone.0114884.g004
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peritoneal injections of 200 mg neutralizing antibodies 15 h and 1 h before
infection. As reported before (Figure 2 and in [30]), infection of C57BL/6 mice
with P. aeruginosa caused a rapid weight loss (Fig. 4.A), with a bacterial load of
104 CFU in BALF and total lung (Fig. 4.B). P. aeruginosa infection provoked
neutrophil recruitment (revealed by myeloperoxidase activity measurement and
cell counts in BALF), and epithelial damage suggested by an increase of proteins in
BALF in all groups post infection (Fig. 4.C-E). However, IL-1b neutralization had
a distinct effect on infection and lung inflammation. Indeed, IL-1b blockade
significantly reduced bacterial load in BALF, and to a lesser extent in lung
(Fig. 4.B), suggesting a substantial difference in bacterial clearance between the
two groups. This was correlated with a decrease in neutrophil recruitment
(Fig. 4.C and D) and an inhibition of protein in BALF as measure of epithelial
damage (Fig. 4.E). Moreover KC and TNF-a production in BALF were
diminished (Fig. 4.G and H), whereas IL-6 was not modified (Fig. 4.I). In
agreement with this, histological analysis showed reduced cell infiltration in anti-
IL-1b treated mice as compared with WT untreated mice after P. aeruginosa
infection (Fig. 4.J and K). These data suggest that IL-1b antibody neutralization
may attenuate P. aeruginosa-induced acute lung inflammation.
Discussion
CF patients display increased susceptibility to chronic infections with opportu-
nistic bacteria, excessive lung inflammation and fibrosis leading to fatal loss of
function eventually [6]. P. aeruginosa has been shown to induce IL-1b through
NLRC4 inflammasome activation [9, 10]. CFTR deficient mice were found to be
more susceptible to P. aeruginosa infection (acute [14, 15] and chronic [16]) and
have an exacerbated inflammatory response to LPS and P. aeruginosa.
Furthermore, F508del CFTR mutant alveolar macrophages display an enhanced
IL-1b production in response to LPS stimulation [18]. Thus, we were interested in
clarifying the role of IL-1b in the resolution of P. aeruginosa infection, in a murine
model with the most common CF mutation F508del CFTR [21–23]. Here, we
show that, after P. aeruginosa infection, excessive activation of IL-1b in F508del
CFTR (d/d) mice compared to WT was accompanied by increased CFU in BALF,
inflammation and lung damage. Further we show that a therapeutic antibody
administration attenuates inflammatory response in an acute model of infection
using WT mice.
In CF patients bacterial infections persist and their chronicity facilitates lung
inflammation, and subsequent tissue remodeling with severe loss of function [1].
CF lungs display excessive immune response, with increased neutrophil
recruitment [8]. We first investigated the role of IL-1b under pathologic
conditions, induced by repeated P. aeruginosa-LPS challenges. We observed LPS-
induced mortality in d/d mice, that was absent in d/d x IL-1R12/2 double
mutants, and a higher inflammation in d/d mice compared to the double mutant,
suggesting a detrimental role of the IL-1R1 pathway in LPS-challenged d/d mice
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(Fig. 1). The deficiency in IL-1R1 apparently protected the mice against LPS-
induced mortality in d/d mice. P.aeruginosa-LPS challenges were responsible for
leucocyte recruitment, including neutrophils. Despite increased cell infiltration in
the lung of d/d mice, collagen deposition and mucus production were only
slightly increased after multiple LPS challenges. Repeated LPS challenges did not
cause epithelial damage and chronic inflammation, which we explain by tolerance
induction [31], that is the reason to switch to P. aeruginosa infection.
No spontaneous inflammation was found in young adult F508del CFTR mutant
on C57BL/6 genetic background under our conditions. Whereas signs of
inflammation and tissue remodeling develop early in most CF patients [32],
results on basal inflammation in murine models are variable [23]. These data are
consistent with published data on the absence of spontaneous pathology such as
mucus plugging, neutrophil accumulation or bronchiectasis, in young mice
deficient or mutated for the Cftr gene [15, 33–35], but neutrophilic inflammation
has been reported in absence of infection [36, 37]. Spontaneous lung pathology
development seems to be dependent on the age of mice [37], genetic background
and animal facility health status [23]. However, in CF mutant mice challenged
with pro-inflammatory agents (P. aeruginosa, LPS) enhanced injury and
inflammation compared to wild type was reported in several independent studies
[14, 15, 26, 38].
Therefore, to get closer to a model of lung infections that occur in CF patients,
we used an acute P. aeruginosa infection model, which is the most current
pathogen found in CF patient [7], in F508del CFTR mice. Twenty hours after P.
aeruginosa infection, d/d mice displayed increased neutrophil recruitment in
BALF as compared with WT mice (Fig. 2). They also showed an increase in
bacterial load and cytokine production, such as IL-1b and TNF-a, in BALF. These
results suggest a higher sensitivity to infection in d/d mice, consistent with
previous studies in CFTR mutant mice, showing an augmentation of bacterial
load and production of pro-inflammatory cytokines after P. aeruginosa infection
[14, 15, 38]. The enhanced production of IL-1b compared to WT after infection
was associated with increased epithelial damage, cell infiltration and CFU (Fig. 2).
Then, we analyzed the effect of IL-1b neutralization at steady state in the lung. We
found that in d/d as well as in WT mice, IL-1b antibody had no significant effect
on survival. Furthermore d/d and WT mice displayed no difference in basal Il1b
mRNA expression, and repeated anti-IL-1b antibody administration had no
significant effect on basal inflammatory parameters and cytokine production.
However, our data suggest that IL-1b may cause an excessive and pathologic
inflammation in challenged CF mutant lungs. IL-1b over-expression in d/d mice
infected with P. aeruginosa was accompanied by a higher bacterial load. Indeed,
excessive production of inflammatory cytokines has been associated with bacterial
persistence in other studies as well. High concentrations of cytokine, such as IL-
1b, IL-6 or TNF-a, enhance intracellular and extracellular bacterial growth of P.
aeruginosa, or S. aureus in the presence of monocytes [39, 40]. Furthermore, IL-1b
release was linked to mortality in a murine model of P. aeruginosa infection after
thermal injury [41].
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Therefore, we tested the effect of a therapeutic antibody against murine IL-1b
in our acute P. aeruginosa infection model in WT mice. IL-1b neutralization has
been successfully tested previously with this antibody in a model of intestinal
inflammation [25]. Twenty hours after P. aeruginosa infection, IL-1b antibody
administration caused a decrease in the inflammatory parameters and in bacterial
load, as compared with NaCl-treated mice. This is consistent with studies by
Schultz et al. who showed that inhibition of the IL-1R1 pathway by either the IL-
1R1 mutation or application of the IL-1b antagonist IL-1RA improved
antibacterial host defense and reduced pro-inflammatory cytokine production
[42]. Reduced neutrophil recruitment by IL-1b neutralization could be due to
reduced endothelial activation, as proinflammatory cytokines activate endothelial
cells. For instance, TNF-a and IL-17 synergize to induce in cultured endothelial
cells the expression of P- and E-selectin, as well as neutrophil chemokines,
increasing neutrophil transmigration [43]. IL-1b produced by activated mono-
cytes was shown to augment the expression of adhesion molecules (ICAM-1, E-
selectin) in vitro [44]. Thus, the diminished leucocyte recruitment we observe with
IL-1b neutralization could be related to a reduced endothelial activation.
Abnormal recruitment and metabolic adaptation of neutrophils in human CF
airways has been demonstrated [45], the molecular mechanism remains to be
established but likely involves IL-1b signaling based on the arguments mentioned
above. We cannot exclude a role of lung fibroblasts and myoblasts. Indeed, IL-1b
stimulated human cardiac fibroblasts overexpress adhesion molecules and
neutrophil chemoattractant [46].
In conclusion we propose that the IL-1b pathway is critical to drive excessive
and detrimental inflammation in F508del mouse model of CF. We show here that
antibody neutralization of IL-1b is well tolerated in mice, has no effect on the
unchallenged lung in WT or F508del CFTR mice, whereas it can reduce pathology
induced by acute bacterial lung infection.
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SUMMARY	
Cystic	 Fibrosis	 (CF)	 lung	 disease	 and	 Chronic	 Obstructive	 Pulmonory	 Disease	 (COPD)	 are	
progressive	 and	 eventually	 fatal	 lung	 diseases	 characterised	 by	 airway	 mucus	
hypersecretion,	 airway	 surface	 liquid	dehydratation,	 chronic	 inflammation	and	 lung	 tissue	
remodelling.	Though	the	etiology	of	the	two	diseases	is	obviously	different	(CF	results	form	
CFTR	 deficiency,	 whereas	 COPD	 from	 chronic	 CS	 exposure),	 however,	 the	 molecular	
mechanisms	involved	in	the	progression	of	 lung	malfunction	are	likely	overlapped,	but	not	
completely	elucidated.	By	studying	pathological	processes	in	the	CF	and	COPD	airway	model	
systems,	we	aim	to	establish	novel	therapeutic	targets.	
	
In	our	studies	we	focused	on	ADAM17	and	EGFR	which	are	both	linked	to	lung	pathology,	by	
regulating	 inflammation,	 tissue	 regeneration,	 and	 mucus	 production.	 ADAM17	 is	 a	
membrane	bound	protease	that	releases	receptor-activating	proteins	from	the	cell	surface	
by	cleaving	extracellular	domains	from	a	large	number	of	target	proteins.	EGFR	is	a	receptor	
for	extracellular	growth	factors,	which	activates	intracellular	protein	kinase	cascades.	They	
are	 both	 activated	 by	 external	 signals,	 including	 pollutants	 like	 cigarette	 smoke,	 viral	 and	
bacterial	infections.	Importantly,	EGFR	and	ADAM17	function	and	activity	are	closely	linked,	
so	that	they	establish	an	EGFR/ADAM17	axis.	ADAM17	sheds	most	of	the	EGFR	ligands	that	
activate	 the	 receptor	 in	 an	 autocrine	 and	 paracrine	manner.	When	 triggered	 by	 external	
signals,	ADAM17	releases	IL-6R	and	AREG	from	airway	epithelial	cells	that	transactivate	IL-
6st/gp130	 and	 EGFR	 receptors	 respectively,	 on	 the	 underlying	 fibroblasts,	myofibroblasts	
and	 smooth	 muscle	 cells.	 The	 IL-6/IL-6R/gp-130	 and	 AREG/EGFR	 pathways	 converge	 in	
STAT3	activation,	a	transcription	factor	and	genetic	modulator	of	CF	lung	disease,	involved	
in		lung	tissue	repair,	inflammation	and	fibrosis.	
	
We	hypothesized	that	hyperactivity	of	airway	epithelial	ADAM17/EGFR	axis	may	contribute	
to	 the	 excessive	 inflammation	 and	 lung	 tissue	 remodelling	 characteristic	 of	 CF	 and	 COPD	
lung	disease.	 Thus	 the	 focal	point	of	 this	 thesis	was	 to	establish	 the	 role	of	ADAM17	and	
EGFR	in	pathology	of	CFTR-related	lung	diseases:	CF	and	COPD.		
	
The	 aim	 of	 this	 thesis	 was	 to	 determine	 whether	 and	 how	 the	 COPD	 status	 and	 CF	
conditions	 affects	 basal	 and	 induced	 ADAM17/EGFR	 activity	 in	 airway	 epithelium.	 We	
addressed	our	hypothesis	 in	 advanced	airway	epithelial	 cell	models:	COPD	and	non-COPD	
primary	bronchial	airway	epithelial	 cells	exposed	 to	cigarette	smoke,	and	 immortalized	CF	
mutant	CFBE41o-	cells	with	induced	CFTR	expression,	both	cultured	on	permeable	filters	in	
air-liquid	 interface	 (ALI-HBEC,	 ALI-CFBE41o-).	 	 In	 ALI-HBEC	 we	 compared	 the	 effect	 of	
cigarette	 smoke	 exposure	 on	 ADAM17/EGFR	 in	 COPD	 and	 non-COPD	 ALI-HBEC	 cells,	 and	
studied	 the	mechanism	 of	 this	 activation.	 In	 ALI-CFBE41o-	 cells	 we	 investigated	 whether	
CFTR	deficiency	hyperactivates	ADAM17/EGFR	as	a	cell	autonomous	defect,	and	we	further	
defined	 the	 druggable	 targets	 upstream	 and	 downstream	 of	 this	 regulator	 to	 potentially	
apply	them	as	an	early	intervention	CF	lung	therapy.		
	
Chapter	 1	 provides	 a	 general	 introduction	 to	 CF	 and	 COPD	 pathology	 and	 describes	 the	
importance	of	anti-inflammatory	therapy	in	CF.	In	the	second	part,	ADAM17	and	EGFR	are	
introduced	and	their	role	in	lung	inflammation	and	remodeling	is	underlined.		
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In	 Chapter	 2	 we	 compared	 CS-induced	 ADAM17	 mediated	 protein	 shedding	 and	 mRNA	
expression	 of	 sIL-6R	 and	 AREG	 in	 COPD	 and	 non-COPD	 (ex)smokers.	We	 showed	 that	 CS	
significantly	induces	IL6R	and	AREG	shedding	into	the	basolateral	medium	from	COPD	cells,	
but	 not	 in	 non-COPD	 cells	 suggesting	 that	 COPD	 disease	 makes	 cells	 more	 sensitive	 to	
external	 triggers.	 Furthermore,	 by	 using	 selective	 inhibitors	 of	 ADAM17	 and	 EGFR	 (TMI-2	
and	AG1478),	we	showed	that	they	not	only	regulate	shedding	of	IL-6R	and	AREG,	but	also	
their	 mRNA	 levels.	 Additionally,	 we	 showed	 that	 upon	 CS	 activation	 ADAM17	 meets	 its	
substrate	 in	 an	 intracellular	 vesicular	 compartment.	 Also	 EGFR	 is	 internalized	 after	 CS	
exposure.	 This	 suggests	 that	 trafficking	 of	 ADAM17	 and	 EGFR	 is	 one	 of	 the	 regulatory	
mechanisms	of	ADAM17/EGFR	axis	activation.	
	
Chapter	 3	 shows	 that	 functional	 expression	 of	 CFTR	 in	 ALI-CFBE41o-	 cells	 reduces	 AREG	
release,	 suggesting	 that	CFTR	deficient	 cells	 have	 intrinsically	 altered	ADAM17	dependent	
responses.	 In	 line	with	this,	we	also	observed	that	CFTR	deficiency	elevates	 levels	of	EGFR	
phosphorylation.	As	in	ALI-HBEC,	AREG	release	depends	on	EGFR	and	ADAM17	to	the	same	
extent.	 In	 CFBE410-cells	 we	 observed	 that	 CFTR	 deficiency	 induces	 increased	 apical	
localization	 of	 EGFR,	 which	 may	 lead	 to	 abnormal	 activation	 of	 ADAM17/EGFR	 axis,	
however,	these	data	need	to	be	confirmed	in	differentiated	primary	airway	epithelial	cells.	
Finally,	we	observed	 that	ADAM17	dependent	 shedding	 is	 sensitive	 to	ROS	 scavengers,	 in	
particular	 extracellular	 glutathione	 (GSH).	 Using	 the	 fluorescent	 redox	 probes	Grx1-roGFP	
expressed	in	cytoplasm	and	Grx1-roGFP-GPI	expressed	at	the	apical	membrane,	we	showed	
that	extracellular,	but	not	intracellular	redox	potential	 is	changed	to	a	more	oxidised	state	
by	 deficient	 CFTR.	 Thus,	 based	 on	 these	 data	we	 propose	 that	 deficient	GSH	 secretion	 in	
CFTR	 deficient	 cells,	 shown	 by	 other	 authors	 in	 analogous	 systems,	 causes	 oxidation	 of	
extracellular	 and	 possible	 intravesicular	 membranes,	 which	 in	 turn	 leads	 to	 enhanced	
activation	of	ADAM17	by	a	known	redox	dependent	conformation	change,	and	concomitant	
abnormal	EGFR	signalling	and	localization.		
Chapter	 4	 Illustrates	 the	 role	 of	 abnormal	 sphingosine	 metabolism	 in	 CF	 lung	 disease,	
providing	 an	 alternative	 intervention	 pathway.	We	 show	 that	 unchallenged	 F508del	 CFTR	
mutant	mice	have	enhanced	infiltration	with	pro-inflammatory	cells	and	abnormal	dendritic	
cell	 activity	 which	 correlates	 with	 reduced	 sphingosine-1-phosphate	 S1P	 in	 lungs.	 Oral	
administration	of	an	inhibitor	of	S1P-lyase	(LX2931,	Lexicon	Pharmaceutics),	increases	tissue	
S1P	 levels	 and	 reduces	 inflammation	 and	 dendritic	 cell	 imbalance.	 Upon	 challenge	 with	
bacterial	 toxins	 (LPS-fMLP)	 LX2931	 reduces	 induced	 MUC5AC	 production	 and	 pro-
inflammatory	cytokines	in	mutant	mice	(TNF-α,	KC,	IFN-γ,	IL-12).	The	S1P	receptor	network	
is	 known	 to	 interact	 with	 the	 EGFR/ADAM	 axis	 through	 intracellular	 kinases,	 providing	 a	
mechanistic	link	between	these	observations.	
Chapter	 5	 Summarizes	 and	 critically	 discusses	 the	 studies	 presented	 in	 this	 thesis	 and	
provides	possible	future	directions	 in	 investigation	of	EGFR-ADAM17	axis	 in	the	context	of	
CF	and	COPD	lung	disease.		
	
Appendix	 presents	 evidence	 that	 CFTR	 mutant	 mice	 show	 excessive	 inflammation,	
increased	IL-1β	production	and	reduced	bacterial	clearance.	CFTR	deficient	mice	with	the	IL-
1R1	knock-out	(double	mutant	F508del	x	IL-1R1)	have	attenuated	inflammation,	providing	a	
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rationale	 for	 targeting	 the	 IL-1β/IL-1R1	 pathway	 in	 CF	 patients.	 A	 therapeutic	 antibody	
reduces	infection	related	pathology	in	this	model.	Importantly	in	the	context	of	this	thesis,	
activation	of	IL-1R	also	activates		ADAM17/EGFR/IL8	signalling,	in	airway	epithelial	cell	lines.	
Thus	 intervention	 in	 the	 IL-1β/IL-R1β	 pathway	 may	 be	 also	 beneficial	 in	 attenuation	 of	
EGFR/ADAM17	signalling	in	the	CF	or	COPD	disease	state,	which	can	be	further	evaluated	in	
differentiated	human	airway	epithelial	cells.		
Taken	together,	our	data	provide	evidence	for	the	involvement	of	the	ADAM17/EGFR	axis	in	
CF	and	COPD	lung	disease.	Although	CF	and	COPD	differ	in	primary	cause,	we	showed	that	
they	share	a	molecular	mechanism	possibly	leading	to	the	development	and	progression	of	
the	 disease.	 CS	 exposure	 in	 COPD	 and	 CFTR	 deficiency	 in	 differentiated	 airway	 epithelial	
cells	 induce	ADAM17	and	EGFR	dependent	protein	 shedding	of	 IL-6R	and	AREG.	ADAM17	
dependent	release	of	EGFR	ligands	may	affect	epithelial	(autocrine)	and	subepithelial	(trans-
signaling)	 receptors.	 This	 implicates	 the	 ADAM17/EGFR	 axis	 in	 inflammation,	 lung	 tissue	
repair	 and	 fibrosis.	 Importantly	 we	 identified	 ROS,	 which	 inactivates	 phosphatases,	 as	 a	
highly	plausible	 link	between	CFTR	deficiency	and	EGFR/ADAM17	axis.	Since	we	 identified	
several	 potential	 druggable	 targets	 for	 intervention	 in	 this	 signalling	 pathway	 (GSH,	 PDI,	
SRC),	future	studies	evaluating	their	exact	mechanism	and	relevance	in	CF	and	COPD	models	
are	of	importance.		
Future	 studies	 are	 directed	 towards	 defining	 the	 role	 of	 CFTR	 deficiency	 in	 the	 abnormal	
regulation	of	redox	potentials,	bioactive	 lipid	synthesis,	and	membrane	protein	trafficking,	
which	 results	 in	 inappropriate	 inflammatory	 and	 repair	 responses	 in	 CF	 lung	 tissue,	 and	
applying	these	in	novel	therapeutic	approaches.  
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SAMENVATTING	
Longziekte	 bij	 cystische	 fibrose	 (CF)	 en	 COPD	 (chronic	 obstructive	 pulmonary	 disease,	
rokerslong)	neemt	toe	met	de	leeftijd,	is	niet	goed	te	behandelen,	en	leidt	tot	ernstig	verlies	
van	 longfunctie	met	 vaak	 de	 dood	 tot	 gevolg.	Beide	 ziektes	worden	 gekenmerkt	 door	 de	
ophoping	van	slijm	in	de	luchtwegen,	uitdroging	van	de	luchtwegen,	chronische	ontsteking,	
moeilijk	 te	bestrijden	bacteriële	 infecties,	 en	onomkeerbare	 verandering	 van	de	 structuur	
van	 de	 longen.	 De	 primaire	 oorzaak	 van	 de	 ziektes	 is	 duidelijk	 verschillend.	 CF	 wordt	
veroorzaakt	 door	 een	 erfelijke	 afwijking	 in	 een	 chloride	 kanaal	 betrokken	 bij	 vloeistof	
transport	door	de	slijmcellaag	(CFTR).	COPD	wordt	vooral	veroorzaakt	door	blootstelling	aan	
sigarettenrook.	 Toch	 vertonen	 de	 moleculaire	 mechanismes	 die	 een	 rol	 spelen	 bij	 het	
ontwikkelen	van	deze	chronische	longziektes	overeenkomsten.	Het	doel	van	ons	onderzoek	
was	 deze	 mechanismes	 in	 het	 laboratorium	 nader	 te	 onderzoeken,	 zodat	 we	 nieuwe	
geneesmiddelen	kunnen	testen	voor	beide	ziektes.	
	
We	 hebben	 ons	 geconcentreerd	 op	 de	 rol	 van	 twee	 eiwitten,	 waarvan	 we	 weten	 dat	 ze	
betrokken	 zijn	 bij	 ontstekingsreacties,	 slijmproductie,	 en	 weefselherstel	 in	 de	 long.		
ADAM17	 is	 een	enzym	dat	meerdere	eiwitten	 van	de	 celmembraan	 losmaakt,	 die	op	hun	
beurt	 via	 specifieke	 bindingseiwitten	 (receptoren)	 processen	 in	 de	 cel	 regelen.	 EGFR	
(epidermal	growth	 factor	 receptor)	 is	een	van	de	ontvangers	 van	die	 signalen,	die	 via	het	
celoppervlak	 worden	 doorgegeven	 aan	 een	 complex	 netwerk	 van	 eiwit	 fosforylerende	
enzymen	 (kinases)	 in	 de	 cel.	 Deze	 activiteit	 wordt	 in	 de	 long	 versterkt	 door	 diverse	
uitwendige	prikkels	zoals	rook,	beschadiging,	en	infecties.	Zoals	ook	uit	ons	onderzoek	blijkt	
beïnvloeden	ADAM17	en	EGFR	elkaar	wederzijds	zodat	ze	samen	een	regelsysteem	vormen	
(EGFR/ADAM17).	ADAM17	knipt	na	stimulatie	niet	alleen	EGFR	bindende	eiwitten	van	een	
cel	los,	waaronder	Amphireguline	(AREG),	maar	ook	de	receptor	van	een	ontstekingsfactor	
(interleukine	 6	 receptor,	 IL6R).	 Hierdoor	 worden	 ook	 nabij-liggende	 cellen	 die	 een	 EGFR	
receptor	of	een	interleukine	receptor	hebben	geactiveerd.	Op	deze	manier	kunnen	prikkels	
die	 het	 oppervlak	 van	 de	 long	 beïnvloeden	 worden	 doorgegeven	 aan	 het	 onderliggende	
bindweefsel	 en	 witte	 bloed	 cellen	 (trans-stimulatie).	 De	 ADAM17/AREG/EGFR	 en	
IL6/IL6R/gp130	 receptor	 systemen	 activeren	 samen	 de	 productie	 van	 eiwitten	 nodig	 voor	
normale	ontstekingsreacties	en	weefselherstel,	onder	andere	via	STAT3,	een	eiwit	dat	in	de	
celkern	de	productie	van	specifieke	messenger	RNA’s	regelt,	en	waarvan	bekend	is	dat	het	
mede	de	ernst	van	CF	longziekte	bepaalt.	
	
De	 Hypothese.	We	 veronderstelden	 bij	 het	 begin	 van	 ons	 onderzoek	 dat	 een	 verhoogde	
activiteit	 van	 het	 ADAM17/EGFR	 systeem	 bijdraagt	 aan	 de	 heftige	 ontstekingsreacties	 en	
structuurveranderingen	van	de	 long	bij	CF	en	COPD.	Daarom	waren	onze	experimenten	er	
vooral	op	gericht	om	de	rol	van	ADAM17	en	EGFR	bij	het	ontstaan	van	chronische	longziekte	
te	analyseren.		
	
We	onderzochten	daarvoor	het	effect	van	COPD	en	CF	op	de	activiteit	van	ADAM17/EGFR	in	
long-slijmhuid	cellen	(epitheel).	 	Hiervoor	kweekten	we	cellen	van	COPD	patiënten,	en	van	
personen	 zonder	 COPD.	 Deze	 cellen	 werden	 onder	 gecontroleerde	 omstandigheden	
blootgesteld	 aan	 sigarettenrook.	 Zo	 konden	 we	 de	 activering	 van	 ADAM17/EGFR	 en	 het	
effect	 van	 chronische	 COPD	 onderzoeken.	 Daarnaast	 gebruikten	 we	 epitheel	 cellen	
oorspronkelijk	geïsoleerd	uit	de	long	van	een	CF	patiënt,	waarin	we	het	ontbrekende	eiwit	
CFTR	konden	activeren.	Op	die	manier	konden	we	vaststellen	dat	het	ontbreken	van	CFTR	
de	 activiteit	 van	 EGFR/ADAM17	 inderdaad	 verhoogt.	 Door	 onder	 andere	 remmers	 van	
ADAM17	en	van	EGFR	 te	 testen,	hebben	we	 laten	zien	dat	dit	proces	door	experimentele	
geneesmiddelen	beïnvloed	kan	worden.	
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Hoofdstuk	 1	voorziet	 in	een	algemene	 inleiding	over	CF	en	COPD	 longziekte,	en	beschrijft	
het	 belang	 van	 anti-ontstekingstherapie	 bij	 de	 bestrijding	 hiervan.	 In	 het	 tweede	 deel	
worden	ADAM17	en	EGFR	in	detail	beschreven,	en	hun	mogelijke	relatie	met	longziekte.		
	
Hoofdstuk	 2	beschrijft	een	onderzoek	met	 longcellen	die	zodanig	op	 filters	zijn	gekweekt,	
dat	ze	zich	gedragen	als	slijmhuidcellen	in	de	luchtwegen,	door	ze	bloot	te	stellen	aan	lucht	
(air-liquid	 interface	culture).	Deze	experimenten	 laten	 zien	dat	 cellen	afkomstig	van	COPD	
patiënten	 na	 behandeling	 met	 sigarettenrook	 een	 sterkere	 ADAM17/EGFR	 activiteit	
vertonen	 dan	 cellen	 van	 niet-CF	 patiënten,	 waarbij	 de	 groeifactor	 AREG	 en	 de	
ontstekingsfactor	 IL6R	 aan	 de	 bloedzijde	 van	 de	 cellaag	 worden	 uitgescheiden.	 Dit	
suggereert	dat	de	 longen	van	COPD	patiënten	een	 sterkere	 reactie	op	 rook	 vertonen	dan	
normaal.	Verder	hebben	we	laten	zien	dat	remmers	van	zowel	EGFR	als	ADAM17	niet	alleen	
de	uitscheiding	van	AREG	en	IL6R	verminderen,	maar	ook	de	productie	van	de	bijbehorende	
messenger	RNA’s,	wat	duidt	op	de	betrokkenheid	van	transcriptiefactoren	 in	de	kern.	Een	
onverwacht	resultaat	is	dat	ADAM17	na	activering	door	sigarettenrook	binnen	in	de	cel	een	
interactie	 aangaat	 met	 AREG	 en	 IL6R,	 niet	 op	 het	 oppervlak	 waar	 de	 producten	 worden	
uitgescheiden.	 Ook	 EGFR	 wordt	 na	 activering	 vanaf	 het	 celoppervlak	 naar	 binnen	
getransporteerd.	 Het	 transport	 van	 deze	 membraaneiwitten	 in	 de	 cel	 na	 stimulatie	 is	
blijkbaar	een	onderdeel	 is	 van	het	 regelmechanisme.	Dit	moet	nader	onderzocht	worden,	
en	zal	van	belang	zijn	bij	de	ontwikkeling	van	nieuwe	geneesmiddelen.	
	
Hoofdstuk	 3	 laat	 zien	 dat	 onze	 hypothese	 juist	 was.	 De	 productie	 van	 de	 groeifactor	
amphireguline	(AREG)	door	CF	luchtweg	epitheelcellen	neemt	af	wanneer	we	ze	een	actieve	
vorm	 van	 eiwit	 CFTR	 laten	 maken.	 Productie	 van	 AREG	 is	 ook	 in	 deze	 cellen	 volledig	
afhankelijk	van	ADAM17	en	EGFR.	De	activering	van	EGFR,	gemeten	als	 fosforylering	door	
kinases	 is	 hoger	 in	 cellen	 zonder	 CFTR.	 Verder	 zien	 we	 meer	 EGFR	 op	 het	 aan	 de	 lucht	
blootgestelde	deel	van	de	celmembraan.	Het	verband	tussen	deze	verhoogde	activiteit	en	
de	afwezigheid	van	CFTR	hebben	we	nader	onderzocht.	Onze	metingen	 laten	zien	dat	het	
CFTR	defect	een	verhoogde	oxidatie	van	de	celmembraan	veroorzaakt.	We	constateerden	
ook	dat	stoffen	die	de	oxidatie	van	de	celmembraan	verminderen,	met	name	glutathion,	de	
uitscheiding	van	AREG	sterk	verminderen.	Oxidatie	veroorzaakt	een	stressreactie	in	de	cel,	
en	 die	 beschermt	 zich	 daartegen	 onder	 andere	 door	 de	 uitscheiding	 van	 een	 natuurlijk	
antioxidant:	glutathion.	Andere	onderzoekers	hadden	al	laten	zien	dat	glutathion	transport	
in	CF	cellen	minder	 is	dan	normaal.	We	concluderen	dan	ook	dat	 in	CF	 luchtweg	cellen	de	
oxidatie-stress	veroorzaakt	door	onvoldoende	glutathion	transport	 leidt	 tot	hyperactiviteit	
van	 EGFR/ADAM17.	 Waarschijnlijk	 komt	 dit	 door	 een	 verandering	 in	 de	 structuur	 van	
ADAM17,	 gecombineerd	 met	 een	 verandering	 van	 het	 intracellulaire	 transport	 van	
EGFR/ADAM17.	Samenvattend	betekent	dit	waarschijnlijk	dat	ook	CF	epitheel	 cellen	 in	de	
long	van	een	patiënt	 spontaan	een	verhoogde	activiteit	 van	het	EGFR/ADAM17	vertonen,	
ook	als	er	geen	bacteriële	 infectie	 is	 in	die	 long,	met	versterkte	 inflammatie	en	fibrose	tot	
gevolg.	
	
Hoofdstuk	 4	maakt	 gebruik	 van	 een	 CF	muismodel	 dat	we	 eerder	 gemaakt	 hebben,	met	
dezelfde	erfelijke	afwijking	als	de	meeste	CF	patiënten	(F508del	CFTR).	In	dit	model	stelden	
we	 eerst	 met	 een	 geavanceerde	 methode	 vast	 dat	 de	 muizen	 longontsteking	 vertonen,	
zonder	dat	 ze	worden	blootgesteld	aan	 infecties	of	 andere	 stressfactoren.	Blijkbaar	 is	het	
CFTR	 defect	 op	 zichzelf	 voldoende	 om	 witte	 bloedcellen	 te	 activeren	 tot	 een	
ontstekingsreactie.	 Verder	 vonden	 we	 dat	 de	 productie	 van	 een	 bekende	 signaalstof	
betrokken	bij	 longontsteking,	 sphingosine-fosfaat	 (S1P)	sterk	verlaagd	 is	 in	de	 long	van	de	
CF	 muizen.	 Wanneer	 we	 de	 S1P	 verhogen	 met	 behulp	 van	 een	 experimenteel	 medicijn	
tegen	reumatische	ontstekingen	(LX2931	Lexicon	Pharmaceutics),	zien	we	een	afname	van	
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de	longontsteking	in	CF	muizen.	Ook	wordt	de	ontstekingsreactie	op	bacteriële	toxines	in	de	
long	 minder	 langdurig.	 S1P	 en	 zijn	 receptoren	 maken	 deel	 uit	 van	 een	 groter	
signaalnetwerk,	waar	ook	EGFR/ADAM17	deel	van	uitmaakt,	en	dat	beïnvloed	wordt	door	
CFTR.	
	
Hoofdstuk	5	geeft	een	samenvatting	en	een	kritische	analyse	van	de	studies,	en	geeft	aan	
wat	 de	 volgende	 stappen	 zijn	 in	 het	 onderzoek	 naar	 de	 relatie	 tussen	 EGFR/ADAM17	 en	
chronische	longziekte.			
	
Appendix	 beschrijft	 in	 een	 gerelateerde	 studie	 dat	 F508del	 CFTR	 muizen	 meer	 moeite	
hebben	om	een	bacteriële	infectie	te	overleven	dan	gezonde	muizen,	en	dat	ze	daarbij	een	
verhoogde	productie	van	het	 signaaleiwit	 IL1b	vertonen.	Een	mutatie	 in	een	 receptor	van	
IL1b,	 en	 de	 toediening	 van	 een	 antilichaam	 tegen	 IL1b	 verminderen	 de	 gevoeligheid	 van	
muizen	 voor	 bacteriële	 infectie.	 Daarbij	 is	 van	 belang	 voor	 onze	 studie	 dat	 IL1b	
EGFR/ADAM17	activeert,	en	dus	ook	deel	uitmaakt	van	dit	CFTR	afhankelijke	regelnetwerk.	
Dit	biedt	een	alternatieve	mogelijkheid	om	 in	 te	grijpen	 in	het	proces	van	excessieve	 long	
inflammatie	in	CF	en	mogelijk	bij	COPD.	
	
Samenvattend	geven	onze	resultaten	aan	dat	het	EGFR/ADAM17	systeem	betrokken	 is	bij	
zowel	 CF	 als	 COPD	 longziekte.	 Hoewel	 deze	 ziektes	 verschillen	 wat	 betreft	 hun	 primaire	
oorzaak,	 laten	we	 zien	dat	 ze	een	gemeenschappelijk	moleculair	mechanisme	hebben	dat	
mede	verantwoordelijk	kan	zijn	voor	het	ontstaan	en	voortschrijden	ervan.	Sigarettenrook	
en	 CFTR	 defecten	 in	 luchtwegslijmhuidcellen	 activeren	 EGFR/ADAM17	 afhankelijke	
uitscheiding	 van	 signaalmoleculen	 (IL6R	 en	 AREG).	 Dit	 kan	 de	 slijmproductie,	 het	
bindweefsel,	 en	 de	 witte	 bloedcellen	 in	 het	 weefsel	 activeren,	 wat	 kan	 bijdragen	 tot	 de	
typische	ziekteverschijnselen	van	CF	en	COPD.	Verder	wijzen	onze	studies	er	op	dat	vooral	
oxidatiestress	 de	 verbindende	 schakel	 is	 tussen	 het	 CFTR	 defect	 en	 EGFR/ADAM17	
activering.	 Dit	 biedt	 meerdere	 mogelijkheden	 tot	 nader	 onderzoek	 naar	 toepassing	 van	
nieuwe	geneesmiddelen	die	dit	regelsysteem	beïnvloeden.	
	
Toekomstige	studies	worden	gericht	op	de	rol	van	CFTR	bij	het	regelen	van	oxidatiestress,	
de	productie	van	signaalmoleculen,	en	het	transport	van	membraan	eiwitten,	wat	in	de	CF	
long	 leidt	 dit	 tot	 heftige	 ontstekingsreacties	 en	 abnormaal	 weefselherstel.	 De	 resultaten	
kunnen	ons	helpen	om	nieuwe	geneesmiddelen	te	ontwikkelen.		
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- PhD Workshop, Dusseldorf  (poster presentation: The role of the 
sheddasses (Adam17) in Cystic Fibrosis – Chronic lung disease)  
- NRS Young Investigator Symposium, Animal models in pulmonary 
research, Utrecht  
- PhD Workshop, Luxemburg (oral presentation: COPD and Cystic 
Fibrosis a tale of two diseases) 
 
2011 
2011 
 
2012 
 
2012 
 
 
2013 
 
32 hours 
0,3 ECTS 
 
32 hours 
 
0,3 ECTS 
 
 
32 hours 
Presentations 
- Oral presentation, Leiden (The role of ADAM17 and IL6 pathway 
in Cystic Fibrosis in HT29 adenocarinoma cells) 
- Oral presentation, Utrecht (The role of ADAM17 and IL6 pathway 
in Cystic Fibrosis Lungs) 
- One year evaluation presentation (The role of ADAM17 and IL6 
pathway in Cystic Fibrosis and COPD) 
- Oral presentation, Leiden (The role of ADAM17 and IL6 pathway 
in chronic lung disease: Cystic Fibrosis and COPD) 
- Oral presentation Utrecht (Does CFTR regulate shedding of 
cytokines and growth factors in CF ling disease?)  
- Monday morning meeting (CF) 
- Monday morning meeting (COPD) 
- Oral Presentation, Sophia Children Hospital (COPD and CF) 
- Oral Presentation, Utrecht (The role of ADAM17 in chronic 
inflammatory lung diseases: CF and COPD) 
- Oral Presentation, ErasmusMC, CF meeting (Metalloproteases in 
CF and COPD, primary bronchial epithelial cells in culture as a 
surrogate model for lung pathology) 
 
2011 
 
2011 
 
2012 
 
2012 
 
2012 
 
2012 
2013 
2013 
2013 
 
2013 
 
 
 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
1 ECTS 
1 ECTS 
1 ECTS 
 
1 ECTS 
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- Monday morning meeting  
(The mode of action of ADAM17 in resolution of inflammation in 
CF. The pulmonary models to understand the mechanisms of 
lung fibrosis) 
Long Dagen, Utrecht (poster presentation) 
- NRS Young Investigator Symposium, Animal models in 
pulmonary research, Utrecht (poster presentation) 
- Oral presentation, Utrecht CF meeting (ADAM17 and 
inflammatory responses in CFTR deficient cells and Lung 
organoids as a tool for drug screening in CF pathology) 
- Monday morning meeting (The influence of CFTR potentiators 
and correctors on inflammatory responses in CF lung disease) 
- Monday Morning meeting (The strategies in CF therapy) 
- Long Dagen (poster presentation) 
- Oral Presentation, Montreal (The mode of action of ADAM17 in 
resolution of inflammation in chronic lung diseases) 
2013 
 
2013 
 
2014 
2014 
 
2014 
 
 
2014 
 
2014 
 
2015 
1 ECTS 
 
0.5 ECTS 
 
1 ECTS 
1 ECTS 
 
1 ECTS 
 
 
1 ECTS 
 
1 ECTS 
 
1 ECTS 
(Inter)national conferences 
- FEBS, Italy (Poster Presentation) 
- The 7th European CF Young Investigator Meeting, Paris (Oral 
presentation) 
- Basic Science Meeting Malta (Oral and Poster presentation) 
- North American Cystic Fibrosis Conference, NACFC, Atlanta 
(Poster presentation) 
 
2011 
2013 
 
2014 
 
2014 
 
1.4 ECTS  
1.4 ECTS 
 
1.4 ECTS 
 
1.4 ECTS 
Other 
- Short-term fellowship EMBO award 
(4 month internship in Professor Lukacs GL Laboratory at McGill 
University (Montreal) under supervision of Veit G, Associate 
Professor) 
 
2015 
 
 
4 months 
 
2. Teaching 
Supervising practicals and excursions, Tutoring 
- Internship Technician (M. Veltman) 
- Internship Technician (S. Nieuwenhuize)  
- Internship Technician (A. Labasati) 
 
2011 
2012 
2013 
 
9 months 
9 months 
7 months 
Other 
- Journal Club (presentation: “Cigarette smoke exposure induces 
CFTR internalization and insolubility, leading to airway surface liquid 
dehydration”) 
- Journal Club (presentation: An HNF4a-miRNA Inflammatory 
Feedback Circuit Regulates Hepatocellular Oncogenesis) 
- Journal Club (presentation: Cell surface annexin regulate ADAM-
mediated ectodomain shedding of proAREG) 
- Journal Club (Functional engrafment of colon epithelium expanded 
in vitro from a single adult Lgr5+ stem cell) 
- Journal Club (A special population of regulatory T cells potentiates 
muscular repair) 
 
 
 
 
2012 
 
 
2012 
 
2013 
 
2014  
 
2015 
 
0.25 ECTS 
 
 
0.25 ECTS 
 
0.25 ECTS 
 
0.25 ECTS 
 
0.25 ECTS 
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